# EDGAR Filing Document

**Accession Number:** 0001964979
**File Stem:** 0001193125-25-185331
**Filing Date:** 2025-8
**Character Count:** 276271
**Document Hash:** 261f6c4f9a7277bd5f35992985c24608
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-185331.hdr.sgml**: 20250821

**ACCESSION NUMBER**: 0001193125-25-185331

**CONFORMED SUBMISSION TYPE**: 424B3

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250821

**DATE AS OF CHANGE**: 20250821

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALLURION TECHNOLOGIES, INC.
- **CENTRAL INDEX KEY:** 0001964979
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B3
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-274564
- **FILM NUMBER:** 251241128

**BUSINESS ADDRESS:**
- **STREET 1:** 11 HURON DR STE 200
- **CITY:** NATICK
- **STATE:** MA
- **ZIP:** 01760
- **BUSINESS PHONE:** 508-647-4000

**MAIL ADDRESS:**
- **STREET 1:** 11 HURON DR STE 200
- **CITY:** NATICK
- **STATE:** MA
- **ZIP:** 01760

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALLURION TECHNOLOGIES HOLDINGS, INC.
- **DATE OF NAME CHANGE:** 20230207

##### [**Table of Contents**](#toc)
**Filed Pursuant to Rule 424(b)(3)** 

**Registration No. 333-274564** 

**Prospectus Supplement No. 27** 

**(To Prospectus dated December 15, 2023)**![LOGO](g941205g0821082136001.jpg)

## ALLURION TECHNOLOGIES, INC.
**Up to 56,548,268 Shares of Common Stock** 

This prospectus supplement no. 27 (this "Prospectus Supplement") amends and supplements the prospectus dated December 15, 2023 (as supplemented or amended from time to time, the "Prospectus") which forms part of our Registration Statement on Form S-1/A (Registration Statement No. 333-274564). This Prospectus Supplement is being filed to update and supplement the information included or incorporated by reference in the Prospectus with the information contained in our Amended Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on August 19, 2025 (the "10-Q/A"). Accordingly, we have attached the 10-Q/A to this Prospectus Supplement.

This Prospectus Supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This Prospectus Supplement should be read in conjunction with the Prospectus, and if there is any inconsistency between the information in the Prospectus and this Prospectus Supplement, you should rely on this Prospectus Supplement.

Our common stock is listed on The New York Stock Exchange ("NYSE") under the symbol "ALUR" and our public warrants are listed on the NYSE under the symbol "ALUR.WS". On August 20, 2025, the last quoted sale price for shares of our common stock as reported on the NYSE was $2.13 per share, and the last quoted sale price for our public warrants as reported on the NYSE was $0.0314 per warrant.

**We are an "emerging growth company" under applicable federal securities laws and will be subject to reduced public company reporting requirements.** 

**Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in "Risk Factors" beginning on page 26 of the Prospectus.** 

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued under the Prospectus or determined if the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.** 

**The date of this Prospectus Supplement is August 21, 2025.** 

------

##### [**Table of Contents**](#toc)
**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, DC 20549** 

**FORM 10-Q/A** 

**(Amendment No. 1)** 

**(Mark One)** 

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the quarterly period ended March 31, 2025** 

**OR** 

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the transition period from _________________ to _________________** 

**Commission File Number: 001-41767** 

## Allurion Technologies, Inc.
**(Exact Name of Registrant as Specified in its Charter)** 

---

| | |
|:---|:---|
| **Delaware** | **92-2182207** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer<br>Identification No.)** |
| **11 Huron Drive**<br> **Natick, MA** | **01760** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (508) 647-4000** 

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | ALUR | The New York Stock Exchange |
| Warrants to purchase<br>0.056818 shares of Common Stock for $202.50 per share | ALUR WS | The New York Stock Exchange |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 12, 2025, the registrant had 7,457,758 shares of common stock, $0.0001 par value per share, outstanding.

------

##### [**Table of Contents**](#toc)
**EXPLANATORY NOTE** 

This Amendment No. 1 on Form 10-Q/A ("Form 10-Q/A") amends and restates certain items in Allurion Technologies, Inc.'s (the "Company") Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, initially filed with the Securities and Exchange Commission (the "SEC") on May 15, 2025 (the "Original Form 10-Q").

In this Form 10-Q/A, the Company is restating its previously issued unaudited condensed consolidated financial statements for the quarters ended March 31, 2025 and 2024, as further described below.

The Company previously filed Amendment No. 1 to its Annual Reports on Form 10-K for the fiscal year ended December 31, 2024 with the SEC on August 19, 2025 (the "Form 10-K/A") to restate its previously issued audited consolidated financial statements as of and for the fiscal year ended December 31, 2024. Further, the Company is filing amendments to (i) its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as amended, (together with the Form 10-K/A, the "Annual Reports"), to restate its previously issued audited consolidated financial statements as of and for the fiscal year ended December 31, 2023 and (ii) its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2024, June 30, 2024, and September 30, 2024 (the "Quarterly Reports") to restate its previously issued unaudited condensed consolidated financial statements for the fiscal quarters ended March 31, 2024, June 30, 2024, and September 30, 2024.

The Company does not intend to amend any other reports previously filed with the SEC. Accordingly, investors and other readers should rely only on the financial information and related disclosures regarding the periods described above (the "Affected Periods") in this Form 10-Q/A, such amendments to the Annual Reports and Quarterly Reports described in the preceding paragraph, and in any other future filings with the SEC (as applicable) and should not rely on the prior reports of its independent registered public accounting firm on the consolidated financial statements as of and for the years ended December 31, 2023 and 2024, as applicable, or any previously furnished or filed reports, press releases, investor presentations or similar communications relating to the Affected Periods.

**Items Amended in this Filing** 

This Form 10-Q/A amends and restates the following items of the Original Form 10-Q:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Part I - Item 1. Financial Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Part I - Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Part I - Item 4. Controls and Procedures

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Part II - Item 6. Exhibits

In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the certifications specified in Rule 13a-14 under the Exchange Act from the Company's Chief Executive Officer, dated as of the date hereof, are being filed or furnished, as applicable, with this Form 10-Q/A as Exhibits 31.1 and 32.1. This Form 10-Q/A also includes an updated signature page.

This Form 10-Q/A sets forth the information in the original Form 10-Q in its entirety, as such information is amended and restated where necessary to reflect the restatement and related revisions. Except as provided above, this Form 10-Q/A does not amend, update or change any other items or disclosures or otherwise reflect events occurring after the date of the Original Form 10-Q to the date this Form 10-Q/A is filed. Accordingly, this Form 10-Q/A should be read in conjunction with the Company's other SEC filings.

Except as otherwise provided, the disclosures in this Form 10-Q/A are made as of the date of the Original Form 10-Q and do not reflect any events that occurred after the date of the Original Form 10-Q or modify or update any other disclosures in the Original Form 10-Q affected by subsequent events. As such, forward-looking statements included in this Form 10-Q/A may represent management's views as of the date of the Original Form 10-Q and should not be assumed to be accurate as of any date thereafter.

**Restatement Background** 

As described in the Company's Current Report on Form 8-K filed with the SEC on August 14, 2025, while preparing its unaudited condensed consolidated financial statements for the quarter ended June 30, 2025, the Company identified an error (the "Error") in the Company's historical consolidated financial statements as of and for the years ended December 31, 2023 and December 31, 2024, and the quarter and year-to-date periods ended March 31, 2024, June 30, 2024, September 30, 2024, and March 31, 2025 that caused both overstatements and understatements of Other comprehensive income (loss) as reflected in the consolidated statements of comprehensive income (loss), Other income (expense) as reflected in the consolidated statements of operations, Net income (loss) as reflected in the consolidated statements of comprehensive loss and consolidated statements of operations, and Accumulated other comprehensive income (loss) and Accumulated deficit as reflected in the consolidated balance sheets and consolidated statements of stockholders' deficit. The Company determined that the Error originated from the existing material weaknesses related to the lack of sufficient levels of staff with public company and technical accounting experience to maintain proper control activities and perform risk assessment and monitoring activities. These adjustments were inadvertently booked in the wrong direction consistently since the fourth quarter of 2023. The Error had no impact to revenue, gross profit, operating expenses, operating profit (loss) or cash and cash equivalents.

i

------

##### [**Table of Contents**](#toc)
Additionally, the Company corrected an item that was previously identified and concluded as an immaterial error to its condensed consolidated financial statements as of and for the quarter ended March 31, 2024. This item primarily relates to Other liabilities and Other income (expense) misclassifications.

As a result, the Company is restating the accompanying condensed consolidated financial statements as of and for the quarters ended March 31, 2025 and 2024.

**Internal Control Considerations** 

Following the identification of the Error and in connection with the restatement, the Company's management has re-evaluated the effectiveness of the Company's disclosure controls and procedures and internal control over financial reporting as of March 31, 2025. The Company's management determined that the Error and the related restatements were the result of the existing material weaknesses in the Company's internal control over financial reporting, which was previously concluded to be ineffective as of March 31, 2025. See Part I—*Item 4. Controls and Procedures*, in this Form 10-Q/A for additional information related to these material weaknesses in disclosure controls and procedures and internal control over financial reporting and the related remedial measures.

ii

------

##### [**Table of Contents**](#toc)
**Table of Contents** 

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
|  **PART I.** | [FINANCIAL INFORMATION](#toc941205_1) | 1 |
|  Item 1. | [Financial Statements (Unaudited)](#toc941205_2) | 1 |
|  | [Condensed Consolidated Balance Sheets (Restated)](#toc941205_3) | 1 |
|  | [Condensed Consolidated Statements of Operations (Restated)](#toc941205_4) | 2 |
|  | [Condensed Consolidated Statements of Comprehensive Income (Loss) (Restated)](#toc941205_5) | 3 |
|  | [Condensed Consolidated Statements of Stockholders' Deficit (Restated)](#toc941205_6) | 4 |
|  | [Condensed Consolidated Statements of Cash Flows (Restated)](#toc941205_7) | 5 |
|  | [Notes to Unaudited Condensed Consolidated Financial Statements (Restated)](#toc941205_8) | 7 |
|  Item 2. | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#toc941205_9) | 43 |
|  Item 3. | [Quantitative and Qualitative Disclosures About Market Risk](#toc941205_10) | 56 |
|  Item 4. | [Controls and Procedures](#toc941205_11) | 56 |
|  **PART II.** | [OTHER INFORMATION](#toc941205_12) | 58 |
|  Item 1. | [Legal Proceedings](#toc941205_13) | 58 |
|  Item 1A. | [Risk Factors](#toc941205_14) | 58 |
|  Item 2. | [Unregistered Sales of Equity Securities and Use of Proceeds](#toc941205_15) | 59 |
|  Item 3. | [Defaults Upon Senior Securities](#toc941205_16) | 59 |
|  Item 4. | [Mine Safety Disclosures](#toc941205_17) | 59 |
|  Item 5. | [Other Information](#toc941205_18) | 59 |
|  Item 6. | [Exhibits](#toc941205_19) | 60 |
|  [Signatures](#toc941205_20) | [Signatures](#toc941205_20) | 62 |

---

iii

------

##### [**Table of Contents**](#toc)
**SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS** 

This Quarterly Report on Form 10-Q/A contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, which are not purely historical, include, but are not limited to, statements regarding the plans, strategies and prospects, both business and financial, of Allurion Technologies, Inc. ("Allurion", the "Company", "we", "our", or "us"). Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors. Such risks, uncertainties and other factors could cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events, or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words "believes", "estimates", "expects", "projects", "target", "goal", "forecasts", "may", "will", "potential", "should", "would", "could", "future", "seeks", "plans", "predicts", "propose", "scheduled", "anticipates", "intends", or similar expressions. Such statements are based on the beliefs and assumptions of the management of Allurion. Although Allurion believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, Allurion cannot assure you that it will achieve or realize these plans, intentions or expectations.

Forward-looking statements in this Quarterly Report on Form 10-Q/A include, but are not limited to, statements about the ability of Allurion to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• realize the benefits expected from the business combination between Allurion and Compute Health Acquisition Corp.
pursuant to that certain Business Combination Agreement, dated as of February 9, 2023, by and among Allurion, Allurion Technologies, LLC, which was previously known as Allurion Technologies Opco, Inc. (formerly Allurion Technologies, Inc.)
prior to the consummation of the Business Combination, Compute Health Acquisition Corp., Compute Health Corp., and Compute Health LLC;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• successfully defend litigation that may be instituted against Allurion;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• manage various conflicts of interest that could arise among us and our affiliates, investors, directors, and
officers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• successfully deploy our cash and cash equivalents and proceeds from the Chardan Equity Facility (as defined
herein);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• maintain the listing of Allurion securities on the New York Stock Exchange, and the potential liquidity and
trading of such securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• acquire sufficient sources of funding if and when needed;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• attract and retain key employees, officers, and directors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• implement and achieve business plans, forecasts, and other expectations, including any financial projections
provided to our investors, and identify and realize additional opportunities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• manage risks associated with the management team of Allurion having limited experience operating as a public
company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• commercialize current and future products and services and create sufficient demand among health care providers
and patients for such products, including the recent launch of our compounded GLP-1 program and achieving the expected benefits of such program;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• successfully complete current and future preclinical studies and clinical trials of the swallowable,
Procedureless<sup>TM</sup>intragastric balloon for weight loss developed by Allurion (the "Allurion Balloon") and any other future product candidates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• obtain market acceptance of the Allurion Balloon as safe and effective in any market in which it is or becomes
approved;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• cost-effectively sell existing and future products through distribution arrangements with distributors and/or
successfully adopt a direct sales force as part of a hybrid sales model that includes both distributors and a direct sales effort;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• timely collect accounts receivable from our customers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• obtain regulatory approval or clearance in the United States and certain jurisdictions for current and future
products and maintain previously obtained approvals and/or clearances in those jurisdictions where products and services are currently offered;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• successfully resume sales of the Allurion Balloon in any country that suspends sales of our products;

iv

------

##### [**Table of Contents**](#toc)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• accurately forecast customer demand and manufacture sufficient quantities of products that patients and health
care providers request;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• successfully compete in the highly competitive and rapidly changing regulated industries in which we operate, and
effectively address changes in such industries, including changes in competitors' products and services and changes in the laws and regulations that affect us;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• successfully manage any future international expansion of our business and navigate business, regulatory,
political, operational, financial, and economic risks associated with doing business internationally;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• successfully manage any future growth or contraction in Allurion's business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• contract with third-party suppliers, manufacturers and providers and monitor such third parties' ability to
perform adequately under those arrangements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• comply with applicable legal and regulatory obligations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• obtain and maintain intellectual property protection for our products and technologies and acquire or license (on
commercially reasonable terms) intellectual property from third parties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• sell products, and use proprietary technologies, without infringing, misappropriating, or otherwise violating the
proprietary rights or intellectual property of third parties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• manage the impact of any significant acquisitions, dispositions, and other similar or material transactions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the restatement of our prior financial statements and our ability to implement and maintain effective internal
controls over financial reporting, including our ability to remediate the existing material weaknesses in our internal controls; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• manage the effects of natural disasters, acts of war or terrorism, the spread and/or abatement of infectious
diseases, general economic and political conditions such as recessions, interest rates, fuel prices, trade wars, and currency fluctuations, and other events beyond our reasonable control, including with respect to potential operational disruptions,
labor disruptions, increased costs, and impacts to demand related thereto, on our ability to implement business plans, forecasts, and other expectations.

We have based the forward-looking statements contained in this Quarterly Report on Form 10-Q/A primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations, prospects, business strategy, and financial needs. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties, assumptions and other factors described under the heading "Risk Factors" in this Quarterly Report on Form 10-Q/A and in the section entitled "Risk Factors" within our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (the "SEC") on March 27, 2025, as amended by Amendment No. 1 to the Annual Report on Form 10-K filed with the SEC on August 19, 2025 (together, the "Annual Report on Form 10-K"). These risks are not exhaustive. Other sections of this Quarterly Report on Form 10-Q/A include additional factors that could adversely impact our business and financial performance. Moreover, Allurion operates in very competitive and rapidly changing environments. New risks and uncertainties emerge from time to time and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q/A.

We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.

In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q/A, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and such statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

v

------

##### [**Table of Contents**](#toc)
**PART I-FINANCIAL INFORMATION** 

**Item 1. Financial Statements.** 

**ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES**

**UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS**

**(dollars in thousands, except share amounts)**

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2025** | **December 31,<br>2024** |
|  | **(Restated)** | **(Restated)** |
|  **Assets** |  |  |
|  Current assets: |  |  |
|  Cash and cash equivalents | $20408 | $15379 |
|  Accounts receivable, net of allowance of doubtful accounts of $6,455 and $6,701, respectively | 8309 | 7134 |
|  Inventory, net | 3352 | 3400 |
|  Prepaid expenses and other current assets | 1097 | 1243 |
|  Total current assets | 33166 | 27156 |
|  Property and equipment, net | 2297 | 2469 |
|  Right-of-use asset | 1870 | 2079 |
|  Other long-term assets | 1081 | 1109 |
|  **Total assets** | $38414 | $32813 |
|  **Liabilities and Stockholders' Deficit** |  |  |
|  Current liabilities: |  |  |
|  Accounts payable | $4976 | $6572 |
|  Current portion of lease liabilities | 829 | 869 |
|  Accrued expenses and other current liabilities | 10092 | 11422 |
|  Total current liabilities | 15897 | 18863 |
|  Convertible notes payable | 30960 | 35710 |
|  Warrant liabilities | 9264 | 4567 |
|  Revenue Interest Financing liability | 50000 | 49200 |
|  Earn-out liabilities | 180 | 1090 |
|  Lease liabilities, net of current portion | 1186 | 1344 |
|  Other liabilities | 717 | 17 |
|  **Total liabilities** | $108204 | $110791 |
|  Commitments and Contingencies (Note 17) |  |  |
|  Stockholders' deficit: |  |  |
|  Preferred stock, $0.0001 par value - 100,000,000 shares authorized as of March 31, 2025; no shares issued and outstanding as of March 31, 2025 and December 31, 2024 |  |  |
|  Common stock, $0.0001 par value - 1,000,000,000 shares authorized as of March 31, 2025; 5,963,549 and 2,710,607 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 5 | 3 |
|  Additional paid-in capital | 157843 | 152596 |
|  Accumulated other comprehensive income | (3930) | (8370) |
|  Accumulated deficit | (223708) | (222207) |
|  **Total stockholders' deficit** | (69790) | (77978) |
|  **Total liabilities and stockholders' deficit** | $38414 | $32813 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

##### [**Table of Contents**](#toc)
**ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES**

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS** 

**(dollars in thousands, except share and per share amounts)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
|  | **2025** | **2024** |
|  | **(Restated)** | **(Restated)** |
|  Revenue | $5580 | $9386 |
|  Cost of revenue | 1419 | 2520 |
|  Gross profit | 4161 | 6866 |
|  Operating expenses: |  |  |
|  Sales and marketing | 3621 | 6145 |
|  Research and development | 2624 | 5725 |
|  General and administrative | 5198 | 6386 |
|  Total operating expenses: | 11443 | 18256 |
|  Loss from operations | (7282) | (11390) |
|  Other income (expense): |  |  |
|  Interest expense |  | (1931) |
|  Changes in fair value of warrants | 5669 | 3131 |
|  Changes in fair value of debt | 3330 |  |
|  Changes in fair value of Revenue Interest Financing and PIPE Conversion Option | (3820) | (2100) |
|  Changes in fair value of earn-out liabilities | 910 | 14190 |
|  Other income (expense), net | (213) | 172 |
|  Total other income: | 5876 | 13462 |
| (Loss) income before income taxes | (1406) | 2072 |
|  Provision for income taxes | (95) | (76) |
|  Net (loss) income | $(1501) | $1996 |
|  Net (loss) income per share |  |  |
|  Basic | $(0.31) | $1.04 |
|  Diluted | $(0.31) | $0.96 |
|  Weighted-average shares outstanding |  |  |
|  Basic | 4778542 | 1911181 |
|  Diluted | 4778542 | 1967885 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

##### [**Table of Contents**](#toc)
**ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES**

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)** 

**(dollars in thousands)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
|  | **2025** | **2024** |
|  | **(Restated)** | **(Restated)** |
|  Net loss (income) | $(1501) | $1996 |
|  Other comprehensive income: |  |  |
|  Change in fair value of Revenue Interest Financing due to change in credit risk | 3020 | 2200 |
|  Change in fair value of RTW Convertible Notes due to change in credit risk | 1420 |  |
|  Comprehensive income | $2939 | $4196 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

##### [**Table of Contents**](#toc)
**ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES**

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT**

**(dollars in thousands, except share amounts)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Sock** | **Common Sock** | | | | |
|  | | | **Additional**<br>**Paid-in<br>Capital** | **Accumulated<br>Other**<br>**Comprehensive<br>Loss** | **Accumulated**<br>**Deficit** | **Stockholders'**<br>**Deficit** |
|  |<br>**Shares** |<br>**Amount** | **Additional**<br>**Paid-in<br>Capital** | **Accumulated<br>Other**<br>**Comprehensive<br>Loss** | **Accumulated**<br>**Deficit** | **Stockholders'**<br>**Deficit** |
|  **Balance as of January 1, 2024 (Restated)** | 1907529 | $2 | $143010 | $700 | $(215009) | $(71297) |
|  Exercise of stock options | 186 |  | 9 |  |  | 9 |
|  Issuance of common stock for the exercise of Public Warrants | 6 |  |  |  |  |  |
|  Issuance of common stock from equity line financing (Note 13) | 5730 |  | 378 |  |  | 378 |
|  Issuance of common stock in connection with vesting of RSU awards | 2505 |  |  |  |  |  |
|  Stock-based compensation expense |  |  | 552 |  |  | 552 |
|  Other comprehensive income (Restated) |  |  |  | 2200 |  | 2200 |
|  Net income (Restated) |  |  |  |  | 1996 | 1996 |
|  **Balance as of March 31, 2024 (Restated)** | 1915956 | $2 | $143949 | $2900 | $(213013) | $(66162) |
|  **Balance as of January 1, 2025 (Restated)** | 2710607 | $3 | $152596 | $(8370) | $(222207) | $(77978) |
|  Exercise of stock options |  |  |  |  |  |  |
|  Issuance of common stock in connection with vesting of RSU awards | 3505 |  |  |  |  |  |
|  Issuance of common stock in connection with RTW Private Placement, net of issuance costs | 841751 |  | 2500 |  |  | 2500 |
|  Issuance of common stock in connection with January Public Offering, net of issuance costs | 1240000 | 1 | 1262 |  |  | 1263 |
|  Issuance of common stock in connection with February Public Offering and Leavitt Private Placement, net of issuance costs | 1167686 | 1 | 588 |  |  | 589 |
|  Stock-based compensation expense |  |  | 897 |  |  | 897 |
|  Other comprehensive income (Restated) |  |  |  | 4440 |  | 4440 |
|  Net loss (Restated) |  |  |  |  | (1501) | (1501) |
|  **Balance as of March 31, 2025 (Restated)** | 5963549 | $5 | $157843 | $(3930) | $(223708) | $(69790) |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

##### [**Table of Contents**](#toc)
**ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES**

**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(dollars in thousands)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
|  | **2025** | **2024** |
|  | **(Restated)** | **(Restated)** |
|  **Operating Activities:** |  |  |
|  Net (loss) income | $(1501) | $1996 |
|  Adjustments to reconcile net (loss) income to net cash used in operating activities: |  |  |
|  Non-cash lease expense | 212 | 199 |
|  Depreciation and amortization | 203 | 367 |
|  Stock-based compensation | 897 | 552 |
|  Provision for uncollectible accounts | 72 |  |
|  Unrealized exchange (gain) loss | (335) | 314 |
|  Provision for inventory | 25 | 209 |
|  Change in fair value of warrant liabilities | (5669) | (3131) |
|  Change in fair value of derivative liabilities |  | 62 |
|  Change in fair value of debt | (3330) |  |
|  Change in fair value of Revenue Interest Financing and PIPE Conversion Option | 3820 | 2100 |
|  Change in fair value of earn-out liabilities | (910) | (14190) |
|  Change in fair value of Share Obligation | 700 |  |
|  Non-cash interest expense |  | 315 |
|  Issuance costs associated with warrants recorded at fair value | 1137 |  |
|  Changes in operating assets and liabilities: |  |  |
|  Accounts receivable | (883) | 1673 |
|  Inventory | 22 | 330 |
|  Prepaid expenses, other current and long-term assets | 147 | 244 |
|  Lease liabilities | (199) | (238) |
|  Accounts payable | (2409) | 1551 |
|  Accrued expenses and other current liabilities | (1468) | (989) |
|  Net cash used in operating activities | $(9469) | $(8636) |
|  **Investing Activities:** |  |  |
|  Purchases of property and equipment |  | (104) |
|  Net cash used in investing activities | $— | $(104) |
|  **Financing Activities:** |  |  |
|  Proceeds from equity offerings, net of issuance costs | 14499 |  |
|  Proceeds from option and warrant exercises |  | 9 |
|  Proceeds from equity line financing |  | 378 |
|  Net cash provided by financing activities | $14499 | $387 |
|  Net increase (decrease) in cash and cash equivalents and restricted cash | 5030 | (8353) |
|  Cash and cash equivalents and restricted cash at beginning of period | 15718 | 38421 |
|  Cash and cash equivalents and restricted cash at end of period | $20748 | $30068 |
|  **Supplemental disclosure of cash flow information** |  |  |
|  Cash paid for interest | $— | $1831 |
|  **Supplemental cash flow information on non-cash investing and financing activities** |  |  |
|  Purchase of property and equipment included in accounts payable |  | 73 |
|  Deferred financing costs in accounts payable and accrued expenses | 921 |  |
|  Change in fair value of RTW Convertible Notes through OCI | 1420 |  |
|  Change in fair value of Revenue Interest Financing through OCI | 3020 | 2200 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

##### [**Table of Contents**](#toc)
**ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES**

A reconciliation of the amounts of cash and cash equivalents and restricted cash in the condensed consolidated balance sheets to the amount in the condensed consolidated statements of cash flows is as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **March 31,**<br>**2025** | **December 31,**<br>**2024** |
|  Cash and cash equivalents | $20408 | $15379 |
|  Restricted cash included in other long-term assets | 340 | 339 |
|  Cash and cash equivalents and restricted cash shown in the statement of cash flows | $20748 | $15718 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

##### [**Table of Contents**](#toc)
**1. Organization and Basis of Presentation** 

***Organization***

Allurion Technologies, Inc. ("Allurion" or the "Company") is a vertically integrated medical device company that is developing, manufacturing, and commercializing innovative weight loss experiences centered around its Allurion<sup>™</sup> Balloon. The Allurion Balloon is the world's first and only swallowable, procedureless<sup>™</sup> intragastric balloon for weight loss that does not require surgery, endoscopy, or anesthesia for placement. Allurion sells the Allurion Balloon and connected scale through distributors or directly to health care providers.

The Company also offers tiered access to artificial intelligence ("AI")-powered remote patient monitoring tools, a mobile app for patients and a clinic dashboard for providers, referred to as the Allurion Virtual Care Suite ("VCS") and, collectively with the Allurion Balloon, referred to as the "Allurion Program." The base tier of the VCS is free of charge to those purchasing the Allurion Balloon, as well as customers looking for a weight-loss management platform for patients utilizing other weight loss treatments, including anti-obesity medications and bariatric surgery. More full-scale versions of the VCS are available to health care providers on an upgrade basis. Allurion currently markets the Allurion Program in over 50 countries, and the Company operates subsidiaries in the United States, France, the United Arab Emirates, the United Kingdom, Italy, Spain, Australia and Mexico.

***Business Combination Agreement***

On February 9, 2023, Allurion Technologies Opco, Inc. (formerly Allurion Technologies, Inc., "Legacy Allurion") and Allurion Technologies, Inc. (formerly Allurion Technologies Holdings, Inc.) entered into the Business Combination Agreement (as subsequently amended on May 2, 2023, the "Business Combination Agreement") with Compute Health Acquisition Corp. ("CPUH" or "Compute Health"), Compute Health Corp. ("Merger Sub I") and Compute Health LLC ("Merger Sub II" and, together with Merger Sub I, the "Merger Subs"). Pursuant to the Business Combination Agreement, on August 1, 2023 (the "Closing Date"), the Mergers (as defined below) were consummated in three steps: (a) Compute Health merged with and into Allurion (the "CPUH Merger"), with Allurion surviving the CPUH Merger as a publicly listed entity (the time at which the CPUH Merger became effective, the "CPUH Merger Effective Time") and becoming the sole owner of the Merger Subs; (b) three hours following the consummation of the CPUH Merger, Merger Sub I merged with and into Legacy Allurion (the "Intermediate Merger" and the time at which the Intermediate Merger became effective, the "Intermediate Merger Effective Time"), with Legacy Allurion surviving the Intermediate Merger and becoming a direct, wholly-owned subsidiary of Allurion; and (c) thereafter, Legacy Allurion merged with and into Merger Sub II (the "Final Merger" and, collectively with the CPUH Merger and the Intermediate Merger, the "Mergers", and together with all other transactions contemplated by the Business Combination Agreement, the "Business Combination"), with Merger Sub II surviving the Final Merger and remaining a direct, wholly-owned subsidiary of Allurion (the time at which the Final Merger became effective, the "Final Merger Effective Time"). Shares of Allurion's Common Stock (defined below) began trading on the New York Stock Exchange ("NYSE") under the ticker symbol "ALUR" on August 2, 2023. Upon completion of the Business Combination, Legacy Allurion's business operations continued as our business operations.

The Business Combination was accounted for as a reverse capitalization in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Under this method of accounting, Compute Health was treated as the "acquired" company for financial reporting purposes and Legacy Allurion was the accounting "acquirer." Accordingly, the Business Combination was treated as the equivalent of Legacy Allurion issuing stock for the net assets of Compute Health, accompanied by a recapitalization. As a result of the reverse recapitalization, the assets and liabilities of the Company are presented at their historical carrying values, and the assets and liabilities of Compute Health are recognized on the acquisition date and measured on the basis of the net proceeds from the capital transaction, with no goodwill or other intangible assets recorded. This determination is primarily based on the fact that, immediately following the Business Combination, Legacy Allurion stockholders had a majority of the voting power of Allurion, Legacy Allurion controlled the majority of the board seats of Allurion, and Legacy Allurion senior management comprised all of the senior management of Allurion. The equity structure has been restated in all comparative periods up to the Closing Date to reflect the number of shares of the Company's common stock, par value $0.0001 per share ("Common Stock," "Allurion Common Stock" or the "Company's Common Stock"), issued to Legacy Allurion stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to Legacy Allurion's convertible preferred stock and Legacy Allurion common stock prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio of approximately 0.9780 (the "Exchange Ratio") established in the Business Combination. The Exchange Ratio established in the Business Combination is prior to the Reverse Stock Split (as defined below) and did not change as a result of the Reverse Stock Split. As a result of this retrospective application, certain prior period balances within the condensed consolidated financial statements have changed. Refer to Note 4, *Business Combination* for further discussion regarding the closing of the Business Combination with Compute Health.

Unless otherwise indicated, references in this Quarterly Report on Form 10-Q/A to the "Company", "our", and "Allurion" refer to the condensed consolidated operations of Allurion Technologies, Inc. and its subsidiaries after giving effect to the Business Combination. References to CPUH and Compute Health refer to Compute Health Acquisition Corp. and its subsidiaries prior to the consummation of the Business Combination, and references to "Legacy Allurion" refer to Allurion Technologies, Inc. prior to the consummation of the Business Combination.

------

##### [**Table of Contents**](#toc)
***Basis of Presentation***

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Any reference in these notes to the applicable accounting guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification ("ASC"), and Accounting Standards Update ("ASU"), of the Financial Accounting Standards Board ("FASB"). They should be read in conjunction with our audited financial statements as of and for the year ended December 31, 2024 included in the Company's Annual Report on Form 10-K filed with the SEC on March 27, 2025, as amended by Amendment No. 1 to the Annual Report on Form 10-K filed with the SEC on August 19, 2025 (together, the "Annual Report on Form 10-K"). The financial statements as of March 31, 2025 and for the three months ended March 31, 2025 and 2024 presented in this report are unaudited; however, in the opinion of management, such financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. The results of operations for the periods presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.

Our foreign operations are subject to exchange rate fluctuations and foreign currency transaction costs. The functional currency for all of our foreign subsidiaries is the United States dollar except Allurion Australia Pty Ltd., which uses the Australian dollar. When remeasuring from a local currency to the functional currency, assets and liabilities are remeasured into U.S. dollars at exchange rates in effect at the balance sheet dates and results of operations transacted in local currency are remeasured into U.S. dollars using average exchange rates for the period presented. A gain from remeasurement of $0.3 million and a loss from remeasurement of $0.3 million for the three months ended March 31, 2025 and 2024, respectively, are recorded in the statements of operations within Other income (expense), net. The Company translates the foreign functional currency financial statements to U.S. dollars for Allurion Australia Pty Ltd. using the exchange rates at the balance sheet date for assets and liabilities, the period average exchange rates for revenues and expenses, and the historical exchange rates for equity transactions. The effects of foreign currency translation adjustments were immaterial for the three months ended March 31, 2025 and 2024.

***Reverse Stock Split***

The Company held its annual meeting of stockholders on December 16, 2024 (the "Annual Meeting"), and upon the recommendation of the Board of Directors (the "Board") of the Company, the Company's stockholders approved a certificate of amendment to the Company's Amended and Restated Certificate of Incorporation (as amended and restated from time to time, the "Charter") to effect a reverse stock split of the Company's Common Stock at a ratio between 1-for-10 and 1-for-25, with the final ratio to be determined by the Board in its sole discretion.

On December 23, 2024, following the Annual Meeting, the Board approved a reverse stock split of the Common Stock at a ratio of 1-for-25 (the "Reverse Stock Split"). Effective as of 12:01 a.m. Eastern Time on January 3, 2025, the Company filed an amendment to its Charter to effectuate the Reverse Stock Split.

As a result of the Reverse Stock Split, every 25 shares of the Company's Common Stock issued or outstanding were automatically reclassified into one validly issued, fully-paid and non-assessable new share of Common Stock, subject to the treatment of fractional shares as described below, without any action on the part of the holders. Trading of the Common Stock on the NYSE commenced on a split-adjusted basis at market open on January 3, 2025 under the existing trading symbol "ALUR."

No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive fractional shares as a result of the Reverse Stock Split were automatically entitled to receive an additional fraction of a share of Common Stock to round up to the next whole share.

Proportional adjustments were also made to the number of shares of Common Stock awarded and available for issuance under the Company's equity incentive plans, as well as the exercise price and the number of shares issuable upon the exercise or conversion of the Company's outstanding stock options, restricted stock units and other equity securities under the Company's equity incentive plans. Additionally, all outstanding convertible notes were adjusted in accordance with their terms, which resulted, among other changes to the convertible note terms, in proportionate adjustments being made to the number of shares issuable upon exercise of such convertible notes and to the exercise and redemption prices of such convertible notes. All outstanding warrants were also adjusted in accordance with their terms, which resulted, among other changes to the warrant terms, in proportionate adjustments being made to the number of shares issuable upon exercise of such warrants and to the exercise and redemption prices of such warrants. Specifically, following the effectiveness of the Reverse Stock Split, every 25 shares of Common Stock that may be purchased pursuant to the exercise of public warrants will represent one share of Common Stock that may be purchased pursuant to such warrants. Accordingly, for the Company's warrants trading under the symbol "ALUR WS" on the NYSE, each whole public warrant following the Reverse Stock Split is exercisable for 0.056818 shares of Common Stock at an exercise price of $202.50 per share, which is based on each public warrant being exercisable for 1.420455 shares of Common Stock before the Reverse Stock Split, adjusted for the 25:1 reverse stock split ratio.

------

##### [**Table of Contents**](#toc)
Unless otherwise indicated, all authorized, issued, and outstanding shares and per share amounts contained in the accompanying condensed consolidated financial statements have been adjusted to reflect the 1-for-25 Reverse Stock Split for all periods presented. As a result, net income per share was also retrospectively adjusted for periods ended prior to the Reverse Stock Split.

The Company has evaluated whether there are certain events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q/A are issued.

The Company has incurred recurring losses since inception, anticipates net losses and negative operating cash flows for the near future, and may be unable to remain in compliance with certain financial covenants required under its credit facilities. Through March 31, 2025, the Company has funded its operations primarily with proceeds from the sale of its Common Stock and convertible preferred stock, issuance of convertible notes, issuance of term loans, and funds received upon consummation of the Business Combination. The Company has incurred recurring losses and cash outflows from operating activities since its inception, including losses from operations of $7.3 million and $11.4 million and cash outflows from operating activities of $9.5 million and $8.6 million for the three months ended March 31, 2025 and 2024, respectively. As of March 31, 2025, the Company had an accumulated deficit of $223.7 million (as restated). The Company expects to continue to generate operating losses for the foreseeable future.

Until such time as we can generate sufficient revenue to fund operations, we expect to use proceeds from the issuance of equity, debt financings, or other capital transactions to fund our operations and satisfy our liquidity requirements, but the amount and timing of such financings are uncertain. Based on the Company's recurring losses from operations incurred since inception, its expectation of continuing operating losses for the foreseeable future, the potential need to raise additional capital to finance its future operations, and the potential of being unable to remain in compliance with certain financial covenants under its credit facilities, the Company has concluded that there is substantial doubt about its ability to continue as a going concern for a period of one year from the date that these condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.

**2.** **Restatement of Previously Issued Condensed Consolidated Financial Statements** 

While preparing its unaudited condensed consolidated financial statements for the quarter ended June 30, 2025, the Company identified an error (the "Error") in the Company's historical consolidated financial statements as of and for the years ended December 31, 2023 and 2024, and the quarter and year-to-date periods ended March 31, 2024, June 30, 2024, September 30, 2024 and March 31, 2025, that caused both overstatements and understatements of Other comprehensive income (loss) as reflected in the consolidated statements of comprehensive income (loss), Other income (expense) as reflected in the consolidated statements of operations, Net income (loss) as reflected in the consolidated statements of comprehensive loss and consolidated statements of operations, and Accumulated other comprehensive income (loss) and Accumulated deficit as reflected in the consolidated balance sheets and consolidated statements of stockholders' deficit. The Company determined that the Error originated from the existing material weakness related to the lack of sufficient levels of staff with public company and technical accounting experience to maintain proper control activities and perform risk assessment and monitoring activities. These adjustments were inadvertently booked in the wrong direction consistently since the fourth quarter of 2023. The Error had no impact to revenue, gross profit, operating expenses, operating loss or cash and cash equivalents.

Additionally, the Company corrected an item that was previously identified and concluded as an immaterial error to its condensed consolidated financial statements as of and for the quarter ended March 31, 2024. This item primarily relates to Other liabilities and Other Income (Expense) misclassifications.

As a result, the Company is restating the accompanying condensed consolidated financial statements as of and for the quarters ended March 31, 2025 and 2024.

------

##### [**Table of Contents**](#toc)
The effects of the restatements on the condensed consolidated financial statements as of and for the three months ended March 31, 2025 are as follows:

**Restated Condensed Consolidated Balance Sheet** 

(dollars in thousands)

---

| | | | |
|:---|:---|:---|:---|
|  | **As of March 31, 2025** | **As of March 31, 2025** | **As of March 31, 2025** |
|  | **As<br>Reported** | **Adjustment** | **As Restated** |
|  **Assets** |  |  |  |
|  Current assets: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cash and cash equivalents | $20408 | $— | $20408 |
|  Accounts receivable, net of allowance of doubtful accounts | 8309 |  | 8309 |
|  Inventory, net | 3352 |  | 3352 |
|  Prepaid expenses and other current assets | 1097 |  | 1097 |
|  Total current assets | 33166 |  | 33166 |
|  Property and equipment, net | 2297 |  | 2297 |
|  Right-of-use asset | 1870 |  | 1870 |
|  Other long-term assets | 1081 |  | 1081 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total assets** | $38414 | $— | $38414 |
|  **Liabilities and Stockholders' Deficit** |  |  |  |
|  Current liabilities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accounts payable | $4976 | $— | $4976 |
|  Current portion of lease liabilities | 829 |  | 829 |
|  Accrued expenses and other current liabilities | 10092 |  | 10092 |
|  Total current liabilities | 15897 |  | 15897 |
|  Convertible notes payable | 30960 |  | 30960 |
|  Warrant liabilities | 9264 |  | 9264 |
|  Revenue Interest Financing liability | 50000 |  | 50000 |
|  Earn-out liabilities | 180 |  | 180 |
|  Lease liabilities, net of current portion | 1186 |  | 1186 |
|  Other liabilities | 717 |  | 717 |
|  **Total liabilities** | 108204 |  | 108204 |
|  Commitments and Contingencies |  |  |  |
|  Stockholders' deficit: |  |  |  |
|  Preferred stock, $0.0001 par value— 100,000,000 shares authorized as of March 31, 2025; no shares issued and outstanding as of March 31, 2025 |  |  |  |
|  Common stock, $0.0001 par value—1,000,000,000 shares authorized as of March 31, 2025; 5,963,549 shares issued and outstanding as of March 31, 2025 | 5 |  | 5 |
|  Additional paid-in capital | 157843 |  | 157843 |
|  Accumulated other comprehensive income (loss) | 3930 | (7860) | (3930) |
|  Accumulated deficit | (231568) | 7860 | (223708) |
|  **Total stockholders' deficit** | (69790) |  | (69790) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Total liabilities and stockholders' deficit** | $38414 | $— | $38414 |

---

------

##### [**Table of Contents**](#toc)
**Restated Condensed Consolidated Statement of Operations** 

(dollars in thousands)

---

| | | | |
|:---|:---|:---|:---|
|  | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** |
|  | **As Reported** | **Adjustment** | **As Restated** |
|  Revenue | $5580 | $— | $5580 |
|  Cost of revenue | 1419 |  | 1419 |
|  Gross profit | 4161 |  | 4161 |
|  Operating expenses: |  |  |  |
|  Sales and marketing | 3621 |  | 3621 |
|  Research and development | 2624 |  | 2624 |
|  General and administrative | 5198 |  | 5198 |
|  Total operating expenses: | 11443 |  | 11443 |
|  Loss from operations | (7282) |  | (7282) |
|  Other income (expense): |  |  |  |
|  Interest expense |  |  |  |
|  Changes in fair value of warrants | 5669 |  | 5669 |
|  Changes in fair value of debt | 6170 | (2840) | 3330 |
|  Changes in fair value of Revenue Interest Financing and PIPE Conversion Option | 2220 | (6040) | (3820) |
|  Changes in fair value of earn-out liabilities | 910 |  | 910 |
|  Other income (expense), net | (213) |  | (213) |
|  Total other income (expense): | 14756 | (8880) | 5876 |
|  Income (loss) before income taxes | 7474 | (8880) | (1406) |
|  Provision for income taxes | (95) |  | (95) |
|  Net Income (loss) | $7379 | $(8880) | $(1501) |
|  Net income (loss) per share |  |  |  |
|  Basic | $1.54 | $(1.85) | $(0.31) |
|  Diluted | $0.20 | $(0.51) | $(0.31) |
|  Weighted-average shares outstanding |  |  |  |
|  Basic | 4778542 |  | 4778542 |
|  Diluted | 6017438 | (1238896) | 4778542 |

---

**Restated Condensed Consolidated Statement of Comprehensive Income** 

(dollars in thousands)

---

| | | | |
|:---|:---|:---|:---|
|  | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** |
|  | **As Reported** | **Adjustment** | **As Restated** |
|  Net income (loss) | $7379 | $(8880) | $(1501) |
|  Other comprehensive loss: |  |  |  |
|  Change in fair value of Revenue Interest Financing due to change in credit risk | (3020) | 6040 | 3020 |
|  Change in fair value of RTW Convertible Notes due to change in credit risk | (1420) | 2840 | 1420 |
|  Comprehensive income | $2939 | $— | $2939 |

---

------

##### [**Table of Contents**](#toc)
**Restated Condensed Consolidated Statement of Cash Flows** 

(dollars in thousands)

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
|  | **Originally<br>Reported** | **Adjustment** | **As Restated** |
|  **Operating Activities:** |  |  |  |
|  Net income (loss) | $7379 | $(8880) | $(1501) |
|  Adjustments to reconcile net income (loss) to net cash used in operating activities: |  |  |  |
|  Non-cash lease expense | 212 |  | 212 |
|  Depreciation and amortization | 203 |  | 203 |
|  Stock-based compensation | 897 |  | 897 |
|  Provision for uncollectible accounts | 72 |  | 72 |
|  Unrealized exchange (gain) loss | (335) |  | (335) |
|  Provision for inventory | 25 |  | 25 |
|  Change in fair value of warrant liabilities | (5669) |  | (5669) |
|  Change in fair value of debt | (6170) | 2840 | (3330) |
|  Change in fair value of Revenue Interest Financing and PIPE Conversion Option | (2220) | 6040 | 3820 |
|  Change in fair value of earn-out liabilities | (910) |  | (910) |
|  Change in fair value of Share Obligation | 700 |  | 700 |
|  Issuance costs associated with warrants recorded at fair value | 1137 |  | 1137 |
|  Changes in operating assets and liabilities: |  |  |  |
|  Accounts receivable | (883) |  | (883) |
|  Inventory | 22 |  | 22 |
|  Prepaid expenses, other current and long-term assets | 147 |  | 147 |
|  Lease liabilities | (199) |  | (199) |
|  Accounts payable | (2409) |  | (2409) |
|  Accrued expenses and other current liabilities | (1468) |  | (1468) |
|  Net cash used in operating activities | $(9469) | $— | $(9469) |
|  **Investing Activities:** |  |  |  |
|  Purchases of property and equipment |  |  |  |
|  Net cash used in investing activities | $— | $— | $— |
|  **Financing Activities:** |  |  |  |
|  Proceeds from equity offerings, net of issuance costs | 14499 |  | 14499 |
|  Proceeds from option and warrant exercises |  |  |  |
|  Proceeds from equity line financing |  |  |  |
|  Net cash provided by financing activities | $14499 | $— | $14499 |
|  Net increase (decrease) in cash and cash equivalents and restricted cash | 5030 |  | 5030 |
|  Cash and cash equivalents and restricted cash at beginning of period | 15718 |  | 15718 |
|  Cash and cash equivalents and restricted cash at end of period | $20748 | $— | $20748 |
|  **Supplemental cash flow information on non-cash investing and financing activities** |  |  |  |
|  Deferred financing costs in accounts payable and accrued expenses | 921 |  | 921 |
|  Change in fair value of RTW Convertible Notes through OCI | (1420) | 2840 | 1420 |
|  Change in fair value of Revenue Interest Financing through OCI | (3020) | 6040 | 3020 |

---

------

##### [**Table of Contents**](#toc)
The effects of the restatements on the condensed consolidated financial statements as of and for the three months ended March 31, 2024 are as follows:

**Restated Condensed Consolidated Statement of Operations** 

(dollars in thousands)

---

| | | | |
|:---|:---|:---|:---|
|  | **Three months ended March 31, 2024** | **Three months ended March 31, 2024** | **Three months ended March 31, 2024** |
|  | **As Reported** | **Adjustment** | **As Restated** |
|  Revenue | $9386 | $— | $9386 |
|  Cost of revenue | 2520 |  | 2520 |
|  Gross profit | 6866 |  | 6866 |
|  Operating expenses: |  |  |  |
|  Sales and marketing | 6145 |  | 6145 |
|  Research and development | 5725 |  | 5725 |
|  General and administrative | 6386 |  | 6386 |
|  Total operating expenses: | 18256 |  | 18256 |
|  Loss from operations | (11390) |  | (11390) |
|  Other income (expense): |  |  |  |
|  Interest expense | (1931) |  | (1931) |
|  Changes in fair value of warrants | 3131 |  | 3131 |
|  Changes in fair value of Revenue Interest Financing and PIPE Conversion Option | 1490 | (3590) | (2100) |
|  Changes in fair value of earn-out liabilities | 14190 |  | 14190 |
|  Other income (expense), net | 172 |  | 172 |
|  Total other income (expense): | 17052 | (3590) | 13462 |
|  Income (loss) before income taxes | 5662 | (3590) | 2072 |
|  Provision for income taxes | (76) |  | (76) |
|  Net income (loss) | $5586 | $(3590) | $1996 |
|  Net income (loss) per share |  |  |  |
|  Basic | $2.92 | $(1.88) | $1.04 |
|  Diluted | $2.78 | $(1.82) | $0.96 |
|  Weighted-average shares outstanding |  |  |  |
|  Basic | 1911181 |  | 1911181 |
|  Diluted | 1967885 |  | 1967885 |

---

**Restated Condensed Consolidated Statement of Comprehensive Income** 

(dollars in thousands)

---

| | | | |
|:---|:---|:---|:---|
|  | **Three months ended March 31, 2024** | **Three months ended March 31, 2024** | **Three months ended March 31, 2024** |
|  | **As Reported** | **Adjustment** | **As Restated** |
|  Net income (loss) | $5586 | $(3590) | $1996 |
|  Other comprehensive income (loss): |  |  |  |
|  Change in fair value of Revenue Interest Financing due to change in credit risk | (2200) | 4400 | 2200 |
|  Comprehensive income | $3386 | $810 | $4196 |

---

------

##### [**Table of Contents**](#toc)
**Restated Condensed Consolidated Statement of Cash Flows** 

(dollars in thousands)

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31, 2024** | **Three Months Ended March 31, 2024** | **Three Months Ended March 31, 2024** |
|  | **As<br>Reported** | **Adjustment** | **As<br>Restated** |
|  **Operating Activities:** |  |  |  |
|  Net income (loss) | $5586 | $(3590) | $1996 |
|  Adjustments to reconcile net income (loss) to net cash used in operating activities: |  |  |  |
|  Non-cash lease expense | 199 |  | 199 |
|  Depreciation and amortization | 367 |  | 367 |
|  Stock-based compensation | 552 |  | 552 |
|  Unrealized exchange (gain) or loss | 314 |  | 314 |
|  Provision for inventory | 209 |  | 209 |
|  Change in fair value of warrant liabilities | (3131) |  | (3131) |
|  Change in fair value of derivative liabilities | 62 |  | 62 |
|  Change in fair value of Revenue Interest Financing and PIPE Conversion Option | (1490) | 3590 | 2100 |
|  Change in fair value of earn-out liabilities | (14190) |  | (14190) |
|  Non-cash interest expense | 315 |  | 315 |
|  Changes in operating assets and liabilities: |  |  |  |
|  Accounts receivable | 1673 |  | 1673 |
|  Inventory | 330 |  | 330 |
|  Prepaid expenses, other current and long-term assets | 244 |  | 244 |
|  Lease liabilities | (238) |  | (238) |
|  Accounts payable | 1551 |  | 1551 |
|  Accrued expenses and other current liabilities | (989) |  | (989) |
|  Net cash used in operating activities | $(8636) | $— | $(8636) |
|  **Investing Activities:** |  |  |  |
|  Purchases of property and equipment | (104) |  | (104) |
|  Net cash used in investing activities | $(104) | $— | $(104) |
|  **Financing Activities:** |  |  |  |
|  Proceeds from issuance of convertible notes—net |  |  |  |
|  Proceeds from option and warrant exercises | 9 |  | 9 |
|  Proceeds from equity line financing | 378 |  | 378 |
|  Payment of deferred financing costs |  |  |  |
|  Net cash provided by financing activities | $387 | $— | $387 |
|  Net increase (decrease) in cash and cash equivalents and restricted cash | (8353) |  | (8353) |
|  Cash and cash equivalents and restricted cash at beginning of period | 38421 |  | 38421 |
|  Cash and cash equivalents and restricted cash at end of period | $30068 | $— | $30068 |
|  **Supplemental disclosure of cash flow information** |  |  |  |
|  Cash paid for interest | $1831 | $— | $1831 |
|  **Supplemental cash flow information on non-cash investing and financing activities** |  |  |  |
|  Purchase of property and equipment included in accounts payable | $73 | $— | $73 |
|  Change in fair value of Revenue Interest Financing through OCI | (2200) | 4400 | 2200 |

---

The impacts of the restatements have been reflected throughout these condensed consolidated financial statements, including Notes 9, 10, 11, 12, 14, and 18.

**3.** **Summary of Significant Accounting Policies** 

There have been no significant changes to the significant accounting policies disclosed in Note 3 of the "Notes to Consolidated Financial Statements" to the consolidated audited financial statements as of and for the year ended December 31, 2024 included in our Annual Report on Form 10-K.

------

##### [**Table of Contents**](#toc)
***Use of Estimates***

The preparation of these condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ from those estimates.

***Risk of Concentration of Credit, Significant Customers and Significant Suppliers***

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable, net. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash, cash equivalents and restricted cash with financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

Significant customers are those that represent more than 10% of the Company's total revenue for the three months ended March 31, 2025 and 2024 or its accounts receivable, net balance as of March 31, 2025 and December 31, 2024. The following table presents customers that represent 10% or more of the Company's total revenue and accounts receivable, net:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Revenue** | **Revenue** | **Accounts Receivable** | **Accounts Receivable** |
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **March 31,** | **December 31,** |
|  | **2025** | **2024** | **2025** | **2024** |
|  Customer A | 11% | N/A | 13% | N/A |
|  Customer B | N/A | N/A | 10% | 14% |

---

The Company relies on third parties for the supply of parts and components for its products as well as third-party logistics providers. In instances where these parties fail to perform their obligations, the Company may be unable to find alternative suppliers of parts and components to satisfactorily deliver its products to its customers on time, if at all, which could have a material adverse effect on the Company's operating results, financial condition and cash flows and damage its customer relationships.

***Recently Adopted Accounting Pronouncements***

In August 2020, the FASB issued ASU 2020-06, *Debt with Conversion and Other Options and Derivatives and Hedging-Contracts in Entity's Own Equity,* which simplifies the accounting for convertible instruments. The guidance removes certain accounting models that separate the embedded conversion features from the host contract for convertible instruments. The Company adopted ASU 2020-06 effective January 1, 2024 under the modified retrospective method of transition approach. The adoption of ASU 2020-06 did not have an impact on the Company's condensed consolidated financial statements.

In November 2023, the FASB issued ASU 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*, which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The adoption of this standard did not have a material impact on the Company's disclosures.

***Recently Issued Accounting Pronouncements Not Yet Adopted***

In December 2023, the FASB issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company's condensed consolidated financial statements and related disclosures.

**4.** **Business Combination** 

As discussed in Note 1, *Organization and Basis of Presentation*, on August 1, 2023 the Company consummated the Business Combination with Compute Health pursuant to the Business Combination Agreement. The Business Combination was accounted for

------

##### [**Table of Contents**](#toc)
as a reverse capitalization in accordance with U.S. GAAP. Under this method of accounting, Compute Health, which was the legal acquirer, was treated as the "acquired" company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of Allurion issuing stock for the net assets of Compute Health, accompanied by a recapitalization.

Upon the closing of the Business Combination, (a) holders of Legacy Allurion common stock received shares of Allurion Common Stock in an amount determined by application of the Exchange Ratio of approximately 0.9780 (the Exchange Ratio established in the Business Combination is prior to the Reverse Stock Split and did not change as a result of the Reverse Stock Split), (b) each then-outstanding share of Legacy Allurion preferred stock was converted into the right to receive shares of Allurion Common Stock equal to the number of shares of Legacy Allurion common stock that would be issued upon conversion of such outstanding share of Legacy Allurion preferred stock based on the applicable conversion ratio multiplied by the Exchange Ratio, (c) each then-outstanding and unexercised Legacy Allurion option was converted into a new Allurion option on the same terms and conditions as were applicable to such Legacy Allurion option based on the Exchange Ratio, (d) each then-outstanding Legacy Allurion warrant was converted into a new Allurion warrant based on the Exchange Ratio ("Rollover Warrant"), (e) each then-outstanding Legacy Allurion restricted stock unit was converted into a rollover restricted stock unit based on the Exchange Ratio, and (f) certain amounts of loans made by Compute Health Sponsor LLC (the "Sponsor") to CPUH, which balance was $3.7 million at the time of the Business Combination, were converted into 21,023 shares of Allurion Common Stock (as adjusted for the Reverse Stock Split). For periods prior to the Business Combination, the reported share and per share amounts have been retroactively converted by applying the Exchange Ratio. The consolidated assets, liabilities, and results of operations prior to the Business Combination are those of Legacy Allurion.

Further, upon the closing of the Business Combination, each then-outstanding share of Compute Health Class A common stock was canceled and extinguished and was converted into the right to receive 1.420455 shares of Allurion Common Stock. Additionally, the Company assumed 13,206,922 outstanding public warrants to purchase an aggregate 750,394 shares of Allurion Common Stock at $202.50 per share.

In connection with the Business Combination, the Company incurred approximately $22.7 million of transaction costs, consisting of legal and other professional fees, of which $15.2 million was recorded to additional paid-in capital as a reduction of proceeds, $2.5 million was recorded as debt issuance costs in connection with the Fortress Term Loan (as defined below), and $5.0 million was recorded as an expense in general and administrative expenses on the condensed consolidated statement of operations and comprehensive loss. Of the $5.0 million recorded as general and administrative expenses, $3.6 million relates to a one-time insurance payment related to any potential matters that might arise from the period prior to the Business Combination, and as such is not capitalized as an asset. An additional $1.2 million relates to direct costs and fees incurred as part of the Revenue Interest Financing with RTW (as defined below).

The following table reconciles the elements of the Business Combination to the condensed consolidated statement of cash flows and the condensed consolidated statement of changes in equity:

---

| | |
|:---|:---|
|  | **December 31, 2023** |
|  Cash—CPUH trust (net of redemptions) | $38395 |
|  Cash—PIPE Investors | 37922 |
|  Gross Proceeds | 76317 |
|  Less: transaction costs paid | (14665) |
|  Net proceeds from the Business Combination | 61652 |
|  Less: warrant liabilities assumed | (13762) |
|  Less: repayment of note assumed in the Business Combination | (2500) |
|  Less: accrued transaction costs at December 31, 2023 | (580) |
|  Business Combination, net of transaction costs | $44810 |

---

------

##### [**Table of Contents**](#toc)
The number of shares of Allurion Common Stock outstanding immediately following the consummation of the Business Combination was as follows:

---

| | |
|:---|:---|
|  | **Common Stock** |
|  Legacy Allurion Equityholders (1) | 1115896 |
|  CPUH Stockholders (2) | 206628 |
|  Shares Issued to PIPE Investors (2) | 215468 |
|  Shares issued to RTW and Fortress (3) | 76000 |
|  Shares issued to convertible note holders | 132049 |
|  CPUH Sponsor Shares (2) | 130509 |
|  Side Letter Termination Shares (3) | 15508 |
|  Total shares of Common Stock immediately after Business Combination | 1892058 |

---

(1) Consists of Legacy Allurion common stock and Legacy Allurion preferred stock, plus the issuance of Allurion
Common Stock in connection with the vesting of RSUs at closing, less the Gaur Trust Contributed Shares (as defined below).

(2) The CPUH Stockholders shares, PIPE shares, and CPUH Sponsor shares are presented combined within the condensed
consolidated statements of stockholders deficit on the "Reverse recapitalization, net of transaction costs" line, which is less the Gaur Trust Contributed Shares.

(3) The shares issued to RTW and Fortress and the Side Letter Termination shares are presented combined within the
condensed consolidated statements of stockholders deficit on the "Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and additional RTW and Fortress shares and issuance of related shares"
line.

***PIPE Investment***

In connection with the execution of the Business Combination Agreement, Allurion and Compute Health entered into subscription agreements, each dated February 9, 2023, with certain accredited investors and qualified institutional buyers (the "PIPE Investors"), pursuant to which, upon the terms and subject to the conditions set forth therein, the PIPE Investors, among other things, purchased an aggregate of 215,468 shares of Allurion Common Stock at a purchase price of $176.00 per share (other than as set forth in the Amended and Restated RTW Side Letter, as defined below), for an aggregate purchase price of $37.9 million, following the CPUH Merger Effective Time (the "PIPE Investment").

***Revenue Interest Financing Agreement, Side Letter and PIPE Conversion Option***

On February 9, 2023, concurrently with the execution of the Business Combination Agreement, the Company entered into the Revenue Interest Financing Agreement (as amended, the "Revenue Interest Financing Agreement") with certain entities that engaged RTW Investments, LP (together with its affiliates, "RTW") as investment manager (the "Revenue Interest Financing"). Pursuant to the Revenue Interest Financing Agreement, at the closing of the Business Combination, RTW paid Allurion an aggregate of $40.0 million (the "Investment Amount"). In exchange for the Investment Amount, Allurion will remit revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to 6.0% of annual net sales prior to December 31, 2026. On or after January 1, 2027, the Company will remit revenue interest payments at a rate up to 10.0% of annual net sales, and it will continue to make revenue interest payments to RTW until December 31, 2030. The Revenue Interest Financing Agreement was amended pursuant to the RIFA Amendment (as defined below) on April 14, 2024. The RIFA Amendment, among other things, increased the rate of revenue interest payments to be paid to RTW on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries. Refer to Note 10, *Revenue Interest Financing, Side Letter, and PIPE Conversion Option* below for further discussion on the Revenue Interest Financing.

Additionally, in connection with the Company entering into the Revenue Interest Financing Agreement, the Company, Compute Health, Legacy Allurion, Merger Sub II and RTW entered into a side letter (the "RTW Side Letter") on February 9, 2023 under which RTW was granted the right to elect to convert up to $7.5 million of its initial PIPE Investment into an additional revenue interest financing by forfeiting a number of shares of Allurion Common Stock acquired by its PIPE Investment. Refer to Note 10, *Revenue Interest Financing, Side Letter, and PIPE Conversion Option* below for further discussion on the Revenue Interest Financing.

On May 2, 2023, the parties amended and restated the RTW Side Letter (as amended, the "Amended and Restated RTW Side Letter"), in connection with the Backstop Agreement (defined below), pursuant to which, among other things, Allurion issued 10,000 shares of Allurion Common Stock to RTW immediately prior to the Intermediate Merger Effective Time.

On October 22, 2024, funds affiliated with RTW provided notice to the Company of their election under the Amended and Restated RTW Side Letter, to surrender 30,000 shares of Common Stock of the Company representing $7.5 million in consideration for the New RIFA (as defined below).

------

##### [**Table of Contents**](#toc)
***Fortress Credit Agreement***

In connection with the closing of the Business Combination, the Company entered into a term loan facility (the "Fortress Term Loan") pursuant to a Credit Agreement and Guaranty, dated as of August 1, 2023 (the "Fortress Credit Agreement"), with Fortress Credit Corp. ("Fortress"), as administrative agent for the lenders party thereto from time to time. Under the terms of the Fortress Term Loan, we borrowed $60.0 million, which was used to repay the outstanding principal, accrued and unpaid interest, and other obligations with respect to the 2021 Term Loan (as defined below). Additionally, per the terms of the Fortress Term Loan and Backstop Agreement (as defined below), Allurion issued an aggregate of 38,000 shares of Allurion Common Stock to an affiliate of Fortress pursuant to a subscription agreement between Allurion and such affiliate. Refer to Note 9, *Debt* for further discussion on the Fortress Term Loan.

***Backstop Agreement***

On May 2, 2023, CFIP2 ALLE LLC, an affiliate of Fortress Credit Corp., and RTW (collectively, the "Backstop Purchasers"), Legacy Allurion, Allurion and Hunter Ventures Limited ("HVL") entered into the backstop agreement (the "Backstop Agreement"). Pursuant to the Backstop Agreement, immediately prior to the Intermediate Merger Closing, (a) each Backstop Purchaser purchased $2 million of the aggregate principal amount outstanding of HVL's Legacy Allurion convertible note issued in February 2023, (b) Allurion canceled the existing HVL Legacy Allurion Convertible Note and issued a new Allurion Convertible Note to HVL for the remaining balance together with all unpaid interest accrued since the date of issuance thereof, (c) Allurion issued new Allurion Convertible Notes to each Backstop Purchaser with an issuance date of August 1, 2023 and an original principal amount of $2 million each and (d) Allurion issued 28,000 shares of Allurion Common Stock to each Backstop Purchaser. Refer to Note 9, *Debt* for further discussion around the Backstop Agreement.

***HVL Termination Agreement***

On May 2, 2023, HVL and Legacy Allurion entered into a letter agreement (the "HVL Termination Agreement"), terminating the side letter agreement entered into between Legacy Allurion and HVL in connection with the issuance of HVL's Legacy Allurion Convertible Note on February 15, 2023. Pursuant to the HVL Termination Agreement, among other things, at the closing of the Business Combination, upon the terms and subject to the conditions set forth therein, Allurion issued to HVL 15,508 shares of Allurion Common Stock. Refer to Note 9, *Debt* for further discussion regarding the HVL Termination Agreement.

***Gaur Contribution Agreement***

On May 2, 2023, Shantanu K. Gaur and Neha Gaur, trustees of The Shantanu K. Gaur Revocable Trust of 2021 (the "Gaur Trust") and Allurion entered into a contribution agreement (the "Gaur Contribution Agreement"), pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, the Gaur Trust contributed to Allurion, as a contribution of capital, 3,170 shares of Allurion Common Stock (the "Gaur Trust Contributed Shares"). The Gaur Trust's contribution of the Gaur Trust Contributed Shares was effective immediately following the consummation of the Business Combination and the issuance of shares of Allurion Common Stock to the Gaur Trust pursuant to the terms of the Business Combination Agreement.

***RSU Forfeiture Agreement***

On May 2, 2023, Krishna Gupta, a member of the Company's Board, entered into a letter agreement with Legacy Allurion (the "RSU Forfeiture Agreement"), pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, Mr. Gupta agreed to forfeit 3,170 restricted stock units of Allurion (the "Forfeited RSUs"). The Forfeited RSUs were terminated and cancelled without consideration therefore immediately following the closing of the Business Combination Agreement.

***Sponsor Contribution Agreement***

On May 2, 2023, the Sponsor and Compute Health entered into a letter agreement (the "Sponsor Contribution Agreement") pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, the Sponsor agreed to contribute to Compute Health, as a contribution of capital, 161,379 shares of Compute Health Class A Common Stock ("Sponsor Contributed Shares"). The Sponsor's contribution of the Sponsor Contributed Shares was made immediately following the CPUH Recapitalization (defined below) and immediately prior to the CPUH Merger Effective Time.

***Sponsor Support Agreement***

On February 9, 2023, Allurion entered into a support agreement (the "Sponsor Support Agreement"), pursuant to which immediately prior to the CPUH Merger Effective time, (a) the Sponsor recapitalized each of the Sponsor's 21,442,500 shares of Compute Health Class B Common Stock, and all 12,833,333 of the Sponsor's warrants to purchase shares of Class A Common Stock, into 2,088,327 shares of Compute Health Class A Common Stock and (b) the additional Class B Holders set forth on Schedule I of the Sponsor Support Agreement recapitalized his or her 30,000 shares of Compute Health Class B Common Stock into 21,120 shares of Compute Health Class A Common Stock (the "CPUH Recapitalization"). Subsequently, at the CPUH Merger Effective Time, each such share of Compute Health Class A Common Stock was converted into shares of Allurion Common Stock at an exchange ratio of 1.420455, prior to giving effect to the Reverse Stock Split.

------

##### [**Table of Contents**](#toc)
***Conversion of Convertible Notes***

In connection with the closing of the Business Combination, outstanding Legacy Allurion Convertible Notes with an aggregate principal amount together with accrued but unpaid interest of approximately $21.8 million were converted into 132,049 shares of Allurion Common Stock with a corresponding recognition of additional paid-in capital ("APIC") of $25.6 million provided for under the terms of such Legacy Allurion Convertible Notes, and are no longer outstanding. Refer to Note 9, *Debt* for further information on the Company's convertible notes.

***Public Warrants and Warrant Amendment***

In connection with the closing of the Business Combination, the Company assumed 13,206,922 outstanding public warrants (the "Public Warrants") to purchase an aggregate 750,394 shares of Allurion Common Stock at $202.50 per share following the Warrant Amendment (defined below). The total value of the liability associated with the Public Warrants was $13.8 million measured at fair value based on the public warrant quoted price. The Company concluded the warrants met the definition of a liability based on the settlement provision that allows the warrant holders to net-share settle their warrants in the event of a failed registration statement within 60 days of the Business Combination or any time a registration is not effective. As such, they have been classified as a liability on the balance sheet. See Note 13, *Capital Stock and Stockholders' Deficit* and Note 11, *Fair Value Measurements* for further information on the Public Warrants and Warrant Amendment.

***Earn-Out Liabilities***

In connection with the closing of the Business Combination, Legacy Allurion equity holders are entitled to receive additional shares of Allurion Common Stock if the share price achieves certain targets (the "Earn-Out Shares"). The Company accounts for the potential issuance of the Earn-Out Shares as a contingent consideration arrangement, which was initially valued and recorded at $53.0 million. See Note 11, *Fair Value Measurements* for further information on the earn-out liabilities.

**5.** **Revenue** 

Revenue by geographic region is based on the country in which our customer is located and is summarized by geographic area as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months<br>Ended March 31,** | **Three Months<br>Ended March 31,** |
|  | **2025** | **2024** |
|  Spain | $749 | $1112 |
|  Egypt | 600 |  |
|  France |  | 1671 |
|  United Kingdom | 81 | 1256 |
|  All Other Countries | 4150 | 5347 |
|  Total Revenues | $5580 | $9386 |

---

There is currently no revenue generated in the United States from sales of the Allurion Balloon. For the three months ended March 31, 2025, $1.8 million of revenue was generated in five countries included within All Other Countries in the table above, representing approximately 32% of Total Revenues, with each country responsible for approximately 5% to 8% of the total. Remaining revenue was generated by sales in 29 other countries included within All Other Countries. For the three months ended March 31, 2024, $2.9 million of revenue was generated in five countries included within All Other Countries, representing approximately 31% of Total Revenues, with each country responsible for approximately 2% to 9% of the total. Remaining revenue was generated by sales in 38 other countries included within All Other Countries.

**6.** **Inventory** 

Inventory consists of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2025** | **December,<br>31 2024** |
|  Finished goods | $1352 | $1789 |
|  Work in progress | 1155 | 763 |
|  Raw materials | 845 | 848 |
|  Total Inventory | $3352 | $3400 |

---

------

##### [**Table of Contents**](#toc)
Inventory is stated net of $1.6 million for the provision for excess and obsolete inventory as of March 31, 2025 and December 31, 2024.

**7.** **Property and Equipment, net** 

Property and equipment consist of the following (in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | **Estimated Useful Life<br>(in Years)** | **March 31,<br>2025** | **December 31,<br>2024** |
|  Computers and purchased software | 3 | $618 | $618 |
|  Leasehold improvements | Shorter of useful life<br>or lease term | 1943 | 1943 |
|  Furniture and fixtures | 5 | 291 | 291 |
|  Machinery and equipment | 3-5 | 3960 | 3960 |
|  Property and equipment-at cost |  | 6812 | 6812 |
|  Less accumulated depreciation and amortization |  | (4529) | (4357) |
|  Construction in progress |  | 14 | 14 |
|  Property and equipment-net |  | $2297 | $2469 |

---

Depreciation expense was $0.2 million and $0.4 million for each of the three months ended March 31, 2025 and 2024, respectively, recorded as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2025** | **2024** |
|  Cost of revenue | $127 | $201 |
|  Research and development | 55 | 49 |
|  General and administrative | 8 | 64 |
|  Sales and marketing | 13 | 53 |
|  Total depreciation and amortization expense | $203 | $367 |

---

**8.** **Accrued Expenses and Other Current Liabilities** 

Accrued expenses and other current liabilities consist of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2025** | **December 31,<br>2024** |
|  Marketing reimbursement | $910 | $821 |
|  Accrued compensation | 1524 | 1046 |
|  Accrued selling and marketing | 140 | 91 |
|  Accrued professional fees | 729 | 1164 |
|  Accrued warranty | 14 | 14 |
|  Accrued restructuring | 2703 | 3165 |
|  Other accrued expenses | 4072 | 5121 |
|  Total accrued expenses and other current liabilities | $10092 | $11422 |

---

In November 2024, the Company's management approved and initiated plans to reduce its cost structure. The Company recorded $3.9 million of restructuring charges and ($0.2) million of restructuring credits, and paid $0.3 million and $0.8 million of restructuring charges during the three months ended March 31, 2025 and the year ended December 31, 2024, respectively, related to this restructuring plan. The restructuring plan initiated during the year ended December 31, 2024 is expected to the be completed during the first half of 2025. Substantially all of the charges represent the severance cost of terminated employees, and are included in

------

##### [**Table of Contents**](#toc)
cost of revenue and operating expenses in the statement of operations. The following table rolls forward the activity in the restructuring accrual for the November 2024 action through the three months ended March 31, 2025:

---

| | |
|:---|:---|
|  Accrual at December 31, 2023 | $— |
|  Restructuring charges and related costs | 3953 |
|  Cash payments | (788) |
|  Accrual at December 31, 2024 | 3165 |
|  Restructuring charges and related costs | (266) |
|  Cash payments | (196) |
|  Accrual at March 31, 2025 | $2703 |

---

**9.** **Debt** 

The components of the Company's third-party debt consist of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2025** | **December 31,<br>2024** |
|  RTW Convertible Notes | $50820 | $50069 |
|  Total principal amounts of debt | 50820 | 50069 |
|  Change in fair value | (19860) | (14359) |
|  Long-term debt, net of current portion and discounts | $30960 | $35710 |

---

***Term Loans***

*2021 Term Loan*

In March 2021, the Company entered into a loan and security agreement (as amended, the "2021 Term Loan" and the "2021 Term Loan Agreement") with Runway Growth Credit Fund, Inc. that provided for borrowings up to $25.0 million.

In December 2021, the 2021 Term Loan Agreement was amended (the "2021 Term Loan Amendment") to extend the maturity date of the 2021 Term Loan to December 30, 2025 and provide for an additional $20.0 million of borrowings. In December 2021, the Company issued warrants exercisable for 132,979 shares of Legacy Allurion Series C preferred stock as consideration for the 2021 Term Loan Amendment and the draw down related to the 2021 Term Loan Agreement. The fair value of these warrants was determined to be $0.3 million upon issuance and are classified as a warrant liability on the condensed consolidated balance sheet as of March 31, 2025 and December 31, 2024 (see Note 11, *Fair Value Measurements*). Upon the closing of the Business Combination and after giving effect to the Reverse Stock Split, these warrants were converted into warrants exercisable for 5,203 shares of Allurion Common Stock.

In June 2022, the 2021 Term Loan Agreement was amended to revise definitional terms for certain milestone events, the final payment amount, and certain financial covenants. In September 2022, the 2021 Term Loan Agreement was further amended to, among other things, increase additional borrowing up to $15.0 million.

During June through December of 2022, the Company drew an additional $30.0 million of the 2021 Term Loan and issued warrants exercisable for 88,440 shares of Series D-1 preferred stock. The fair value of these warrants was determined to be $0.8 million upon issuance and are classified as a warrant liability on the condensed consolidated balance sheets as of March 31, 2025 and December 31, 2024 (see Note 11, *Fair Value Measurements*). Upon the closing of the Business Combination and after giving effect to the Reverse Stock Split, the warrants exercisable for 88,440 shares of Series D-1 preferred stock were converted into warrants exercisable for 3,620 shares of Allurion Common Stock.

On August 1, 2023, the 2021 Term Loan was paid off using the proceeds from the Fortress Term Loan (see below). The total payoff amount was $58.0 million, consisting of $55.0 million repayment of principal, a $1.1 million prepayment fee, and a $1.6 million final payment fee. The prepayment fee was calculated as 2% of the outstanding principal balance as of August 1, 2023. The final payment fee was calculated as 3% of the outstanding principal balance as of August 1, 2023 less the original final payment of $0.1 million. The Company recorded a $3.9 million loss on extinguishment of debt in connection with the 2021 Term Loan repayment.

------

##### [**Table of Contents**](#toc)
*Fortress Term Loan* 

On August 1, 2023, the Company entered into the Fortress Term Loan pursuant to the Fortress Credit Agreement with Fortress that provided gross proceeds of $60 million. The Fortress Term Loan had a maturity date of June 30, 2027 and accrued interest per annum at a rate of 6.44% plus the greater of (i) the Wall Street Journal Prime Rate and (ii) 3.0%, which interest was payable in arrears on a monthly basis. The Fortress Term Loan provided for an exit payment equal to 3.0% of the Fortress Term Loan (the "Exit Fee") due upon prepayment or the maturity date of the Fortress Term Loan, in addition to any early prepayment fee. The Exit Fee is treated as additional interest expense and is accreted over the life of the loan using the effective interest method. Proceeds of the Fortress Term Loan were used, in part, to repay all amounts outstanding under the 2021 Term Loan. In connection with the issuance of the Fortress Term Loan, the Company paid issuance costs of $2.5 million, which were recorded as a debt discount and amortized over the remaining life of the loan.

On December 29, 2023, the Company entered into an amendment to the Fortress Credit Agreement (the "Fortress Amendment"). The Fortress Amendment waived the December 31, 2023 minimum revenue covenant under the Fortress Credit Agreement and modified the minimum liquidity covenant by increasing the minimum liquidity amount from $12.5 million to $33.5 million until March 31, 2024, $23.5 million from April 1, 2024 to June 30, 2024, $16.9 million from July 1, 2024 to September 30, 2024 and $12.5 million on October 1, 2024 and thereafter. The Fortress Amendment also provided that at any time after March 31, 2024, each lender had the right to convert a portion of the outstanding principal amount, not to exceed the lender's proportionate share of a maximum of $20.0 million in aggregate outstanding principal amount, into shares of Allurion Common Stock at a conversion price based on the 30-day volume weighted average price ("VWAP") of Allurion Common Stock on the NYSE ending on the trading day immediately preceding the date of exercise of the lender's conversion right. As part of the Fortress Amendment, the Company prepaid $20.0 million of the principal outstanding under the Fortress Credit Agreement. Additionally, $3.1 million of fees were incurred and considered paid-in-kind and capitalized as an additional debt discount and added to the outstanding principal amount of the loans under the Fortress Amendment. The fees were amortized through interest expense over the remaining life of the loan. The Fortress Amendment was accounted for as a modification under ASC 470, *Debt*. In connection with the modification and related prepayment, the Company wrote off $0.8 million of the unamortized debt issuance costs, which was recorded within interest expense on the condensed consolidated statement of operations for the year ended December 31, 2023.

The Company assessed the terms and features of the Fortress Credit Agreement in order to identify any potential embedded features that would require bifurcation or any beneficial conversion features. The terms and features assessed included, under certain circumstances, a default interest rate of 3% that would apply to all outstanding obligations during the occurrence and continuance of an event of default. In accordance with ASC 815, *Derivatives and Hedging* ("ASC 815"), the Company concluded that this feature is not clearly and closely related to the host instrument and represents an embedded derivative (the "Term Loan Derivative Liability") that is required to be re-measured at fair value on a quarterly basis. At the inception of the Fortress Term Loan, the fair value of the embedded derivative was determined to be immaterial. The Term Loan Derivative Liability was fair valued to zero in connection with the repayment of the Fortress Term Loan, with a corresponding $2.0 million gain recorded in other income, net in the condensed consolidated statement of operations for the year ended December 31, 2024.

On April 16, 2024, the Company repaid all outstanding obligations under the Fortress Term Loan with proceeds from the Amended Note Purchase Agreement (as defined below) with RTW. The total payoff amount was $48.0 million, consisting of $43.1 million repayment of principal, a $2.7 million prepayment fee, a $1.3 million exit fee, $0.6 million of other fees paid directly to Fortress, and $0.3 million of accrued interest. The Company recorded an $8.7 million loss on extinguishment of debt in connection with the Fortress Term Loan repayment in the condensed consolidated statement of operations for year ended December 31, 2024.

Interest expense for the three months ended March 31, 2024 related to the Fortress Term Loan was $1.9 million, consisting of $1.6 million of contractual interest, $0.2 million amortization of the debt discount, and term loan accretion of $0.1 million. The average interest rate during the three months ended March 31, 2024 was 14.94%.

***Convertible Notes***

*2021 Convertible Notes*

In December 2021, the Company entered into a convertible note agreement with investors for gross proceeds of $2.0 million with a stated interest rate of 5.0% per annum (the "2021 Convertible Notes") and a maturity date 36 months from the date of issuance unless previously converted pursuant to their terms of the agreement. No issuance costs were incurred.

The 2021 Convertible Notes provided that, effective upon either a Special Purpose Acquisition Company (i.e. "deSPAC") transaction, closing of a qualified financing, or closing of a non-qualified financing, all of the outstanding principal and interest would automatically convert into shares of Legacy Allurion common stock or shares of the same class or series of capital stock issued in the qualified financing in an amount equal to the balance of the 2021 Convertible Notes on the date of conversion divided by the capped conversion price, calculated by dividing $600.0 million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2021 Convertible Notes.

------

##### [**Table of Contents**](#toc)
On August 1, 2023, in connection with the closing of the Business Combination and after giving effect to the Reverse Stock Split, the outstanding 2021 Convertible Notes were converted into an aggregate 5,345 shares of Allurion Common Stock with a corresponding recognition of APIC of $2.2 million, and are no longer outstanding.

*2022 Convertible Notes*

In January 2022, the Company entered into a convertible note purchase agreement with investors for gross proceeds of $1.1 million with a stated interest rate of 5.0% per annum (the "2022 Convertible Notes"). The 2022 Convertible Notes were to mature 36 months from the issuance date unless previously converted pursuant to the terms of the agreement. Issuance costs were de minimis. The 2022 Convertible Notes had the same terms as the 2021 Convertible Notes.

On August 1, 2023, in connection with the closing of the Business Combination and after giving effect to the Reverse Stock Split, the outstanding 2022 Convertible Notes were converted into an aggregate 3,329 shares of Allurion Common Stock with a corresponding recognition of APIC of $1.2 million, and are no longer outstanding.

*2023 Convertible Notes*

Between February and August 2023, the Company entered into a convertible note purchase agreement, and related side letters, for the sale of convertible notes (the "2023 Convertible Notes") to certain investors for gross proceeds of $28.7 million, with a stated interest rate of 7.0% per annum. The 2023 Convertible Notes provided that they would mature on December 31, 2026 unless previously converted pursuant to the terms of the note purchase agreement. The 2023 Convertible Notes also provided that, effective upon a deSPAC transaction, all of the outstanding principal and interest would automatically convert into a number of shares of Legacy Allurion common stock equal to the balance of the 2023 Convertible Notes on the date of conversion divided by the discounted capped conversion price, calculated by dividing $217.3 million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2023 Convertible Notes.

Additionally, the 2023 Convertible Notes provided that, effective upon the closing of a qualified financing, holders of the 2023 Convertible Notes could optionally accelerate repayment of the principal and interest of the 2023 Convertible Notes or convert all of the outstanding principal and interest into shares of Legacy Allurion common stock or shares of the same class or series of capital stock issued in the qualified financing equal to the balance of the 2023 Convertible Notes on the date of conversion divided by the greater of the capped price or the discounted price. The capped price is calculated by dividing $260.0 million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2023 Convertible Notes, and the discounted price is calculated as 85% of the cash price of the same class or series of capital stock issued in the qualified financing. The 2023 Convertible Notes were accounted for under the fair value option ("FVO") election of ASC 825 as the notes contain embedded derivatives, including the automatic conversion upon a deSPAC transaction prior to the deSPAC deadline, voluntary conversion upon a qualified financing, automatic repayment upon a sale event, and conversion rate adjustment, which would require bifurcation and separate accounting. These convertible notes are initially measured at their issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date.

On May 2, 2023 the Company entered into termination agreements (the "Termination Agreements") with respect to side letters entered into with certain holders of the 2023 Convertible Notes. With respect to the Termination Agreement with HVL, the Company had the right to prepay, in one or more transactions, all or a portion of the outstanding principal amount, plus accrued interest, under such holder's 2023 Convertible Note (the "HVL Bridge Note"), including by way of (a) a $2.0 million payment in cash by the Company to HVL on May 2, 2023, $1.5 million of which was deemed a prepayment penalty and recorded as other expense on the income statement, with the remaining $0.5 million recorded as a reduction of the principal amount, (b) immediately prior to the consummation of the transactions contemplated by the Business Combination Agreement, an additional payment of at least $6.0 million, up to the then-outstanding principal amount, plus accrued interest, under the HVL Bridge Note by way of (i) payment in cash by the Company and/or (ii) the sale and transfer of all or any portion of the HVL Bridge Note, equivalent in value to the portion of the additional payment to be repaid pursuant to this clause (b)(ii), to any person or persons designated in writing by the Company. The Termination Agreements were accounted for as a modification of debt and the modified convertible notes continued to be accounted for under the FVO with any change in fair value recognized in other expense on the income statement.

In addition, under the Termination Agreement executed with HVL, the Company agreed to issue to HVL a number of shares of Allurion Common Stock ("PubCo Additional Shares") equal to (a) the outstanding principal and accrued interest under the HVL Bridge Note immediately prior to the consummation of the transactions contemplated by the Business Combination Agreement (after giving effect to the payment of the repayments) divided by $125.00, plus (b) 12,000 shares of Allurion Common Stock. The PubCo Additional Shares were accounted for as a freestanding financing liability. The liability for the PubCo Additional Shares was initially measured at its issue-date estimated fair value and subsequently remeasured at fair value at each reporting period, with changes in fair value reflected in earnings until the PubCo Additional Shares were issued. A $3.4 million liability was recorded at issuance for the PubCo Additional Shares as Other liabilities on the balance sheet. On August 1, 2023, upon closing of the Business Combination and after giving effect to the Reverse Stock Split, HVL was issued 15,508 PubCo Additional Shares with a corresponding recognition of APIC of $2.7 million, and the liability is no longer outstanding.

------

##### [**Table of Contents**](#toc)
Further on May 2, 2023, RTW and Fortress as the Backstop Purchasers entered into the Backstop Agreement with the Company, Legacy Allurion and HVL. Pursuant to the Backstop Agreement, each Backstop Purchaser agreed that to the extent any HVL Bridge Notes remained outstanding prior to the consummation of the Business Combination, such Backstop Purchaser would, at the closing of the Business Combination, purchase up to $2.0 million of the HVL Bridge Notes from HVL in exchange for shares of Allurion Common Stock (the "Base PubCo Shares", "Backstop Shares" and "Conditional Additional PubCo Shares"). The Base PubCo Shares and Backstop Shares were accounted for as a freestanding financing liability. The Base PubCo Shares and Backstop Shares liability was initially measured at its issue-date estimated fair value and subsequently remeasured at fair value at each reporting period with changes in fair value reflected in earnings until the Base PubCo Shares and Backstop Shares were issued. A $3.3 million liability was recorded at issuance for the Base PubCo Shares and Backstop Shares liability as Other liabilities on the balance sheet. On August 1, 2023, upon closing of the Business Combination, per the terms of the Fortress Term Loan, the Amended and Restated RTW Side Letter and the Backstop Agreement, the Backstop Purchasers were each issued 38,000 shares of Allurion Common Stock with a corresponding recognition of APIC of $13.4 million, and the liability is no longer outstanding.

On August 1, 2023, immediately prior to the closing of the Business Combination, the Company repaid $6.3 million of the HVL Bridge Note, leaving a principal balance of $6.3 million. Each Backstop Purchaser then purchased $2.0 million principal amount of the outstanding portion of the HVL Bridge Note, Allurion canceled the existing HVL Bridge Note and issued a new convertible note to HVL for the remaining balance together with all unpaid interest accrued since the date of issuance of $2.7 million, Allurion issued convertible notes to each Backstop Purchaser with an issuance date of the Closing Date (August 1, 2023) and an original principal amount of $2.0 million each, and Allurion issued 28,000 shares (and after giving effect to the Reverse Stock Split) of Allurion Common Stock to each Backstop Purchaser. Additionally, the outstanding 2023 Convertible Notes were converted into an aggregate 123,376 shares of Allurion Common Stock and (after giving effect to the Reverse Stock Split) with a corresponding recognition of APIC of $22.2 million, and are no longer outstanding.

*RTW Convertible Notes* 

On April 14, 2024, the Company entered into a note purchase agreement (the "Original Note Purchase Agreement") with RTW as agent for the purchasers (the "Purchasers") party thereto from time to time (RTW in such capacity, the "Principal Purchaser"), and Acquiom Agency Services LLC ("Acquiom") as collateral agent for the Purchasers. Subsequently, on April 16, 2024, the Company, the Principal Purchaser, the Purchasers, and Acquiom entered into the First Amendment to the Original Note Purchase Agreement (the Original Note Purchase Agreement as amended, the "Amended Note Purchase Agreement").

Pursuant to the Amended Note Purchase Agreement, the Company issued and sold $48.0 million of convertible senior secured notes (the "RTW Convertible Notes"). The RTW Convertible Notes bear interest at an annual rate of 6%, which interest is paid quarterly in cash or, at the Company's option, in kind for the first three years. The RTW Convertible Notes will mature on April 16, 2031 unless previously converted pursuant to the terms of the Amended Note Purchase Agreement. The RTW Convertible Notes are convertible into shares of Allurion Common Stock, at a Purchaser's election at any time after the earliest of (i) the date on which Stockholder Approval (as defined below) is obtained, (ii) December 31, 2025, (iii) the date of a Fundamental Change Company Notice (as defined in the Amended Note Purchase Agreement), and (iv) the Make-Whole Fundamental Change Effective Date (as defined in the Amended Note Purchase Agreement), subject to certain terms and limitations in the Amended Note Purchase Agreement, based on a conversion rate of 24.6920 shares of Common Stock per $1,000 principal amount of Notes (equivalent to a conversion price of approximately $40.50 per share, which represents a 35% premium to the lowest price per share in an equity financing for capital raising purposes ending on the date on which the Company has raised aggregate gross offering proceeds of at least $15.0 million (the "Next Equity Financing"). On July 1, 2024, the Company consummated the Public Offering, as described elsewhere in this Quarterly Report on Form 10-Q/A, which constituted a Next Equity Financing. The Amended Note Purchase Agreement provides that unless and until requisite approval of the Company's stockholders is obtained ("Stockholder Approval"), the Company will not deliver Allurion Common Stock upon conversion of the RTW Convertible Notes in excess of 1% of the number of shares of Allurion Common Stock outstanding as of April 14, 2024. Stockholder Approval was obtained at the Company's Annual Meeting of Stockholders held on December 16, 2024.

On January 7, 2025, the Company and Allurion Technologies, LLC ("Allurion OpCo") entered into an Omnibus Amendment (the "Omnibus Amendment") with Allurion Australia Pty Ltd, Allurion France, and RTW to amend the Amended Note Purchase Agreement, the Revenue Interest Financing Agreement, and the New RIFA (collectively, the "Existing Documents").

The Omnibus Amendment requires, among other things, (i) the Company and Allurion OpCo to maintain certain minimum balances of unrestricted cash in controlled accounts in the U.S. in the amounts corresponding to the calculations set forth therein, and (ii) the Company to receive minimum trailing 12-month consolidated Revenue (as defined in the Amended Note Purchase Agreement) in amounts set forth therein, tested quarterly beginning with the 12-month period ending September 30, 2025. The Omnibus Amendment also requires that (i) Allurion France shall have successfully regained marketing authorization from the Agence Nationale de Sécurité du Médicament ("ANSM") in France on or prior to December 31, 2025 and (ii) Allurion OpCo shall have received Marketing Authorization from the U.S. Food & Drug Administration for the Commercialization of the Product in the United States no later than June 30, 2026.

------

##### [**Table of Contents**](#toc)
Pursuant to the Omnibus Amendment, the investors and the purchasers party thereto will receive a number of shares of the Company's Common Stock, representing in the aggregate five percent (5%) of the fully-diluted shares outstanding immediately after the closing of the offering and sale of Additional Shares (as defined in the Existing Documents) to be consummated no later than February 15, 2025, in connection with which the Company shall have raised at least $12.0 million aggregate net proceeds (the "Share Obligation"); provided that, in the event the Company cannot issue shares of Common Stock to the Investors and the Purchasers due to applicable law or NYSE listing rules, the Company will instead issue an equivalent (as-converted) number of shares of a newly created series of Series A-1 non-voting preferred stock (the "Series A-1 Preferred Stock") and the Company shall include a proposal in a definitive proxy statement on Schedule 14A seeking stockholder approval no later than December 31, 2025 to allow the conversion of Series A-1 Preferred Stock into Common Stock; provided further that, each share of Series A-1 Preferred Stock outstanding on December 31, 2026 will, except to the extent prohibited by Delaware law governing distributions to stockholders (including the Delaware General Corporation Law), be redeemed by the Company for cash in an amount equal to the as-converted value of the underlying Common Stock.

The RTW Convertible Notes are accounted for under the FVO election of ASC 825 as the notes contain embedded derivatives, including the conversion upon Stockholder Approval, the conversion upon a Fundamental Change Company Notice, the conversion upon a Make-Whole Fundamental Change, redemption upon the event of default, and redemption upon a Fundamental Change, which would require bifurcation and separate accounting. The RTW Convertible Notes were initially measured at their issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The fair value of the RTW Convertible Notes at issuance was $49.1 million, with a corresponding $1.1 million loss recognized in Other income (expense), net in the condensed consolidated statement of operations. In connection with the issuance of the RTW Convertible Notes and RIFA Amendment (as defined below), we incurred $1.4 million in issuance costs, which were directly expensed through general and administrative expense due to the FVO election of the RTW Convertible Notes and Revenue Interest Financing.

The Share Obligation is accounted for as a liability under ASC 480, *Distinguishing Liabilities from Equity* ("ASC 480"). As the Share Obligation was initiated in exchange for amendments of the Amended Note Purchase Agreement, the Revenue Interest Financing Agreement, and the New RIFA, all of which are accounted for under the FVO election, the liability was recorded at its initial fair value of $1.3 million, with an offset to Other income (expense). The liability will be remeasured at estimated fair value on a recurring basis at each reporting period date until it is settled. The Omnibus Amendment results in a modification of the Amended Note Purchase Agreement, the Revenue Interest Financing Agreement, and the New RIFA.

For the three months ended March 31, 2025, the Company recorded a gain of $3.3 million (as restated) and a gain of $1.4 million (as restated) through the condensed consolidated statements of operations and other comprehensive income (loss), respectively.

The Company elected paid in kind interest for the three months ended March 31, 2025 related to the RTW Convertible Notes.

**10.** **Revenue Interest Financing, Side Letter, and PIPE Conversion Option** 

On February 9, 2023, Legacy Allurion entered into the Revenue Interest Financing Agreement. Pursuant to the Revenue Interest Financing, at the closing of the Business Combination, RTW paid Allurion an aggregate of $40.0 million Investment Amount. In exchange for the Investment Amount, Allurion will remit revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to 6.0% of annual net sales prior to December 31, 2026. On or after January 1, 2027, the Company will remit revenue interest payments at a rate up to 10.0% of annual net sales, and it will continue to make revenue interest payments to RTW until December 31, 2030. Such payments were subsequently modified pursuant to the RIFA Amendment, discussed below.

If RTW has not received aggregate revenue interest payments equal to at least 100% of the Investment Amount by December 31, 2027, the Company must make a cash payment in an amount sufficient to catch RTW up to 100% of the Investment Amount. If RTW has not received revenue interest payments equal to at least 240% of the Investment Amount by December 31, 2030, the Company must make a cash payment in an amount sufficient to catch RTW up to 240% of the Investment Amount. In any event, RTW shall not receive aggregated revenue interest payments in excess of 260% of the Investment Amount. In addition, prior to December 31, 2025, the Company may prepay a pre-specified payment amount (the "Prepayment Amount") and terminate the Revenue Interest Financing Agreement. The Prepayment Amount shall be an amount equal to 165% of the Investment Amount less the sum of all revenue interest payments made to RTW prior to such date of prepayment.

The Revenue Interest Financing is accounted for under the FVO election of ASC 825 as the Revenue Interest Financing contains embedded derivatives, including the requirements to settle the Revenue Interest Financing prior to maturity upon the occurrence of certain contingent events and our ability to prepay the Revenue Interest Financing, which would require bifurcation and separate accounting. The Revenue Interest Financing was initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in fair value are recorded as a component of Other income (expense) in the condensed consolidated statements of operations. A portion of the estimated change in fair value must be

------

##### [**Table of Contents**](#toc)
reported in other comprehensive loss to the extent that it is attributable to instrument-specific credit risk. In connection with the issuance of the Investment Amount, we paid $1.2 million in issuance costs in August 2023, which were directly expensed through general and administrative expense due to the FVO election. As of March 31, 2025, the Company has made $4.2 million in royalty payments to RTW. Refer to Note 11, *Fair Value Measurements*, for additional information regarding the changes in fair value of the Revenue Interest Financing.

Concurrently, and in connection with the Amended Note Purchase Agreement, the Revenue Interest Financing Agreement was amended pursuant to an Omnibus Amendment (the "RIFA Amendment") by and among the Company, Allurion Opco, Allurion Australia Pty Ltd, a proprietary limited company organized under the laws of Australia and a wholly-owned subsidiary of the Company, the Original RIFA Investors (as defined therein) and RTW, on April 14, 2024. The RIFA Amendment, among other things, increased the rate of revenue interest payments to be paid to RTW on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries for net sales less than or equal to $100 million prior to December 31, 2026 from 6% to 12% and increased the rate on net sales less than or equal to $100 million on or after January 1, 2027 from 10% to 12%. Additionally, the Prepayment Amount was modified such that, prior to March 31, 2026, the Company is entitled to settle the Revenue Interest Financing for a prepayment amount that would allow the investors to yield a 20% internal rate of return.

The RIFA Amendment was accounted for as a modification with the change in fair value of the option held by RTW, pursuant to which RTW may elect to convert up to $7.5 million of its initial PIPE subscription into an additional revenue interest financing by forfeiting a number of shares of Common Stock acquired by the PIPE subscription (the "PIPE Conversion Option"). As such, the Revenue Interest Financing and PIPE Conversion Option were remeasured as of April 16, 2024 just prior to the RIFA Amendment, to $33.0 million and $6.6 million, respectively. The Revenue Interest Financing and PIPE Conversion Option were subsequently remeasured as of April 16, 2024 under the terms of the RIFA Amendment, to $39.0 million and $4.6 million, respectively.

In connection with the Company entering into the Revenue Interest Financing, if, at any time beginning 12 months and ending 24 months following the closing of the Mergers, the VWAP per share of Allurion Common Stock is less than $176.00 for the average of 20 trading days within any 30 trading day period ("Stock Price Drop"); and the absolute value of the percentage decrease of such Stock Price Drop measured from a reference price of $250.00 per share of Allurion Common Stock is greater than the absolute value of the percentage decrease in the VWAP of a comparable publicly traded peer index as defined in the Amended and Restated RTW Side Letter over the same time period, then RTW may elect to convert up to $7.5 million of its initial PIPE Investment into additional revenue interest financing to be added to the Investment Amount by forfeiting a number of shares of Allurion Common Stock acquired in the PIPE Investment. Such additions to the Investment Amount would result in proportional increases to the minimum aggregate revenue interest payments described above. The PIPE Conversion Option is accounted for as a derivative under ASC 815. The PIPE Conversion Option was initially measured at its issue-date estimated fair value of $3.3 million within Other liabilities on the condensed consolidated balance sheets with corresponding recognition of expense at inception as there is no right received by the Company that meets the definition of an asset and the transaction did not involve a distribution or a dividend. The PIPE Conversion Option liability is subsequently remeasured at its estimated fair value on a recurring basis at each reporting period date, with a gain or loss recognized within Other income (expense).

On October 22, 2024, funds affiliated with RTW provided notice to the Company of their election of the PIPE Conversion Option under the Amended and Restated RTW Side Letter to surrender 30,000 shares of Common Stock of the Company representing $7.5 million in consideration for an additional Revenue Interest Financing Agreement. Accordingly, on October 30, 2024, the Company and the funds affiliated with RTW entered into the additional Revenue Interest Financing Agreement (the "New RIFA"). The New RIFA has substantially identical terms and conditions as the Revenue Interest Financing Agreement except that the amount of financing provided under the New RIFA is equal to the conversion amount of $7.5 million (the "Additional Investment Amount"). The Additional Investment Amount results in proportional increases to the minimum aggregate revenue interest payments described above.

The exercise of the PIPE Conversion Option was accounted for as a settlement of the derivative liability. As such, the PIPE Conversion Option was remeasured as of October 30, 2024 just prior to conversion, to $7.4 million. The PIPE Conversion Option was subsequently reclassified as an addition to the Revenue Interest Financing liability upon conversion into the New RIFA. The New RIFA was accounted for under the FVO election, similar to the Revenue Interest Financing. As such, the New RIFA, together with the Revenue Interest Financing was remeasured as of October 30, 2024 to $48.9 million. Additionally, to account for the 30,000 forfeited shares in connection with the exercise of the PIPE Conversion Option, the total shares were valued based on the October 30, 2024 closing share price of $18.25, resulting in a $0.5 million reduction of APIC. As of March 31, 2025, the fair value of the Revenue Interest Financing and New RIFA was $50.0 million.

For the three months ended March 31, 2025, the Company recorded a $3.8 million loss (as restated) and a $3.0 million gain (as restated) on the Revenue Interest Financing through the condensed consolidated statements of operations and other comprehensive income (loss), respectively. The changes in fair value were recorded in the Changes in fair value of Revenue Interest Financing and PIPE Conversion Option in the condensed consolidated statement of operations.

------

##### [**Table of Contents**](#toc)
**11.** **Fair Value Measurements** 

The following tables present the fair value hierarchy for the Company's assets and liabilities that are measured at fair value at issuance date and on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Fair Value Measurement as of March 31, 2025** | **Fair Value Measurement as of March 31, 2025** | **Fair Value Measurement as of March 31, 2025** | **Fair Value Measurement as of March 31, 2025** | **Fair Value Measurement as of March 31, 2025** |
|  | **Total<br>Carrying<br>Value** | **Level 1** | **Level 2** | **Level 3** |
|  **Assets:** |  |  |  |  |
|  Cash equivalents |  |  |  |  |
|  Money market funds | $17115 | $17115 | $— | $— |
|  Total assets | $17115 | $17115 | $— | $— |
|  **Liabilities:** |  |  |  |  |
|  Legacy Allurion Common Stock Warrant Liabilities | $10 | $— | $— | $10 |
|  Public Warrants | 383 | 383 |  |  |
|  Public Offering Warrants | 1231 |  |  | 1231 |
|  July 2024 Private Placement Warrants | 190 |  |  | 190 |
|  January 2025 Warrants | 2530 |  |  | 2530 |
|  February 2025 Offering Warrants | 4920 |  |  | 4920 |
|  Revenue Interest Financing | 50000 |  |  | 50000 |
|  Earn-out Liability | 180 |  |  | 180 |
|  RTW Convertible Notes | 30960 |  |  | 30960 |
|  Success Fee Derivative Liability | 14 |  |  | 14 |
|  RTW Share Obligation | 700 |  |  | 700 |
|  Total Liabilities | $91118 | $383 | $— | $90735 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Fair Value Measurement as of December 31, 2024** | **Fair Value Measurement as of December 31, 2024** | **Fair Value Measurement as of December 31, 2024** | **Fair Value Measurement as of December 31, 2024** | **Fair Value Measurement as of December 31, 2024** |
|  | **Total<br>Carrying<br>Value** | **Level 1** | **Level 2** | **Level 3** |
|  **Assets:** |  |  |  |  |
|  Cash equivalents |  |  |  |  |
|  Money market funds | $11992 | $11992 | $— | $— |
|  Total assets | $11992 | $11992 | $— | $— |
|  **Liabilities:** |  |  |  |  |
|  Legacy Allurion Common Stock Warrant Liability | $41 | $— | $— | $41 |
|  Public Warrants | 396 | 396 |  |  |
|  Public Offering Warrants | 3630 |  |  | 3630 |
|  July 2024 Private Placement Warrants | 500 |  |  | 500 |
|  Revenue Interest Financing | 49200 |  |  | 49200 |
|  Earn-out Liability | 1090 |  |  | 1090 |
|  RTW Convertible Notes | 35710 |  |  | 35710 |
|  Success Fee Derivative Liability | 14 |  |  | 14 |
|  Total Liabilities | $90581 | $396 | $— | $90185 |

---

***Public Warrants***

As a result of the Business Combination on August 1, 2023, the Company recorded a liability for Public Warrants to purchase the Company's Common Stock. The Public Warrants are traded on the NYSE and are recorded at fair value using the closing price as of March 31, 2025 of $0.029, which is a Level 1 input.

------

##### [**Table of Contents**](#toc)
***Legacy Allurion Warrants, Public Offering Warrants, July 2024 Private Placement Warrants, January 2025 Warrants, and February 2025 Offering Warrants***

The Company has classified the Legacy Allurion Common Stock Warrants, Public Offering Warrants (defined below), July 2024 Private Placement Warrants (defined below), January 2025 Warrants (defined below), and February 2025 Offering Warrants (defined below) within Level 3 of the hierarchy as the fair value is derived using the Black-Scholes option pricing model, which uses a combination of observable (Level 2) and unobservable (Level 3) inputs. See table below for the assumptions used in the pricing model of the Legacy Allurion Common Stock Warrants, Public Offering Warrants, July 2024 Private Placement Warrants, January 2025 Warrants, and February 2025 Offering Warrants:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Measurement<br>Date** | **Interest<br>Rate** | **Exercise<br>Price** | **Estimated<br>Fair Value<br>of Underlying<br>Share Price** | **Expected<br>Volatility** | **Expected<br>Life<br>(Years)** |
|  Legacy Allurion Series C Preferred Stock warrants (as converted to Common) | March 31, 2025 | 4.03 | $168.25 | $3.21 | 105.6% | 6.00 |
|  Legacy Allurion Other Common Stock | March 31, 2025 | 3.89 | 26.25 | 3.21 | 105.6% | 2.44 |
|  Legacy Allurion Series D-1 Preferred Stock <br>warrants (as converted to Common) | March 31, 2025 | 4.03<br> 4.11 | 303.50 | 3.21 | 105.6% | 6.00-7.46 |
|  Public Offering Warrants | March 31, 2025 | 3.93 | 6.00-30.00 | 3.21 | 100.0% | 4.25 |
|  July 2024 Private Placement Warrants | March 31, 2025 | 3.93 | 30.00 | 3.21 | 100.0% | 4.25 |
|  January 2025 Warrants | March 31, 2025 | 3.96 | 6.00 | 3.21 | 95.0% | 5.01 |
|  February 2025 Offering Warrants | March 31, 2025 | 3.96 | 5.23 | 3.21 | 95.0% | 5.01 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Measurement<br>Date** | **Interest<br>Rate** | **Exercise<br>Price** | **Estimated<br>Fair Value<br>of Underlying<br>Share Price** | **Expected<br>Volatility** | **Expected<br>Life<br>(Years)** |
|  Legacy Allurion Series C Preferred Stock warrants (as converted to Common) | December 31, 2024 | 4.44 | $168.25 | $10.75 | 90% | 6.25 |
|  Legacy Allurion Other Common Stock | December 31, 2024 | 4.26 | 26.25 | 10.75 | 90% | 2.69 |
|  Legacy Allurion Series D-1 Preferred Stock <br>warrants (as converted to Common) | December 31, 2024 | 4.44<br> 4.5 | 303.50 | 10.75 | 90% | 6.25-7.71 |
|  Public Offering Warrants | December 31, 2024 | 4.35 | 30.00 | 10.75 | 90% | 4.50 |
|  July 2024 Private Placement Warrants | December 31, 2024 | 4.35 | 30.00 | 10.75 | 90% | 4.50 |

---

Expected dividend yield for all calculations is 0.00%.

------

##### [**Table of Contents**](#toc)
The following table reconciles the changes in fair value for the three months ended March 31, 2025 and 2024 of the warrant liabilities valued using Level 3 inputs:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred Stock<br>Warrants (as<br>converted to<br>Common)** | **Common<br>Stock<br>Warrants** | **Public<br>Offering<br>Warrants** | **July 2024<br>Private<br>Placement<br>Warrants** | **January<br>2025<br>Warrants** | **February 2025<br>Offering<br>Warrants** | **Total** |
|  Balance—January 1, 2024 | $642 | $179 | $— | $— | $— | $— | $821 |
|  Change in fair value | (409) | (108) |  |  |  |  | (517) |
|  Balance—March 31, 2024 | $233 | $71 | $— | $— | $— | $— | $304 |
|  Balance—January 1, 2025 | $32 | $9 | $3630 | $500 | $— | $— | $4171 |
|  Fair value at issuance |  |  |  |  | 5344 | 5021 | 10365 |
|  Change in fair value | (23) | (8) | (2399) | (310) | (2814) | (101) | (5655) |
|  Balance—March 31, 2025 | $9 | $1 | $1231 | $190 | $2530 | $4920 | $8881 |

---

***2019 Term Loan Success Fee Derivative Liability***

The derivative liability for the success fee associated with Legacy Allurion's November 2019 loan and security agreement with Western Alliance Bank (the "2019 Term Loan" and such fee, the "Success Fee") was recorded at fair value as of March 31, 2025 and December 31, 2024 using the following assumptions: weighted-average probability for the likelihood of a change in control or liquidity event within four years from the initial valuation date of the derivative liability and a market-based discount rate that will increase or decrease each period based on changes in the probability in the future cash flows.

***Revenue Interest Financing and PIPE Conversion Option***

The Revenue Interest Financing is accounted for using the FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The fair value of the Revenue Interest Financing was remeasured as of March 31, 2025 using a discounted cash flow ("DCF") method under the income approach utilizing future revenue projections and a discount rate of 22.8%.

The fair value of the PIPE Conversion Option was accounted for as a derivative under ASC 815. Upon the exercise of the PIPE Conversion Option and resulting New RIFA on October 30, 2024, the PIPE Conversion Option was reclassified as an addition to the Revenue Interest Financing liability, and as such there is no PIPE Conversion Option liability as of December 31, 2024 and March 31, 2025.

***Earn-Out Liability***

Upon the closing of the Business Combination, the Earn-Out Shares were accounted for as a liability because the triggering events that determine the number of shares to be earned included events that were not indexed to Allurion Common Stock, with the change in fair value recognized in Change in the fair value of earn-out liabilities in the condensed consolidated statement of operations. The estimated fair value of the Earn-Out Shares was determined using a MCSM with the following assumptions at each valuation date:

---

| | | |
|:---|:---|:---|
|  | **March 31, 2025** | **December 31, 2024** |
|  Stock Price | $3.21 | $10.75 |
|  Risk-free interest rate | 3.9% | 4.3% |
|  Expected term (in years) | 3.3 | 3.6 |
|  Expected volatility | 115.0% | 109.0% |

---

***Term Loan Derivative Liability***

The Term Loan derivative liability associated with the Fortress Term Loan was derecognized during the second quarter of 2024 as the Fortress Term Loan was repaid on April 16, 2024.

***RTW Convertible Notes***

The RTW Convertible Notes are accounted for using the FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently measured at estimated fair value on a recurring basis at each reporting period date. The fair value of the RTW Convertible Notes was remeasured as of March 31, 2025 using a DCF method under the income approach with a MCSM applied to determine the simulated stock price at each payment date and event that may trigger conversion of the RTW Convertible Notes. The fair value was measured using the $48.0 million principal amount of the RTW Convertible Notes and the following assumptions:

------

##### [**Table of Contents**](#toc)

---

| | | |
|:---|:---|:---|
|  | **March 31, 2025** | **December 31, 2024** |
|  Stock Price | $3.21 | $10.75 |
|  Risk-free interest rate | 4.0% | 4.4% |
|  Expected term (in years) | 6.0 | 6.3 |
|  Expected volatility | 92.5% | 90.0% |

---

***Share Obligation***

The Share Obligation is accounted for as a liability under ASC 480, with the liability initially measured at its issue-date estimate fair value and subsequently measured at its estimated fair value on a recurring basis at each reporting period date. The estimated fair value of the Share Obligation was determined using a MCSM with the following assumptions at the valuation date:

---

| | |
|:---|:---|
|  | **March 31, 2025** |
|  Risk-free interest rate | 4.0% |
|  Expected term (in years) | 1.8 |
|  Expected volatility | 167.5% |
|  Expected market yield | 25.9% |

---

The changes in the fair values of the Success Fee derivative liability, Revenue Interest Financing, PIPE Conversion Option, Earn-out liability, Term Loan Derivative liability, RTW Convertible Notes, and Share Obligation categorized with Level 3 inputs for the three months ended March 31, 2025 and 2024 were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Success Fee<br>Derivative<br>Liability** | **Revenue<br>Interest<br>Financing** | **PIPE<br>Conversion<br>Derivative** | **Earn-Out<br>Liability** | **Term Loan<br>Derivative<br>Liability** | **RTW<br>Convertible<br>Notes** | **Share<br>Obligation** | **Total** |
|  Balance—January 1, 2024 (Restated) (1) | $14 | $36200 | $6410 | $23990 | $1895 | $— | $— | $68509 |
|  Change in fair value (Restated) (1) |  | 1000 | 1100 | (14190) | 62 |  |  | (12028) |
|  Change in fair value—OCI (Restated) (1) |  | (2200) |  |  |  |  |  | (2200) |
|  Balance—March 31, 2024 | $14 | $35000 | $7510 | $9800 | $1957 | $— | $— | $54281 |
|  Balance—January 1, 2025 | $14 | $49200 | $— | $1090 | $— | $35710 | $— | $86014 |
|  Fair value upon issuance |  |  |  |  |  |  | 1297 | 1297 |
|  Change in fair value (Restated) (1) |  | 3820 |  | (910) |  | (3330) | (597) | (1017) |
|  Change in fair value—OCI (Restated) (1) |  | (3020) |  |  |  | (1420) |  | (4440) |
|  Balance—March 31, 2025 | $14 | $50000 | $— | $180 | $— | $30960 | $700 | $81854 |

---

(1) As discussed in *FN 2, Restatement of Previously Issued Financial Statements*, the Company identified an
Error in its historical financial statements related to the change in fair value due to instrument specific credit risk for the Revenue Interest Financing and RTW Convertible Notes, as well as a change in fair value of the PIPE Conversion Option.
The only restated numbers in the table above relate to the 'Change in fair value' and 'Change in fair value—OCI' for both the Revenue Interest Financing and RTW Convertible Notes, as well as the 'Change in fair
value' related to the PIPE Conversion Option.

The change in fair value of the Success Fee derivative liability, Revenue Interest Financing, PIPE Conversion Option, Earn-Out liability, Term Loan Derivative liability, RTW Convertible Notes, and Share Obligation at each period is recorded as a component of Other income (expense) in the condensed consolidated statements of operations, with the exception of the changes in fair value associated with the change in credit risk related to the Revenue Interest Financing and RTW Convertible Notes, which is recorded as a component of other comprehensive loss.

**12.** **Income Taxes** 

The Company recorded income tax expense of $0.1 million for each of the three months ended March 31, 2025 and 2024, representing an effective tax rate of 7% (as restated) and (4%) (as restated) in each period, respectively. The tax expense recorded relates to the earnings of the Company's profitable foreign subsidiaries.

As of March 31, 2025 and 2024, the Company maintained a full valuation allowance against its net deferred tax assets as the Company has incurred significant operating losses since inception and has concluded that its net deferred tax asset is not more-likely-than-not realizable.

------

##### [**Table of Contents**](#toc)
As of March 31, 2025 and 2024, the Company has not recorded tax reserves for any uncertain tax provisions.

**13.** **Capital Stock and Stockholders' Deficit** 

***Preferred Equity***

On June 28, 2024, the Company entered into a subscription agreement (the "Subscription Agreement") with RTW, pursuant to which the Company agreed to sell 2,260,159 shares of a newly created series of preferred stock, the Series A non-voting convertible preferred stock, par value $0.0001 per share ("Series A Preferred Stock"), and 90,407 private placement warrants ("July 2024 Private Placement Warrants") to purchase Common Stock, equal to the per share Public Offering (defined below) price for the shares of Common Stock and Public Offering Warrants (defined below) in the Public Offering (the "July 2024 Private Placement"). The July 2024 Private Placement closed on July 1, 2024 with net proceeds received of $2.5 million after deducting offering costs of $0.2 million.

The July 2024 Private Placement Warrants met the definition of a derivative under ASC 815. The gross proceeds from the July 2024 Private Placement were first allocated to the July 2024 Private Placement Warrants based on their issue-date estimated fair value of $1.7 million. The July 2024 Private Placement Warrants are subsequently remeasured at their estimated fair value on a recurring basis at each reporting period date, with a gain or loss recognized within Other income (expense). The remaining gross proceeds of $1.0 million were allocated to the Series A Preferred Stock. Of the $0.2 million in offering costs, $0.1 million was recorded against the Series A Preferred Stock as a reduction of proceeds and $0.1 million was expensed as general and administrative expenses in the condensed consolidated statement of operations and comprehensive loss.

On December 19, 2024, following the Series A Stockholder Approval (as defined below) and after giving effect to the Reverse Stock Split, the 2,260,159 shares of Series A Preferred Stock were converted to 90,407 shares of Common Stock.

Allurion's Charter authorizes the issuance of up to 100,000,000 shares of Allurion preferred stock. As of March 31, 2025, no shares of Allurion Series A Preferred Stock were outstanding. The rights and preferences of the Series A Preferred Shares are as follows:

*Voting Rights*

The Series A Preferred Stockholders have no voting rights.

*Dividend Rights*

The Series A Preferred Stock participates in dividends with Common Stock on an as-converted basis when declared by the Board of Directors. No dividends were declared through March 31, 2025.

*Liquidation Preference*

In the event of any voluntary or involuntary liquidation, dissolution, or winding-up of the Company, payment shall be made to the holders of shares of Series A Preferred Stock on a pari passu basis with all holders of Common Stock. Each Series A Preferred Stock holder shall be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of Common Stock would receive if such holder's Series A Convertible Preferred Stock were fully converted to Common Stock plus an additional amount equal to any dividends declared but unpaid to such share.

*Conversion Rights*

Each share of Series A Preferred Stock is convertible after the date that the Company's stockholders approve the conversion of the Series A Preferred Stock into shares of Common Stock in accordance with the listing rules of the NYSE (the "Series A Stockholder Approval"). Upon the Series A Stockholder Approval, each share of Series A Preferred Stock then outstanding shall automatically convert into (i) a number of shares of Common Stock equal to the number of Series A Preferred Stock outstanding at the time of conversion, adjustable for certain dilutive events, and (ii) pre-funded conversion warrants in the form agreed by the holder and the Company, exercisable for a number of shares of Common Stock equal to the number of Series A Preferred Stock outstanding at the time of conversion, adjustable for certain dilutive events. This Series A Stockholder Approval was received on December 16, 2024.

*Redemption*

Each share of Series A Preferred Stock outstanding on December 31, 2026 (the "Redemption Date") shall be automatically redeemed by the Company for cash at a redemption price equal to the volume-weighted average price per share of the Common Stock on the NYSE during the twenty consecutive trading day period ending and including the trading day immediately preceding the Redemption Date (the "Redemption Price"). The Series A Preferred Stock is redeemable at a determinable price (the Redemption Price) on a fixed date (the Redemption Date), which results in mezzanine equity classification (outside of permanent equity) on the Company's condensed consolidated balance sheet.

------

##### [**Table of Contents**](#toc)
***Common Equity***

Allurion's Charter authorizes the issuance of up to 1,000,000,000 shares of Allurion Common Stock. As of March 31, 2025 and December 31, 2024, 5,963,549 and 2,710,607 shares of Common Stock were issued and outstanding, respectively.

*July 2024 Public Offering*

On June 28, 2024, the Company entered into an underwriting agreement with Jefferies LLC and TD Securities (USA) LLC, as representative of the several underwriters (the "Underwriters"), pursuant to which the Company agreed to issue and sell 576,261 shares of the Company's Common Stock and warrants ("Public Offering Warrants") to purchase up to 576,261 shares of the Company's Common Stock at an offering price of $30.00 per share and accompanying warrant (the "Public Offering"). The Public Offering closed on July 1, 2024 with net proceeds received of $15.2 million after deducting underwriting discounts of $1.0 million and offering costs of $1.0 million. The Underwriters fully exercised their option for additional Public Offering Warrants, with 86,440 additional Public Offering Warrants issued at closing, for a total of 662,701 Public Offering Warrants. Further, the Underwriters exercised a portion of the option with respect to the Common Stock (the "Share Overallotment") on July 5, 2024 for net proceeds of $2.2 million, which resulted in the issuance of 77,091 shares of the Company's Common Stock at an offering price of $30.00 per share.

The Public Offering Warrants met the definition of a derivative under ASC 815 and the Share Overallotment met the requirements for equity classification under ASC 815. The $17.4 million in net proceeds from the Public Offering and exercise of the Share Overallotment were first allocated to the Public Offering Warrants based on their issue-date estimated fair value of $13.2 million. The Public Offering Warrants are subsequently remeasured at their estimated fair value on a recurring basis at each reporting period date, with a gain or loss recognized within Other income (expense). The $0.8 million offerings costs allocated to the Public Offering Warrants were expensed as general and administrative expenses in the condensed consolidated statement of operations and comprehensive loss. The remaining net proceeds of $5.1 million were allocated to Common Stock and APIC.

*RTW Private Placement* 

On January 14, 2025, the Company entered into a subscription agreement (the "RTW Subscription Agreement") with funds affiliated with RTW, pursuant to which the Company agreed to sell 841,751 shares of Common Stock at a purchase price of $2.97 per share (the "RTW Private Placement"). The RTW Private Placement closed on January 16, 2025 with net proceeds received of $2.5 million.

*January 2025 Public Offering and Concurrent Private Placement* 

On January 24, 2025, the Company entered into a securities purchase agreement (the "January 2025 Securities Purchase Agreement") with certain accredited investors named therein, pursuant to which the Company agreed to issue and sell 1,240,000 shares of Common Stock (the "January 2025 Offering") and 1,240,000 accompanying common warrants (the "January 2025 Warrants") to purchase up to 1,240,000 shares of Common Stock upon exercise of the January 2025 Warrants in a concurrent private placement (the "January 2025 Private Placement"), at an offering price of $6.00 per share and accompanying January 2025 Warrant. The January 2025 Offering and January 2025 Private Placement closed on January 27, 2025 with net proceeds of $5.8 million after deducting placement agent fees of $0.6 million and offering costs of $1.0 million.

Certain purchasers in the January 2025 Offering and January 2025 Private Placement are holders of warrants to purchase Common Stock issued in the Public Offering in July 2024. The exercise price for the Public Offering Warrants initially was $30.00 per share. In consideration for such purchasers' purchase of securities in the January 2025 Offering and January 2025 Private Placement, we agreed with each such purchaser to seek stockholder approval to reduce the exercise price of the Public Offering Warrants held by such purchasers to $6.00 per share (the "January Warrant Repricing"). Such Public Offering Warrants will become exercisable at the revised exercise price upon the receipt of such stockholder approval, which approval was obtained on April 10, 2025. The Public Offering Warrants were remeasured to account for the incremental fair value, with the $0.5 million loss recognized within Other income (expense).

The January 2025 Warrants met the definition of a derivative under ASC 815. The $5.8 million in net proceeds were first allocated to the January 2025 Warrants based on their issue-date estimated fair value of $5.3 million. The January 2025 Warrants are subsequently remeasured at their estimated fair value on a recurring basis at each reporting period date, with a gain or loss recognized within Other income (expense). The $0.8 million of offering costs allocated to the January 2025 Warrants were expensed as general and administrative expenses in the condensed consolidated statement of operations and comprehensive loss. The remaining net proceeds of $1.3 million were allocated to Common Stock and APIC.

*February 2025 Public Offering and Concurrent Private Placement and Leavitt Private Placement* 

On February 19, 2025, the Company entered into a securities purchase agreement (the "February 2025 Securities Purchase Agreement") with certain accredited investors named therein, pursuant to which the Company agreed to issue and sell 900,000 shares of Common Stock (the "February 2025 Offering"), and 1,800,000 accompanying common warrants (the "February 2025 Warrants") to purchase up to 1,800,000 shares of Common Stock upon exercise of the February 2025 Warrants in a concurrent private placement

------

##### [**Table of Contents**](#toc)
(the "February 2025 Private Placement"), at an offering price of $5.23 per share and accompanying February 2025 Warrant. The February 2025 Offering and February 2025 Private Placement closed on February 20, 2025 with net proceeds of $3.9 million after deducting placement agent fees of $0.4 million and offering costs of $0.4 million.

Additionally, on February 19, 2025, the Company entered into a subscription agreement (the "Leavitt Subscription Agreement") with an accredited investor affiliated with Leavitt Equity Partners LLC (collectively, "Leavitt"), pursuant to which the Company agreed to issue and sell 267,686 shares of Common Stock (the "Private Placement Shares") and common warrants to purchase up to 535,372 shares of Common Stock (the "Leavitt Private Placement Warrants" and together with the February 2025 Warrants, the "February 2025 Offering Warrants"), at a purchase price of $5.23 per share and accompanying Private Placement Warrant (the "Leavitt Private Placement"). The Leavitt Private Placement closed on February 20, 2025 with net proceeds of $1.3 million after deducting placement agent fees of $0.1 million. Leavitt is a holder of Public Offering Warrants with an initial exercise price of $30.00 per share. In consideration for Leavitt's purchase of securities in the Leavitt Private Placement, we agreed to seek stockholder approval to reduce the exercise price of the Public Offering Warrants held by Leavitt to $6.00 per share (the "February Warrant Repricing"). Such Public Offering Warrants will become exercisable at the revised exercise price upon the receipt of such stockholder approval, which approval was obtained on April 10, 2025. The Public Offering Warrants were remeasured to account for the incremental fair value, with the $0.2 million loss recognized within Other income (expense).

The February 2025 Offering Warrants met the definition of a derivative under ASC 815. The $5.2 million in net proceeds were first allocated to the February 2025 Offering Warrants based on their issue-date estimated fair value of $5.0 million. The February 2025 Offering Warrants are subsequently remeasured at their estimated fair value on a recurring basis at each reporting period date, with a gain or loss recognized within Other income (expense). The $0.4 million of offering costs allocated to the February 2025 Offering Warrants were expensed as general and administrative expenses in the condensed consolidated statement of operations and comprehensive loss. The remaining net proceeds of $0.6 million were allocated to Common Stock and APIC.

The number of shares of Common Stock that have been reserved for issuance upon the potential conversion or exercise, as applicable, of the Company's securities as of March 31, 2025, is as follows:

---

| | |
|:---|:---|
|  Outstanding options to purchase Common Stock | 252171.0 |
|  Restricted Stock Units | 100995.0 |
|  Warrants to purchase Common Stock | 4340343.0 |
|  Shares of Common Stock issued upon the exercise of Public Warrants | 750383.0 |
|  Earn-Out shares | 360000.0 |
|  Convertible Notes | 2570322.0 |
|  Total | 8374214.0 |

---

***Warrants to Purchase Common Stock***

In connection with the closing of the Business Combination, all outstanding warrants to purchase Legacy Allurion preferred stock and Legacy Allurion common stock were converted into Rollover Warrants to purchase Allurion Common Stock using the Exchange Ratio. As of March 31, 2025, there were 14,457 Rollover Warrants outstanding to purchase Common Stock. Upon the closing of the Business Combination, certain Legacy Allurion preferred stock and Legacy Allurion common stock warrants that were converted into Rollover Warrants were determined to be equity classified.

In connection with the Public Offering and July 2024 Private Placement, we issued the Public Offering Warrants and July 2024 Private Placement Warrants. As of March 31, 2025, there were 662,701 Public Offering Warrants and 90,407 July 2024 Private Placement Warrants outstanding to purchase Common Stock. In connection with the January 2025 Public Offering and concurrent January 2025 Private Placement, and the February 2025 Public Offering and concurrent February 2025 Private Placement and Leavitt

------

##### [**Table of Contents**](#toc)
Private Placement, we issued the January 2025 Warrants and February 2025 Offering Warrants. As of March 31, 2025, there were 1,240,000 January 2025 Warrants and 2,335,372 February 2025 Offering Warrants outstanding to purchase Common Stock.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **March 31, 2025** | **March 31, 2025** | **March 31, 2025** | **March 31, 2025** | **March 31, 2025** | **March 31, 2025** |
| **Issuance Date** | **Remaining<br>Contractual Term<br>(in years)** | **Underlying Equity Instrument** | **Balance Sheet<br>Classification** | **Shares Issuable<br>Upon Exercise<br>of Warrant** | **Weighted<br>Average Exercise<br>Price** |
|  12/1/2014 | 0.1 | Common stock | Equity | 77 | $61.00 |
|  3/30/2021 | 6.0 | Common stock | Liability | 5203 | 168.25 |
|  9/15/2022 | 7.5 | Common stock | Liability | 1810 | 303.50 |
|  6/4/2022 | 7.2 | Common stock | Liability | 1810 | 303.50 |
|  1/17/2017 | 1.8 | Common stock | Equity | 2934 | 0.50 |
|  8/3/2017 | 2.3 | Common stock | Equity | 392 | 28.25 |
|  9/8/2017 | 2.4 | Common stock | Liability | 1151 | 26.25 |
|  6/19/2018 | 3.2 | Common stock | Liability | 720 | 26.25 |
|  6/25/2019 | 4.2 | Common stock | Liability | 360 | 26.25 |
|  7/1/2024 | 4.3 | Common stock | Liability | 753108 | 11.42 |
|  1/27/2025 | 4.8 | Common stock | Liability | 1240000 | 6.00 |
|  2/20/2025 | 4.9 | Common stock | Liability | 2335372 | 5.23 |
|  |  |  |  | 4342937 |  |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| **Issuance Date** | **Remaining<br>Contractual Term<br>(in years)** | **Underlying Equity Instrument** | **Balance Sheet<br>Classification** | **Shares Issuable<br>Upon Exercise<br>of Warrant** | **Weighted<br>Average Exercise<br>Price** |
|  12/1/2014 | 0.1 | Common stock | Equity | 209 | $61.00 |
|  3/30/2021 | 6.2 | Common stock | Liability | 5203 | 168.25 |
|  9/15/2022 | 7.7 | Common stock | Liability | 1810 | 303.50 |
|  6/4/2022 | 7.4 | Common stock | Liability | 1810 | 303.50 |
|  1/17/2017 | 2.0 | Common stock | Equity | 2934 | 0.50 |
|  8/3/2017 | 2.6 | Common stock | Equity | 392 | 28.25 |
|  9/8/2017 | 2.7 | Common stock | Liability | 1151 | 26.25 |
|  6/19/2018 | 3.5 | Common stock | Liability | 720 | 26.25 |
|  6/25/2019 | 4.5 | Common stock | Liability | 360 | 26.25 |
|  7/1/2024 | 4.5 | Common stock | Liability | 753108 | 30.00 |
|  |  |  |  | 767697 |  |

---

In Compute Health's initial public offering, it sold units at a price of $10.00 per unit, which consisted of one share of Class A Common Stock, $0.0001 par value, of Compute Health ("Class A Common Stock") and one-half of a redeemable warrant (each a "Public Warrant") that entitled the holder to purchase one share of Class A Common Stock of CPUH at a price of $11.50 per share. On July 26, 2023, Compute Health's Public Warrant holders approved an amendment (the "Warrant Amendment") to the warrant agreement that governed all Compute Health's Public Warrants. Per the terms of the Warrant Amendment, upon completion of the Business Combination, each of the outstanding Compute Health Public Warrants became exercisable for 0.056818 shares of the Company's Common Stock, par value $0.0001 per share, at an exercise price of $202.50 per share and each whole Compute Health Public Warrant was exchanged for 0.6125 (prior to giving effect to the Reverse Stock Split) Allurion Public Warrants in the Business Combination. The Public Warrants will expire August 1, 2030, seven years after the completion of the Business Combination, or earlier upon redemption or liquidation.

The Company may redeem the outstanding Public Warrants for cash at a price of $0.25 per Public Warrant at any time commencing 90 days after the completion of the Business Combination, and provided that the last sales price of the Company's Common Stock equals or exceeds $316.75 per share for any 20 trading days within a 30-day trading period ending on the third trading day prior to the date on which notice of redemption is given.

The Company may redeem the outstanding Public Warrants for shares of our Common Stock at a price of $2.50 per Public Warrant at any time commencing 90 days after the completion of the Business Combination, and provided that the last sales price of the Company's Common Stock equals or exceeds $176.00 per share for any 20 trading days within a 30-day trading period ending on the third trading day prior to the date on which notice of redemption is given. Holders of the Public Warrants will be able to exercise

------

##### [**Table of Contents**](#toc)
their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the fair market value (the "Redemption Fair Market Value") of the shares of the Company's Common Stock. The Redemption Fair Market Value is determined based on the volume weighted average price of the Company's Common Stock for the ten trading days immediately following the date on which notice of redemption is sent to the holders. As of March 31, 2025, the Company has not redeemed any of the outstanding Public Warrants. As of March 31, 2025, there were 13,206,720 outstanding Public Warrants exercisable for 750,383 shares of Allurion Common Stock.

***Chardan Equity Facility***

On December 18, 2023, we entered into a ChEF Purchase Agreement (the "Purchase Agreement") and a Registration Rights Agreement, each with Chardan Capital Markets ("Chardan") related to a "ChEF," Chardan's committed equity facility (the "Chardan Equity Facility"). Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to Chardan up to the lesser of (i) $100,000,000 in aggregate gross purchase price of newly issued shares of the Company's Common Stock, and (ii) 379,299 shares of Common Stock, which number of shares is equal to 19.99% of the shares of the Common Stock outstanding immediately prior to the execution of the Purchase Agreement (the "Exchange Cap"). In consideration for Chardan's entry into the Purchase Agreement, Allurion issued to Chardan 1,421 shares of Allurion Common Stock (the "Commitment Shares"). The Company recorded $0.1 million to additional paid-in capital and $0.1 million of expense in connection with the issuance of the Commitment Shares. The Company expensed an additional $0.1 million related to a non-refundable structuring fee immediately following commencement. As of March 31, 2025, the Company had sold 75,618 shares of Common Stock to Chardan at a purchase price of $1.0 million in connection with the Purchase Agreement.

**14.** **Net Income (Loss) per Share** 

Basic and diluted net income (loss) per share was calculated as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2025** | **2024** |
|  | **(Restated)** | **(Restated)** |
|  Numerator: |  |  |
|  Net (loss) income attributable to common shareholders—Basic | $(1501) | $1996 |
|  Adjustment for change in fair value of liability classified warrants |  | (108) |
|  Net income attributable to common stockholders—Diluted | $(1501) | $1888 |
|  Denominator: |  |  |
|  Basic weighted-average common stock outstanding | 4778542 | 1911181 |
|  Effect of potentially dilutive securities |  |  |
|  Stock options |  | 44971 |
|  Restricted stock units |  | 6883 |
|  Warrants |  | 4850 |
|  Diluted weighted-average common stock outstanding | 4778542 | 1967885 |
|  Basic net (loss) income per common share | $(0.31) | $1.04 |
|  Diluted net (loss) income per common share | $(0.31) | $0.96 |

---

------

##### [**Table of Contents**](#toc)
The Company excluded the following potential shares of Common Stock, presented based on amounts outstanding at each period end, from the computation of diluted net income per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect. As the triggering event under which the Earn-Out Shares become issuable has not been met as of March 31, 2025 and March 31, 2024, the Earn-Out Shares have been excluded from the computation of diluted net income per share.

---

| | | |
|:---|:---|:---|
|  | **As of March 31,** | **As of March 31,** |
|  | **2025** | **2024** |
|  | **(Restated)** | |
|  Outstanding options to purchase Common Stock | 252171 | 112446 |
|  Restricted Stock Units | 100995 | 19358 |
|  Warrants to purchase preferred stock (as converted to warrants to purchase Common Stock) |  | 8822 |
|  Warrants to purchase Common Stock | 4342937 |  |
|  Shares of Common Stock issued upon the exercise of Public Warrants | 750383 | 750388 |
|  Earn-Out Shares | 360000 | 360000 |
|  Convertible notes (as converted to common stock) | 2532336 |  |
|  Total | 8338822 | 1251014 |

---

**15.** **Stock Based Compensation** 

***Stock Incentive Plans***

The Company's 2010 Stock Incentive Plan (the "2010 Plan") provided for the grant of qualified incentive stock options, nonqualified stock options, and other awards to the Company's employees, officers, directors, advisors, and outside consultants to purchase the Company's Common Stock. On December 11, 2020, the Company's Board of Directors adopted the Amended and Restated 2020 Stock Option and Grant Plan (the "2020 Plan"), which provided for the grant of qualified incentive stock options, nonqualified stock options, and other awards to the Company's employees, officers, directors, advisors, and outside consultants to purchase the Company's Common Stock. Each stock option from the 2010 Plan and the 2020 Plan that was outstanding immediately prior to the Business Combination, whether vested or unvested, was cancelled and exchanged for a stock option to purchase Allurion Common Stock based on the Exchange Ratio. The per share exercise price for each stock option was divided by the Exchange Ratio.

In connection with the closing of the Business Combination, the Company adopted the 2023 Stock Option and Incentive Plan (the "2023 Plan"), which provides for the award of stock options (both incentive and non-qualified), stock appreciation rights, restricted stock units ("RSUs"), restricted stock awards, cash-based awards, and dividend equivalent rights. As of March 31, 2025, a total of 486,301 shares of Allurion Common Stock are available for issuance under the 2023 Plan. The 2023 Plan provides that the number of shares reserved for issuance under the 2023 Plan will automatically increase each January 1, beginning January 1, 2024 and ending January 1, 2033, by 5% of the number of fully diluted outstanding shares of Allurion Common Stock as of the immediately preceding December 31 or such lesser amount as determined by the Board and the compensation committee of the Board.

As of March 31, 2025, 353,166 options and RSUs were issued and outstanding under the 2010 Plan, 2020 Plan, and 2023 Plan. As of December 31, 2024, 370,272 options and RSUs were issued and outstanding under the 2010 Plan, 2020 Plan, and 2023 Plan. The stock options generally vest over a four-year period and expire 10 years from the date of grant.

Stock-based compensation expense included in the condensed consolidated statement of operations was as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months<br>Ended March 31,** | **Three Months<br>Ended March 31,** |
|  | **2025** | **2024** |
|  Cost of revenue | $12 | $5 |
|  Selling, general, and administrative | 794 | 550 |
|  Research and development | 91 | (3) |
|  Total stock-based compensation expense | $897 | $552 |

---

------

##### [**Table of Contents**](#toc)
***Stock Options***

The following table summarizes the option activity under the 2010 Plan, 2020 Plan, and the 2023 Plan during the three months ended March 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Number of<br>Options** | **Weighted<br>Average<br>Exercise<br>Price** | **Weighted<br>Average<br>Remaining<br>Contractual<br>Term** | **Aggregate<br>Intrinsic<br>Value** |
|  | | (per option) | (in years) | (in thousands) |
|  Outstanding-January 1, 2025 | 265772 | $58.19 | 7.4 | $— |
|  Granted |  |  |  |  |
|  Cancellations and forfeitures | (13601) | 48.13 |  |  |
|  Exercised |  |  |  |  |
|  Outstanding- March 31, 2025 | 252171 | 58.11 | 7.2 |  |
|  Exercisable at March 31, 2025 | 132135 | $61.83 | 5.6 | $— |

---

Total stock compensation expense related to stock option awards during the three months ended March 31, 2025 was $0.5 million. As of March 31, 2025, there was approximately $3.8 million of unrecognized compensation costs related to unvested stock options granted under the 2010 Plan, 2020 Plan, and 2023 Plan, which is expected to be recognized over a weighted-average vesting term of 2.5 years. There were no stock options granted during the three months ended March 31, 2025. The weighted average grant-date fair value of the stock option awards granted during the three months ended March 31, 2024 was $49.25 per option.

The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model and the assumptions noted in the table below. Expected volatility for the Company's Common Stock was determined based on an average of the historical volatility of a peer group of public companies that are similar to the Company. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The expected term of options granted to non-employees is the remaining contractual term of the award. The assumed dividend yield is based upon the Company's expectation of not paying dividends in the foreseeable future. The risk-free rate for periods within the expected life of the option is based upon the U.S. Treasury yield curve in effect at the time of grant.

There were no option grants during the three months ended March 31, 2025. The assumptions used in the Black Scholes option-pricing model for the three months ended March 31, 2024 are as follows:

---

| | |
|:---|:---|
|  | **Three Months Ended**<br>**March 31,** |
|  | **2024** |
|  Expected volatility | 71% |
|  Risk-free interest rate | 4.14% |
|  Expected dividend yield | 0% |
|  Expected term (in years) | 6.1 |

---

***Restricted Stock Units***

In December 2022, the Company issued RSUs to a member of the Board of Directors with vesting subject to both a performance-based closing condition dependent on the successful Business Combination with Compute Health and time-based vesting conditions. See Note 4, *Business Combination* for information about the closing of the Business Combination with Compute Health. Upon the satisfaction of the closing condition, 62.5% of the RSUs awarded vested. Thereafter, the remaining 37.5% of the RSUs vest monthly over a period of two years. All RSUs are subject to forfeiture if the grantee's continuous service relationship as a member of the Board of Directors terminates prior to vesting. In October 2023 and March 2024, the Company issued RSUs to the members of the Board that vest in equal installments over three years. In November 2024, additional RSUs were issued with annual vesting over two years. All RSUs are subject to forfeiture if the grantee's continuous service relationship as a member of the Board of Directors or employee of the Company terminates prior to vesting.

------

##### [**Table of Contents**](#toc)
The following table summarizes the restricted stock unit activity under the 2020 Plan and 2023 Plan during the three months ended March 31, 2025:

---

| | | |
|:---|:---|:---|
|  | **Number of RSUs** | **Weighted<br>Average Grant<br>Date Fair Value** |
|  | | (per share) |
|  Outstanding-January 1, 2025 | 104500 | $30.99 |
|  Granted |  |  |
|  Cancellations and forfeitures |  |  |
|  Vested | (3505) | 99.20 |
|  Outstanding-March 31, 2025 | 100995 | $35.29 |

---

Total stock compensation expense related to RSUs for the three months ended March 31, 2025 was $0.4 million. As of March 31, 2025, there were $2.0 million of unrecognized compensation costs related to nonvested RSUs granted under the 2020 Plan and 2023 Plan, which is expected to be recognized over a remaining weighted- average vesting term of 1.69 years. There were no restricted stock units granted during the three months ended March 31, 2025. The weighted average grant-date fair value of time-vested restricted stock units granted during the 3 months ended March 31, 2024 was $65.25 per share.

***Employee Stock Purchase Plan***

In connection with the closing of the Business Combination, the Company adopted the 2023 Employee Stock Purchase Plan (the "2023 ESPP"). Under the 2023 ESPP plan, substantially all employees may voluntarily enroll to purchase the Company's Common Stock through payroll deductions at a price equal to 85% of the lower of the fair market values of the stock as of the beginning or end of the offering period. An employee's payroll deductions under the 2023 ESPP are limited to 15% of the employee's compensation.

A total of 131,435 shares of the Company's Common Stock are reserved and authorized for issuance under the 2023 ESPP as of March 31, 2025. In addition, the number of shares of Common Stock available for issuance under the 2023 ESPP automatically increases each January 1, beginning on January 1, 2024 and each January thereafter, by the lesser of (i) 1% of the fully diluted outstanding shares of our Common Stock as of the immediately preceding December 31, (ii) 64,000 shares of our Common Stock, or (iii) such lesser number of shares determined by the administrator of the 2023 ESPP. As of March 31, 2025, no shares have been issued under the 2023 ESPP.

**16. Employee Benefit Plan** 

The Company has a 401(k) retirement plan that covers eligible U.S. employees. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. The Company may elect to make a discretionary contribution or match a discretionary percentage of employee contributions. During each of the three months ended March 31, 2025 and 2024, the Company's matching contributions to the plan were less than $0.1 million.

**17. Commitments and Contingencies** 

***Leases***

With respect to contracts involving the use of assets, if the Company has the right to direct the use of the asset and obtain substantially all economic benefits from the use of an asset, it accounts for the service contract as a lease.

In February 2023 and August 2023, the Company executed amendments to three of its leases in Natick, Massachusetts and its Hudson, Massachusetts lease, respectively. The amendments were accounted for as a modification of the existing lease agreements, with impacts to the lease term, lease payments, and related lease liability for each of the four leases. As a result of these amendments, the leases in Natick and Hudson will now expire between November 2025 and March 2028, and additional operating lease assets obtained in exchange for lease obligations were $0.9 million. In April 2024, the Company executed an amendment to one of its leases in Natick, Massachusetts. The amendment was accounted for as a modification of the existing lease agreement, with impacts to the lease term, lease payments, and related lease liability for the lease. As a result of this amendment, the lease in Natick expired on March 31, 2025 and additional operating lease assets obtained in exchange for lease obligations were less than $0.1 million. In February 2024, the Company terminated one of its leases in Paris, France.

------

##### [**Table of Contents**](#toc)
As of March 31, 2025, the Company was a party to six different leases for office, manufacturing, and laboratory space under non-cancelable office leases in three cities. These leases total approximately 51,000 square feet and will expire between November 2025 and March 2028. The Company has a right to extend certain of these leases for periods between three and five years. Under its real property leases, the Company pays base rent and a proportional share of operating expenses. Such operating expenses are subject to annual adjustment and are accounted for as variable payments in the period in which they are incurred. The Company also holds immaterial leases related to vehicles and office equipment.

The components of right-of-use ("ROU") assets and lease liabilities are included in the condensed consolidated balance sheets. The short-term portion of the Company's operating lease liability is recorded as part of Accrued expenses and other current liabilities on the condensed consolidated balance sheets.

*Aggregate Lease Information* 

Other pertinent lease information for the three months ended March 31, 2025 and 2024 is as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31, 2025** | **March 31, 2024** |
|  Operating lease costs | $258 | $278 |
|  Short-term lease costs | 4 | 10 |
|  Variable operating lease costs | 84 | 77 |
|  Operating cash flows paid for amounts in the measurement of lease liabilities | 247 | 292 |

---

Future commitments under non-cancelable operating lease agreements as of March 31, 2025 are as follows (in thousands):

---

| | |
|:---|:---|
| 2025 | $785 |
| 2026 | 725 |
| 2027 | 642 |
| 2028 | 108 |
|  Total lease payments | $2260 |
|  Less: present value adjustment | (245) |
|  Present value of total lease liabilities | 2015 |
|  Less: current lease liability | (829) |
|  Long-term lease liabilities | $1186 |

---

The weighted-average remaining lease terms and discount rates related to our leases were as follows:

---

| | | |
|:---|:---|:---|
|  | **March 31, 2025** | **March 31, 2024** |
|  Weighted - average remaining lease term (in years) | 2.7 | 3.4 |
|  Weighted-average discount rate | 9.8% | 9.9% |

---

***Product Liability***

The Company has not received any material product liability claims but nevertheless has obtained and maintains insurance related to potential product liability claims.

***Litigation and Claims***

In the normal course of operations, the Company may become involved in various claims and legal proceedings related to, for example, the validity or scope of its intellectual property rights, employee-related matters, securities class actions, or adverse patient reactions. Additionally, during the normal course of business, the Company may be a party to legal claims that may not be covered by insurance. As of March 31, 2025 and December 31, 2024, the Company has not recorded accruals for probable losses related to any existing or pending litigation or claims as the Company's management has determined that there are no matters where a potential loss is probable and reasonably estimable. The Company does not believe that any existing or pending claims would have a material impact on the Company's condensed consolidated financial statements.

***French Regulatory Decision***

On August 6, 2024, it was announced that the ANSM, the French regulatory authority, had suspended sales of the Allurion Balloon in France, and the Company withdrew the device from the French market. The Company implemented a remediation plan to reduce certain risks associated with the advertising, follow-up program, and adverse events for the Allurion Balloon. For the year ended December 31, 2024, the Company recognized a reduction to revenues of $1.2 million for customer returns of the Allurion Balloon, and no sales to France during the second half of 2024. On February 12, 2025, ANSM cleared the Company to resume sales of the Allurion Balloon, effective immediately.

------

##### [**Table of Contents**](#toc)
***NYSE Continued Listing Standards***

On August 29, 2024, we received written notice from the NYSE notifying us that as of August 29, 2024, we were not in compliance with the continued listing standard set forth in Section 802.01B of the NYSE's Listed Company Manual (the "Minimum Market Capitalization Standard") because our average market capitalization was less than $50.0 million over the consecutive 30 trading-day period ended August 29, 2024 and our last reported stockholders' equity as of August 29, 2024 was less than $50.0 million. In accordance with applicable NYSE procedures, within 45 days of receipt of the notice, we submitted a plan to the NYSE outlining measures that would bring us into conformity with the Minimum Market Capitalization Standard within 18 months of receipt of the written notice (the "Cure Period"). We submitted a business plan to the NYSE demonstrating our ability to regain compliance with the NYSE's rules, which the NYSE has accepted, and as a result we are subject to quarterly monitoring for compliance with the business plan and our Common Stock will continue to trade on the NYSE during the Cure Period, subject to our compliance with other NYSE continued listing requirements.

**18. Segment Information** 

Segment reporting is prepared on the same basis that the Company's chief executive officer, who is our chief operating decision maker ("CODM"), manages the business, makes operating decisions, and assesses performance. The Company operates in one segment. We have selected net income (loss) as our reported measure of profit or loss because it is regularly provided to our CODM, allows our CODM to make decisions on resource allocations, and allows our CODM to assess performance of the business.

Disclosures about significant segment expenses and long-lived assets by geography are presented below. Refer to Note 5, *Revenue* for information on revenue by geography. Significant segment expenses are set forth in the following table (in thousands):

Significant segment expenses are set forth in the following table (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2025** | **2024** |
|  | **(Restated)** | **(Restated)** |
|  Revenue | $5580 | $9386 |
|  Less: |  |  |
|  Cost of revenue | 1419 | 2520 |
|  Sales and marketing | 3621 | 6145 |
|  Clinical trials and medical affairs | 1264 | 3271 |
|  Product development | 429 | 1045 |
|  Digital | 402 | 747 |
|  Quality and regulatory | 529 | 662 |
|  General and administrative | 5198 | 6386 |
|  Other segment items (1) | (5781) | (13386) |
|  Net (loss) income | $(1501) | $1996 |

---

(1) Other segment items included in Net income primarily include changes in fair value of warrant liabilities,
changes in fair value of debt, changes in fair value of the Revenue Interest Financing, loss on extinguishment of debt, interest expense, and other income.

Long-lived assets, consisting of property and equipment, net and ROU assets by geography were as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2025** | **December 31,<br>2024** |
|  United States | $3605 | $3929 |
|  France | 562 | 619 |
|  All other countries |  |  |
|  Long-lived assets | $4167 | $4548 |

---

------

##### [**Table of Contents**](#toc)
**19. Related-party Transactions** 

***Lease Agreement with Related Party***

In August 2022, the Company entered into an operating lease agreement for additional office space in Paris, France with LNMP JPBC Invest. The Company's then-Trade Marketing Director was the signor of this lease for LNMP JPBS Invest. Additionally, the Company's former Chief Commercial Officer is also a partner of LNMP JPBC Invest. The lease agreement included lease payments of approximately $0.1 million per year. The term of the lease was August 1, 2022 through July 31, 2025. The Company concluded that the commercial terms of the lease agreement were competitive, at the current market rate and conducted at arm's-length. This lease was terminated in February 2024.

***Convertible Note Agreement with RTW***

Pursuant to the Amended Note Purchase Agreement, on April 16, 2024, we issued and sold $48.0 million aggregate principal amount of convertible notes to RTW. RTW holds more than 5% of our outstanding Common Stock, has the right to designate an independent director nominee to be elected by our stockholders, is entitled to designate one representative to serve as a non-voting observer on our Board, and had the right to approve an additional director nominee for election. In September 2024, we expanded our Board and appointed a new director in satisfaction of certain of these obligations to RTW as set forth in the Amended Note Purchase Agreement. Refer to Note 9, *Debt*, for additional information regarding the RTW Convertible Notes.

***RTW Participation in Public Offering***

In connection with the Public Offering, the Company issued and sold 9,594 shares of Common Stock and accompanying warrants to funds affiliated with RTW, for an aggregate purchase price of approximately $0.3 million. The Public Offering closed on July 1, 2024.

***Private Placement with RTW***

On June 28, 2024, pursuant to the Subscription Agreement, the Company agreed to sell to RTW 2,260,159 shares of Series A Preferred Stock (as converted to 90,407 shares of Common Stock on December 19, 2024 following the Series A Stockholder Approval and after giving effect to the Reverse Stock Split), and 90,407 July 2024 Private Placement Warrants (after giving effect to the the Reverse Stock Split), for an aggregate purchase price of approximately $2.7 million. The Private Placement closed on July 1, 2024.

***Exercise of PIPE Conversion Option and New RIFA with RTW***

On October 22, 2024, funds affiliated with RTW provided notice to the Company of their election of the PIPE Conversion Option under the Amended and Restated RTW Side Letter, to surrender 30,000 shares of Common Stock of the Company representing $7.5 million in consideration for an additional Revenue Interest Financing Agreement. Accordingly, on October 30, 2024, the Company and the funds affiliated with RTW entered into the New RIFA. The New RIFA has substantially identical terms and conditions as the Revenue Interest Financing Agreement except that the amount of financing provided under the New RIFA is equal to the conversion amount of $7.5 million.

***January 2025 Private Placement with RTW***

On January 14, 2025, the Company entered into the RTW Subscription Agreement with funds affiliated with RTW, pursuant to which the Company agreed to sell 841,751 shares of Common Stock at a purchase price of $2.97 per share. The RTW Private Placement closed on January 16, 2025 with net proceeds received of $2.5 million.

**20. Subsequent Events** 

***Stockholder Approval of Warrant Repricing***

On April 10, 2025, the Company's stockholders approved the January Warrant Repricing and the February Warrant Repricing, and the applicable Public Offering Warrants became exercisable at the reduced exercise price of $6.00 per share.

***Second Amendment to Amended Note Purchase Agreement***

On April 15, 2025, the Company, the purchasers of the RTW Convertible Notes (the "Purchasers") and RTW, as agent for the purchasers (the "Purchasers") entered into the Second Amendment to Note Purchase Agreement (the "Second Amendment to Note Purchase Agreement"), which amended the Amended Note Purchase Agreement to reflect additional conversion and other provisions, including provisions permitting the conversion of the RTW Convertible Notes at reduced conversion prices, resulting in the potential issuance of additional shares, which had been approved by the Company's stockholders at the Special Meeting of Stockholders held on April 10, 2025.

------

##### [**Table of Contents**](#toc)
The Second Amendment to Note Purchase Agreement provides for the mandatory conversion of $5.0 million of principal amount of RTW Convertible Notes in the event the Company's market capitalization, as determined in accordance with the rules of the NYSE or such other nationally recognized securities exchange upon which the Common Stock is then listed, is reasonably expected to fall below $15.0 million (the "Market Capitalization Condition"). In the event such Market Capitalization Condition is triggered, the Purchasers shall provide notice to the Company, and the Company shall accept such notice, to convert $5.0 million aggregate principal amount of the RTW Convertible Notes at the Floor Conversion Rate (defined below), and such amount shall be converted into 1,492,539 shares of Common Stock of the Company.

On April 16, 2025, the Purchasers provided notice of conversion of $5.0 million of principal amount of the RTW Convertible Notes based on the closing price of the Common Stock on the immediately preceding trading day and resulting market capitalization of less than $15.0 million. The parties agreed that it is reasonably expected that such market capitalization will remain below $15.0 million for the period of time that would result in delisting under NYSE rules and, accordingly, that the Market Capitalization Condition has been triggered and such mandatory conversion of $5.0 million of principal amount of the RTW Convertible Notes shall occur at the floor price of $3.35 per share. The Company subsequently issued an aggregate of 1,492,539 shares of Common Stock (subject to rounding for fractional shares) in accordance with the terms of the Second Amendment to Note Purchase Agreement.

In the event such Market Capitalization Condition is triggered, the Purchasers also have the right to provide notice to convert up to an additional $5.0 million of aggregate principal amount of the RTW Convertible Notes into shares of Common Stock at an agreed conversion rate. The Company has the right to accept or reject such conversion in its sole discretion. The Company and the Purchasers will mutually agree on the agreed conversion rate, *provided* that it is not more than 298.5075 shares of Common Stock per $1,000 principal amount of the RTW Convertible Notes, reflecting a floor conversion price of $3.35 per share of Common Stock (such rate, the "Floor Conversion Rate").

In addition, without regard to the Market Capitalization Condition, the Purchasers may provide notice to convert up to an additional $5.0 million aggregate principal amount of the RTW Convertible Notes into shares of Common Stock at the 5-Day VWAP Conversion Rate, which the Company may accept or reject in its sole discretion. The "5 Day VWAP Conversion Rate" is the lesser of (i) the quotient of $1,000 divided by the daily volume weighted average price of the Common Stock for the five consecutive trading day period ending on the trading day immediately preceding the date of the delivery of RTW's notice, discounted by five percent and (ii) the Floor Conversion Rate.

Finally, during the one year period ending on April 15, 2026, the Purchasers in their sole discretion may provide notice to convert up to an additional $1.0 million aggregate principal amount of the RTW Convertible Notes in any 30-day period into shares of Common Stock at the 5-Day VWAP Conversion Rate. If the Purchasers do not exercise their right to provide a notice to convert all or a portion of $1.0 million aggregate principal amount of the RTW Convertible Notes per month, any shortfall may be included in the amount to be converted in a subsequent 30-day period. The maximum principal amount of the RTW Convertible Notes that may be converted under such monthly conversion provision is $12.0 million. The Company may accept or reject any such monthly conversion in its sole discretion.

The Second Amendment to Note Purchase Agreement also contains an agreement by the Purchasers that, without the prior written consent of the Company, until the Voting Agreement Termination Date (defined below), at any meeting of the Company's stockholders, including any postponement, recess or adjournment thereof, or in any other circumstance in which a vote, consent or other approval of stockholders is sought, the Purchasers will either, at their sole option (i) abstain from voting the shares of Common Stock issued pursuant to the new conversion provisions set forth in the Second Amendment to Note Purchase Agreement described above, or (ii) vote such shares in proportion to the votes cast on the applicable matter with respect to the shares of Common Stock beneficially owned by persons other than the Purchasers or any of their affiliates. Such voting agreement shall terminate upon the earlier of (i) the effective date of any Fundamental Change or Make-Whole Fundamental Change (as such terms are defined in the Amended Note Purchase Agreement) and (ii) the date on which the Purchasers and their affiliates collectively have the power to vote shares of Common Stock (including the shares issued upon conversion pursuant to the Second Amendment to Note Purchase Agreement) representing less than 9.9% of the voting power of the outstanding shares of the Company (such date, the "Voting Agreement Termination Date").

------

##### [**Table of Contents**](#toc)
**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.** 

The following discussion and analysis includes information that our management believes is relevant to an assessment and understanding of our condensed consolidated results of operations and financial condition. The discussion and analysis should be read together with the unaudited consolidated financial statements as of and for the three months ended March 31, 2025 and March 31, 2024 included in this Quarterly Report on Form 10-Q/A, and the audited consolidated financial statements as of and for the years ended December 31, 2024 and December 31, 2023 that are included in our Annual Report on Form 10-K filed with the SEC on March 27, 2025, as amended by Amendment No. 1 to the Annual Report on Form 10-K filed with the SEC on August 19, 2025 (together, the "Annual Report on Form 10-K"). This discussion may contain forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the sections titled "Cautionary Statement Regarding Forward-Looking Statements" and "Risk Factors" in our Annual Report on Form 10-K and this Quarterly Report on Form 10-Q/A. For purposes of this section, all references in this discussion and analysis to "Allurion," the "Company", "we," "us," or "our" refers to the business and operations of Allurion Technologies, Inc. and its consolidated subsidiaries following the consummation of the Business Combination and to Legacy Allurion and its consolidated subsidiaries prior to the consummation of the Business Combination. "Legacy Allurion" refers to Allurion Technologies, LLC, which was previously known as Allurion Technologies Opco, Inc. (formerly Allurion Technologies, Inc.) prior to the consummation of the Business Combination.

**Restatement of Previously Issued Financial Statements** 

As discussed in the Explanatory Note to this Form 10-Q/A, the Company is restating its previously issued unaudited condensed consolidated financial statements as of and for the three months ended March 31, 2025 and March 31, 2024. As a result, the previously reported financial information as of and for the three months ended March 31, 2025 and March 31, 2024 in this "*Management's Discussion and Analysis of Financial Condition and Results of Operations*" has been amended and restated to reflect the restatement. See Note 2 "*Restatement of Previously Issued Financial Statements*" to the unaudited consolidated financial statements included in this Form 10-Q/A for further detail regarding the restatement, including descriptions of the adjustments and the impacts on our unaudited consolidated financial statements.

Other than the effect of the restatement noted above, this section has not been otherwise modified and does not reflect any information or events occurring after May 15, 2025, the filing date of the Original Form 10-Q, or modify or update those disclosures affected by events that occurred at a later date or facts that subsequently became known to the Company, except to the extent they are otherwise required to be included and discussed herein.

**Overview**

Allurion is a leading medical device company that is focused on creating a best-in-class weight loss platform to treat obese and overweight patients. Our platform, the Allurion Program (the "Allurion Program"), features the world's first and only swallowable, procedureless<sup>™</sup> intragastric balloon for weight loss (the "Allurion Balloon") and offers artificial intelligence ("AI")-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging and video telehealth that are delivered by the Allurion Virtual Care Suite ("VCS").

The Allurion Program was designed to achieve metabolically healthy weight loss, which entails losing weight, maintaining that weight loss, and maintaining or increasing muscle mass in the process. Unlike other options that lead to short-term weight loss and muscle wasting, the Allurion Program is intended to deliver longer lasting results while reducing fat and not muscle. We believe the Allurion Program is also synergistic in combination with other weight loss therapies, including glucagon-like peptide 1 ("GLP-1") receptor agonists.

Our proprietary intragastric balloon, the Allurion Balloon, is swallowed as a capsule under the guidance of a health care provider without surgery, endoscopy, or anesthesia for placement.

The Allurion VCS is comprised of tools to support patients' weight loss experience, which we believe benefit both patients and health care providers:

1. For Allurion Program patients: Every current Allurion Program patient receives an Allurion Connected Scale ("Allurion Connected Scale") and access to our mobile app (the "App"), which integrates data from the Allurion Connected Scale to conveniently monitor weight, muscle mass, body fat, activity, sleep, and several other critical metrics. The App can also enable secure messaging and video telehealth with the patient's care team and can deliver content from Allurion's proprietary behavior change program—and library of 100 weight loss actions related to diet, nutrition, exercise, mental health, sleep, goal setting, and a number of other topics—directly to the patient. The App is available in 15 languages.

------

##### [**Table of Contents**](#toc)
In addition to its use by Allurion Balloon patients, we believe the VCS can potentially be a platform for optimal long-term follow up after other medical and surgical weight loss interventions in the future. We have incorporated a Treatment Tracking and Clinic-Led Onboarding feature into the VCS that enables seamless onboarding and management of patients undergoing one or multiple weight loss treatments, including gastric balloons such as the Allurion Balloon, surgery, or medication, and in April 2024, launched the VCS in the United States for patients utilizing other weight loss treatments, including anti-obesity medications and bariatric surgery.

Our Allurion Program products are currently sold in Europe, the Middle East, Africa, Latin America, Canada and the Asia-Pacific region.

Since our inception, we have incurred significant operating losses. Our ability to generate revenue and achieve cost improvements sufficient to achieve profitability will depend on the successful further development and commercialization of our products and receipt and maintenance of regulatory approvals. We generated revenue of $5.6 million and $9.4 million for the three months ended March 31, 2025 and 2024, respectively, and incurred losses from operations of $7.3 million and $11.4 million for those same periods, respectively. We expect to continue to incur net losses for the foreseeable future as we focus on obtaining regulatory approvals for our products in new markets, refining our sales and marketing strategies, and continuing research and development efforts to further enhance our existing products. Further, following the closing of the Business Combination, we have incurred, and expect to continue to incur, additional costs associated with operating as a public company. As a result, we will need additional funding for expenses related to our operating activities, including selling, marketing, general and administrative, and research and development expenses.

Because of the numerous risks and uncertainties associated with obtaining and maintaining regulatory approval, market acceptance of our products, product development and enhancement, and commercialization, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. Until such time, if ever, as we can generate substantial revenue sufficient to achieve profitability, we expect to finance our operations through a combination of equity offerings and debt financings. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we are unable to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the further development and commercialization efforts of one or more of our products, or may be forced to reduce or terminate our operations. See the subsection entitled— "*Liquidity and Capital Resources*" below.

**Recent Developments**

***Reverse Stock Split***

On January 3, 2025, our 1-for-25 reverse stock split (the "Reverse Stock Split") was effective following approval by stockholders at the Company's 2024 annual meeting in December 2024. As a result, every 25 shares of our issued Common Stock were combined into one share of our Common Stock. No fractional shares of our Common Stock were issued as a result of the Reverse Stock Split. Stockholders who would otherwise have held a fraction of a share of Common Stock of the Company automatically received an additional fraction of a share of Common Stock to round up to the next whole share. The shares of our Common Stock retained a par value of $0.0001 per share. Trading of the Common Stock on the NYSE commenced on a split-adjusted basis at market open on January 3, 2025 under the existing trading symbol "ALUR."

***Omnibus Amendment***

On January 7, 2025, we entered into an Omnibus Amendment (the "Omnibus Amendment") by and among us, Allurion Technologies, LLC ("Allurion OpCo"), Allurion Australia Pty Ltd, Allurion France, and RTW Investments, LP (together with its affiliates, "RTW") and certain of its affiliates, to amend (i) the Note Purchase Agreement, dated as of April 14, 2024 (as amended, the "Amended Note Purchase Agreement"), by and among us, RTW and Acquiom Agency Services LLC, the Revenue Interest Financing Agreement, dated as of February 9, 2023 (as amended, the "Revenue Interest Financing Agreement"), by and among us and RTW (such financing, the "Revenue Interest Financing") and the additional Revenue Interest Financing Agreement, dated as of October 30, 2024 (as amended, the "New RIFA"), by and among us and RTW (collectively, the "Existing Documents").

The Omnibus Amendment requires (i) us and Allurion OpCo to maintain certain minimum balances of unrestricted cash in controlled accounts in the United States in the amounts corresponding to the calculations set forth therein, and (ii) us to receive minimum trailing 12-month consolidated Revenue (as defined in the Existing Documents) at amounts designated in the Omnibus Amendment, tested quarterly beginning with the 12-month period ending September 30, 2025. The Omnibus Amendment also requires that (i) Allurion France shall have successfully regained marketing authorization from the Agence Nationale de Sécurité du Médicament ("ANSM") to resume the Commercialization (as defined in the Existing Documents) of the Product (as defined in the

------

##### [**Table of Contents**](#toc)
Existing Documents) in France on or prior to December 31, 2025, which occurred in February 2025 as discussed further below, and (ii) Allurion OpCo shall have received marketing authorization from the U.S. Food and Drug Administration (the "FDA") for the commercialization of the Product in the United States no later than June 30, 2026.

Pursuant to the Omnibus Amendment, the purchasers shall receive a number of shares of the Common Stock, representing five percent of our fully-diluted shares outstanding (without regard to any beneficial ownership limitations) immediately after the closing of the offering and sale of Additional Shares (as defined in the Existing Documents) to be consummated no later than February 15, 2025, in connection with which we raised at least $12.0 million in aggregate net proceeds; *provided* that, in the event we cannot issue shares of Common Stock to the purchasers thereunder due to applicable law, we shall instead issue an equivalent (as-converted) number of shares of a newly created series of Series A-1 non-voting preferred stock, par value $0.0001 per share (the "Series A-1 Preferred Stock"), and will include a proposal in a definitive proxy statement on Schedule 14A seeking stockholder approval no later than December 31, 2025 to allow the conversion of Series A-1 Preferred Stock into Common Stock; *provided further* that, each share of Series A-1 Preferred Stock outstanding on December 31, 2026 shall, except to the extent prohibited by Delaware law governing distributions to stockholders (including the Delaware General Corporation Law), be redeemed by us for cash in an amount equal to the as-converted value of the underlying Common Stock.

The Omnibus Amendment also provides that we will ensure RTW shall have the right to designate one director to the Board, which director is currently Nicholas Lewin, and as of the Amendment Effective Date (as defined in the Omnibus Amendment), RTW has the right to designate a second director to the Board, which additional director is initially R. Jason Richey.

***Topline AUDACITY FDA Pivotal Trial Results***

On January 8, 2025, we announced topline results from our AUDACITY pivotal trial evaluating the safety and efficacy of the Allurion Balloon. The AUDACITY trial was an open-label, multicenter, randomized, controlled trial and was the first FDA pivotal trial on an intragastric balloon for weight loss to report primary outcomes beyond nine months. The AUDACITY trial achieved its responder rate co-primary endpoint by demonstrating that more than 50% of Allurion Balloon subjects lost more than 5% of their total body weight at 48 weeks (58%; p-value = 0.0089). At 48 weeks, Allurion Balloon subjects exhibited substantially greater weight loss compared to control subjects with a 3.77% mean difference in total body weight loss, resulting in a 2.69% superiority margin. This margin was less than the pre-specified 3% superiority margin needed to meet the comparative co-primary endpoint (p-value=0.1616). At 40 weeks, the 4.22% mean difference in total body weight loss between groups exceeded a 3% superiority margin.

The rate of serious adverse events in Allurion Balloon subjects in the AUDACITY trial was 3.1%, the lowest reported in a pivotal FDA trial for a liquid-filled intragastric balloon indicated for weight loss.

Based on the results of the AUDACITY trial, we plan to submit the fourth and final module of the premarket approval application to the FDA.

***January 2025 RTW Private Placement***

On January 14, 2025, we entered into a subscription agreement (the "January 2025 Subscription Agreement") with funds affiliated with RTW, pursuant to which we agreed to issue and sell 841,751 shares of Common Stock for an aggregate purchase price of approximately $2.5 million at a purchase price of $2.97 per share (the "January 2025 RTW Private Placement"). The January 2025 RTW Private Placement closed on January 16, 2025.

***January 2025 Public Offering and Concurrent Private Placement***

On January 24, 2025, we entered into a securities purchase agreement (the "January 2025 Securities Purchase Agreement") with certain accredited investors named therein, pursuant to which we agreed to issue and sell 1,240,000 shares of Common Stock (the "January 2025 Offering") and 1,240,000 accompanying common warrants (the "January 2025 Warrants") to purchase up to 1,240,000 shares of Common Stock upon exercise of the January 2025 Warrants in a concurrent private placement (the "January 2025 Private Placement"), at an offering price of $6.00 per share and accompanying January 2025 Warrant. The January 2025 Offering and January 2025 Private Placement closed on January 27, 2025 with net proceeds of approximately $5.8 million, after deducting the placement agent fees and estimated offering expenses payable by the Company.

***February 2025 Public Offering and Concurrent Private Placement***

On February 19, 2025, we entered into a securities purchase agreement (the "February 2025 Securities Purchase Agreement") with certain accredited investors named therein, pursuant to which we agreed to issue and sell 900,000 shares of Common Stock (the "February 2025 Offering"), and 1,800,000 accompanying common warrants (the "February 2025 Warrants") to purchase up to 1,800,000 shares of Common Stock upon exercise of the February 2025 Warrants in a concurrent private placement (the "February 2025 Private Placement"), at an offering price of $5.23 per share and accompanying February 2025 Warrant. The February 2025 Offering and February 2025 Private Placement closed on February 20, 2025, and resulted in net proceeds of approximately $3.9 million, after deducting the placement agent fees and estimated offering expenses payable by the Company.

------

##### [**Table of Contents**](#toc)
***Leavitt Private Placement***

On February 19, 2025, we entered into a subscription agreement (the "Leavitt Subscription Agreement") with an accredited investor affiliated with Leavitt Equity Partners LLC (collectively, "Leavitt"), pursuant to which we agreed to issue and sell 267,686 shares of Common Stock (the "Private Placement Shares") and common warrants to purchase up to 535,372 shares of Common Stock (the "Leavitt Private Placement Warrants" and together with the February 2025 Warrants, the "February 2025 Offering Warrants"), at a purchase price of $5.23 per share and accompanying Leavitt Private Placement Warrant (the "Leavitt Private Placement"). The Leavitt Private Placement closed on February 20, 2025 with net proceeds of $1.3 million after deducting placement agent fees of $0.1 million.

***Resumption of Sales in France***

On February 13, 2025, we announced that we were relaunching the Allurion Balloon in France after the ANSM, the French regulatory authority, repealed its temporary suspension of sales of the device following our completion of the remediation plan we developed in cooperation with the agency and we were cleared to resume sales of the Allurion Balloon, effective immediately.

***Second Amendment to Note Purchase Agreement***

On April 15, 2025, we entered into the Second Amendment to Note Purchase Agreement (the "Second Amendment to Note Purchase Agreement") with the purchasers of the RTW Convertible Notes (the "Purchasers") and RTW, as agent for the purchasers, which amended the Amended Note Purchase Agreement to reflect additional conversion and other provisions, including provisions permitting the conversion of a portion of the RTW Convertible Notes at reduced conversion prices, resulting in the potential issuance of additional shares, which was approved by our stockholders at the Special Meeting of Stockholders held on April 10, 2025.

The Second Amendment to Note Purchase Agreement provides for the mandatory conversion of $5.0 million of principal amount of the RTW Convertible Notes in the event our market capitalization, as determined in accordance with the rules of the NYSE or such other nationally recognized securities exchange upon which the Common Stock is then listed, is reasonably expected to fall below $15.0 million (the "Market Capitalization Condition"). In the event such Market Capitalization Condition is triggered, the Purchasers shall provide notice to the Company, and the Company shall accept such notice, to convert $5.0 million aggregate principal amount of the RTW Convertible Notes at the Floor Conversion Rate (defined below), and such amount shall be converted into 1,492,539 shares of our Common Stock.

On April 16, 2025, the Purchasers provided notice of conversion of $5.0 million of principal amount of the RTW Convertible Notes based on the closing price of the Common Stock on the immediately preceding trading day and resulting market capitalization of less than $15.0 million. The parties that it is reasonably expected that such market capitalization will remain below $15.0 million for the period of time that would result in delisting under NYSE rules and, accordingly, that the Market Capitalization Condition had been triggered and such mandatory conversion of $5.0 million of principal amount of the RTW Convertible Notes shall occur at the floor price of $3.35 per share. The Company subsequently issued an aggregate of 1,492,539 shares of Common Stock (subject to rounding for fractional shares) in accordance with the terms of the Second Amendment to Note Purchase Agreement.

In the event such Market Capitalization Condition is triggered, the Purchasers also have the right to provide us notice to convert up to an additional $5.0 million of aggregate principal amount of the RTW Convertible Notes into shares of Common Stock at an agreed conversion rate. We have the right to accept or reject such conversion in our sole discretion. The parties will mutually agree on the agreed conversion rate, *provided* that it is not more than 298.5075 shares of Common Stock per $1,000 principal amount of the RTW Convertible Notes, reflecting a floor conversion price of $3.35 per share of Common Stock (such rate, the "Floor Conversion Rate").

In addition, without regard to the Market Capitalization Condition, the Purchasers may provide us notice to convert up to an additional $5.0 million aggregate principal amount of the RTW Convertible Notes into shares of Common Stock at the 5-Day VWAP Conversion Rate, which we may accept or reject in our sole discretion. The "5 Day VWAP Conversion Rate" is the lesser of (i) the quotient of $1,000 divided by the daily volume weighted average price of the Common Stock for the five consecutive trading day period ending on the trading day immediately preceding the date of the delivery of the notice, discounted by five percent and (ii) the Floor Conversion Rate.

Finally, during the one year period ending on April 15, 2026, the Purchasers in their sole discretion may provide us notice to convert up to an additional $1.0 million aggregate principal amount of the RTW Convertible Notes in any 30-day period into shares of Common Stock at the 5-Day VWAP Conversion Rate. If the Purchasers do not exercise their right to provide a notice to convert all or a portion of $1.0 million aggregate principal amount of the RTW Convertible Notes per month, any shortfall may be included in the amount to be converted in a subsequent 30-day period. The maximum principal amount of the RTW Convertible Notes that may be converted under such monthly conversion provision is $12.0 million. We may accept or reject any such monthly conversion in our sole discretion.

------

##### [**Table of Contents**](#toc)
The Second Amendment to Note Purchase Agreement also contains an agreement by the Purchasers that, without our prior written consent, until the Voting Agreement Termination Date (defined below), at any meeting of our stockholders, including any postponement, recess or adjournment thereof, or in any other circumstance in which a vote, consent or other approval of stockholders is sought, the Purchasers will either, at their sole option (i) abstain from voting the shares of Common Stock issued pursuant to the new conversion provisions set forth in the Second Amendment to Note Purchase Agreement described above, or (ii) vote such shares in proportion to the votes cast on the applicable matter with respect to the shares of Common Stock beneficially owned by persons other than the Purchasers or any of their affiliates. Such voting agreement shall terminate upon the earlier of (i) the effective date of any Fundamental Change or Make-Whole Fundamental Change (as such terms are defined in the Amended Note Purchase Agreement) and (ii) the date on which the Purchasers and their affiliates collectively have the power to vote shares of Common Stock (including the shares issued upon conversion pursuant to the Second Amendment to Note Purchase Agreement) representing less than 9.9% of the voting power of the outstanding shares of the Company (such date, the "Voting Agreement Termination Date").

**Key Factors Affecting Our Operating Results**

We believe that our performance and future success depend on many factors that present significant opportunities but also pose risks and challenges, including those discussed below and in the "Risk Factors" section of our Annual Report on Form 10-K.

• *Market Acceptance*. The growth of our business depends on our ability to gain broader acceptance of our
current products by continuing to make health care providers aware of the benefits of our products to generate increased demand and frequency of use, and thus increase our sales. Our ability to grow our business will also depend on our ability to
expand our customer base in existing or new target markets. Although we have increased the number of patients treated with our products through our established relationships and focused sales efforts, we cannot provide assurance that our efforts
will continue to increase the use of our products.

• *Regulatory approval and timing and efficiency of new product introductions*. We must successfully obtain
timely approvals, maintain regulatory approval, successfully implement any remediation programs required by regulators to resume sales of the Allurion Balloon, and introduce new products that gain acceptance with health care providers. For our sales
to grow, we will also need to obtain regulatory approval of our existing product and any new products or modifications/enhancements to our existing products in the markets that we operate in and new markets as applicable.

• *Sales force size and effectiveness.* The speed at which newly hired salespeople become effective can impact
our revenue growth or our costs incurred in anticipation of such growth. We intend to continue to improve and increase performance in our sales and marketing organization, and expand our international programs to help facilitate further adoption of
our products as well as broaden awareness of our products to new customers.

• *Product and geographic mix; timing.* Our financial results, including our gross margins, may fluctuate from
period to period based on the timing of orders, fluctuations in foreign currency exchange rates, and the number of available selling days in a particular period, which can be impacted by a number of factors, such as holidays or days of severe
inclement weather in a particular geography, the mix of products sold, and the geographic mix of where products are sold.

**Operating Segments**

We operate our business in a single segment and as one reporting unit, which is how our chief operating decision maker ("CODM"), our chief executive officer, reviews financial performance and allocates resources. The CODM reviews financial information presented on a regular basis at the consolidated level for purposes of allocating resources and evaluating financial performance. Since we operate as one operating segment, all required financial segment information can be found in the consolidated financial statements.

**Components of Our Results of Operations**

***Revenue***

We derive revenue from the sale of the Allurion Balloon to customers, which are either distributors or health care providers. The Allurion Balloon is the foundation of the Allurion Program, a holistic weight loss program that offers patients the opportunity to receive, and clinic and other health care providers the ability to deliver, behavior change assistance through their use of our remote patient support and monitoring tools.

***Cost of Revenue***

Cost of revenue consists primarily of costs that are closely correlated or directly related to the delivery of our products, including material costs, labor costs, and depreciation expense for fixed assets.

------

##### [**Table of Contents**](#toc)
***Operating Expenses***

*Sales and Marketing Expenses*

Sales and marketing expenses consist primarily of salaries and related expenses (including commissions) for our sales and marketing personnel. Marketing programs consist of advertising, training events, brand building, product marketing activities, and shipping costs.

*Research and Development Expenses*

Our research and development expenses consist of costs associated with performing research and development activities such as registering our products in various jurisdictions and performing clinical trials. These costs include salaries and benefits, stock-based compensation, non-capitalizable software development costs, product development costs, materials and supplies, clinical trial activities, registration expenses, depreciation of equipment, and other outside services.

*General and Administrative Expenses*

General and administrative expenses consist primarily of salaries and personnel-related costs, including stock-based compensation, for our personnel in executive, information technology, finance and accounting, human resources and other administrative functions. General and administrative expenses also include legal fees relating to corporate matters; professional fees paid for accounting, auditing, consulting and tax services; insurance costs; travel expenses; office and information technology costs; and facilities, depreciation and other expenses related to general and administrative activities, which include direct or allocated expenses for rent and maintenance of facilities and utilities.

***Other Income (Expense)***

*Interest Expense*

Interest expense consists of interest expense associated with outstanding borrowings under our debt obligations as well as the amortization of debt issuance costs and discounts associated with such borrowings.

*Change in Fair Value of Warrants*

The change in fair value of warrants consists of the expense recognized upon the mark to market of our warrant liabilities.

*Change in Fair Value of Debt*

The change in fair value of debt consists of the expense recognized upon the mark to market of our convertible debt.

*Change in Fair Value of Revenue Interest Financing and PIPE Conversion Option* 

The change in fair value of Revenue Interest Financing and PIPE Conversion Option (as defined below) consists of the expense recognized upon the mark to market of the Revenue Interest Financing with RTW and the issuance and mark to market of the PIPE Conversion Option. See Note 11, *Fair Value Measurements* for further information.

*Change in Fair Value of Earn-out Liabilities* 

The change in fair value of earn-out liabilities consists of the gain or loss recognized upon mark to market of the contingent earn-out consideration. See Note 11, *Fair Value Measurements* for further information.

*Other Income, net*

Other income, net consists of interest earned on our invested cash balances, which primarily consist of deposit accounts and money market funds, foreign currency transaction gains and losses, and expense associated with our Success Fee derivative liability and Share Obligation liability (as defined in Note 9, *Debt* in the accompanying notes to the condensed consolidated financial statements). See Note 11, *Fair Value Measurements* for further information.

------

##### [**Table of Contents**](#toc)
**Results of Operations**

***Comparison of the Three Months Ended March 31, 2025 and 2024 (unaudited)***

The following table summarizes our results of operations for the three months ended March 31, 2025 and 2024 (in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2025** | **2024** | **Change** |
|  | **(Restated)** | **(Restated)** | **(Restated)** |
|  Revenue | $5580 | $9386 | $(3806) |
|  Cost of revenue | 1419 | 2520 | (1101) |
|  Gross profit | 4161 | 6866 | (2705) |
|  Operating expenses: |  |  |  |
|  Sales and marketing | 3621 | 6145 | (2524) |
|  Research and development | 2624 | 5725 | (3101) |
|  General and administrative | 5198 | 6386 | (1188) |
|  Total operating expenses: | 11443 | 18256 | (6813) |
|  Loss from operations | (7282) | (11390) | 4108 |
|  Other income (expense): |  |  |  |
|  Interest expense |  | (1931) | 1931 |
|  Changes in fair value of warrants | 5669 | 3131 | 2538 |
|  Changes in fair value of debt | 3330 |  | 3330 |
|  Changes in fair value of Revenue Interest Financing and PIPE <br>conversion option | (3820) | (2100) | (1720) |
|  Changes in fair value of earn-out liabilities | 910 | 14190 | (13280) |
|  Other income (expense), net | (213) | 172 | (385) |
|  Total other income (expense): | 5876 | 13462 | (7586) |
| (Loss) income before income taxes: | (1406) | 2072 | (3478) |
|  Provision for income taxes: | (95) | (76) | (19) |
|  Net (loss) income | $(1501) | $1996 | $(3497) |

---

***Revenue***

Revenue decreased $3.8 million, or 41%, to $5.6 million for the three months ended March 31, 2025 compared to the same period in 2024. The decrease in revenue was primarily the result of not selling product in France during the three months ended March 31, 2025 compared to revenue of $1.7 million in the same period in 2024, as well as lower investment in sales and marketing as we move our strategy from business to business to customer and away from direct to customer.

***Cost of Revenue***

Cost of revenue decreased $1.1 million, or 44%, to $1.5 million for the three months ended March 31, 2025 compared to the same period in 2024. The decrease in cost of revenue was a direct result of decreased gastric balloon units sold coupled with operating efficiencies from the restructuring implemented during the fourth quarter of 2024.

***Gross Profit***

Gross profit decreased $2.7 million, or 39%, to $4.2 million for the three months ended March 31, 2025 compared to the same period in 2024. The decrease in gross profit was primarily the result of a decrease in revenue and sales volume of our gastric balloon system.

***Operating Expenses***

*Sales and Marketing Expenses*

Sales and marketing expenses decreased $2.5 million, or 41%, to $3.6 million for the three months ended March 31, 2025 compared to the same period in 2024. The decrease in sales and marketing expenses was primarily the result of a $1.6 million decrease in salaries and related benefits due to lower headcount as a result of the restructuring implemented during the fourth quarter of 2024 and a $1.1 million decrease in marketing expenditures driven by a reorganization of our selling and marketing spend focusing on more efficient channels and geographies. These decreases are partially offset by a $0.3 million increase in shipping and logistics expense.

------

##### [**Table of Contents**](#toc)
*Research and Development Expenses*

Research and development expenses decreased $3.1 million, or 54%, to $2.6 million for the three months ended March 31, 2025 compared to the same period in 2024. The decrease in research and development expenses was primarily the result of a $1.5 million decrease in costs related to the AUDACITY clinical trial as it nears completion, a $0.7 million decrease attributable to salaries and related benefit costs due to lower headcount as a result of the restructuring implemented during the fourth quarter of 2024, and a $0.2 million decrease in outside consulting costs.

*General and Administrative Expenses*

General and administrative expenses decreased $1.2 million, or 19%, to $5.2 million for the three months ended March 31, 2025 compared to the same period in 2024. The decrease in general and administrative expenses was primarily the result of a $1.5 million decrease in salaries and related benefit costs due to lower headcount as a result of the restructuring implemented during the fourth quarter of 2024. This decrease was partially offset by a $0.4 million increase in legal and professional fees, primarily driven by $1.4 million of one-time financing costs during the three months ended March 31, 2025.

***Other income (expense)***

*Interest Expense*

Interest expense decreased $1.9 million, or 100%, to zero for the three months ended March 31, 2025 compared to the same period in 2024. The decrease in interest expense was due to the termination of our Fortress Term Loan in April 2024.

*Change in Fair Value of Warrants* **** 

The $5.7 million gain attributable to the change in fair value of warrants for the three months ended March 31, 2025, compared to the same period in 2024, was due to mark to market fluctuations in our warrant liabilities due to the decline in value of our Common Stock during the applicable periods, as well as the issuance of the Public Offering Warrants, July 2024 Private Placement Warrants, January 2025 Warrants, and February 2025 Offering Warrants, for which there were no comparable mark to market fluctuations in the prior period.

*Change in Fair Value of Debt* **** 

The $3.3 million gain (as restated) attributable to the change in fair value of debt for the three months ended March 31, 2025, compared to the same period in 2024, was due to mark to market fluctuations in our convertible debt during the period.

*Change in Fair Value of Revenue Interest Financing and PIPE Conversion Option*

The $3.8 million loss (as restated) attributable to the change in fair value of the Revenue Interest Financing and PIPE Conversion Option for the three months ended March 31, 2025, compared to the same period in 2024, was due to mark to market fluctuations in our Revenue Interest Financing during the period.

*Change in Fair Value of Earn-Out Liabilities* 

The $0.9 million gain attributable to the change in the fair value of earn-out liabilities for the three months ended March 31, 2025 was due to the decrease in the Company's stock price during the period.

*Other Income, Net*

The change in Other income, net for the three months ended March 31, 2025, compared to the same period in 2024, was a loss of $0.2 million attributable to a $0.7 million loss related to the Share Obligation. This loss was partially offset by a $0.4 million gain related to fluctuations in exchange rates of foreign currencies and $0.2 million of interest income during the three months ended March 31, 2025.

***Provision for Income Taxes***

We recorded a provision for income taxes of $0.1 million for the three months ended March 31, 2025. The provision for income taxes is due to net income in certain foreign jurisdictions.

**Liquidity and Capital Resources**

Since our inception, we have primarily obtained cash to fund our operations through the sale of Common Stock and preferred stock, issuance of term loans, and issuance of convertible debt instruments. As of March 31, 2025, we had $20.4 million in cash and cash equivalents. We incurred operating losses of $7.3 million and $11.4 million for the three months ended March 31, 2025 and 2024, respectively. We incurred cash outflows from operating activities of $9.5 million and $8.6 million during the three months ended March 31, 2025 and 2024, respectively. As of March 31, 2025, we had an accumulated deficit of $223.7 million (as restated). We expect to continue to generate operating losses for the foreseeable future.

Our future capital requirements will depend on many factors, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the emergence of competing innovative weight loss solutions and other adverse business developments;

------

##### [**Table of Contents**](#toc)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the timing and extent of our sales and marketing, and research and development, expenditures; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any investments or acquisitions we may choose to pursue in the future.

Our revenue for the three months ended March 31, 2025 was $5.6 million, which represented a year-over-year decrease of 41%. The decrease in revenue was primarily the result of the result of not selling product in France during the three months ended March 31, 2025 compared to revenue of $1.7 million in the same period in 2024, as well as lower investment in sales and marketing as we move our strategy from business to business to consumer and away from direct to consumer. If our current cash and anticipated revenue and resulting cash flows from operations are insufficient to satisfy our liquidity requirements, due to increased expenditures, lower demand for our sales of our gastric balloon system, the occurrence of other events, or the realization of the risks described in our Annual Report on Form 10-K under the heading "Risk Factors," we may be required to raise additional capital through the issuances of public or private equity or debt financing or other capital sources earlier than expected.

Until such time as we can generate sufficient revenue to fund operations, we expect to use proceeds from the issuance of equity, debt financings, or other capital transactions to fund our operations and satisfy our liquidity requirements, but the amount and timing of such financings are uncertain. We may be unable to increase our revenue, raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to increase our revenue, raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue our operations or the development and commercialization of one or more of our product candidates and other strategic initiatives. Based on our recurring losses from operations incurred since inception, the expectation of continuing operating losses for the foreseeable future, and the potential need to raise additional capital to finance our future operations and debt service payments, we have concluded that there is substantial doubt about our ability to continue as a going concern for a period of one year from the date that the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q/A are issued.

***Financing Arrangements***

*Leavitt Private Placement* 

On February 20, 2025, we received net proceeds of $1.3 million from the issuance of 267,686 shares of Common Stock and 535,372 Leavitt Private Placement Warrants at an offering price of $5.23 per share and accompanying warrant.

*February 2025 Public Offering and Concurrent Private Placement* 

On February 20, 2025, we received net proceeds of $3.9 million from the issuance of 900,000 shares of Common Stock and 1,800,000 February 2025 Warrants at an offering price of $5.23 per share and accompanying warrant.

*January 2025 Public Offering and Concurrent Private Placement* 

On January 27, 2025, we received net proceeds of $5.8 million from the issuance of 1,240,000 shares of Common Stock and 1,240,000 January 2025 Warrants at an offering price of $6.00 per share and accompanying warrant.

*January 2025 RTW Private Placement* 

On January 16, 2025, we received net proceeds of $2.5 million from the issuance of 841,751 shares of Common Stock to funds affiliated with RTW as a purchase price of $2.97 per share.

*Public Offering and Concurrent Private Placement* 

On July 1, 2024, we received $15.2 million in net proceeds from the issuance of 576,261 shares of Common Stock and 662,701 Public Offering Warrants and $2.5 million in net proceeds from the sale and issuance of 2,260,159 shares of Series A Preferred Stock (as converted to 90,407 shares of Common Stock following the Series A Stockholder Approval and Reverse Stock Split) and 90,407 July 2024 Private Placement Warrants in the July 2024 Private Placement, in each case at an offering price of $30.00 per share and accompanying warrant. On July 5, 2024, the underwriters in the public offering partially exercised their option to purchase an additional 77,091 shares of Common Stock for additional net proceeds of $2.2 million.

*Amended Note Purchase Agreement* 

On April 16, 2024, we received $48.0 million in gross proceeds from the Amended Note Purchase Agreement with RTW, which proceeds were used to repay all outstanding principal, accrued and unpaid interest, and other obligations with respect to the Fortress Term Loan.

As of March 31, 2025, $48.0 million of the RTW Convertible Notes remains outstanding and is included in convertible notes payable, net of discounts on our condensed consolidated balance sheets. See Note 9, *Debt*, in the notes to our unaudited interim condensed consolidated financial statements for the three months ended March 31, 2025 and 2024 included within this Quarterly Report on Form 10-Q/A for additional details regarding the RTW Convertible Notes.

On April 15, 2025, we entered into the Second Amendment to Note Purchase Agreement with the Purchasers and RTW. On April 16, 2025, pursuant to the Second Amendment to Note Purchase Agreement, the Purchasers provided notice of conversion of

------

##### [**Table of Contents**](#toc)
$5.0 million of principal amount of the RTW Convertible Notes based on the closing price of the Common Stock on the immediately preceding trading day and resulting market capitalization of less than $15.0 million. The parties agreed that the Market Capitalization Condition was triggered and such mandatory conversion of $5.0 million of principal amount of the RTW Convertible Notes shall occur at the floor price of $3.35 per share. We subsequently issued an aggregate of 1,492,539 shares of Common Stock (subject to rounding for fractional shares) in accordance with the terms of the Second Amendment to Note Purchase Agreement.

*Chardan Purchase Agreement* 

On December 18, 2023, we entered into the Purchase Agreement with Chardan. Pursuant to the Purchase Agreement, we have the right from time to time at our option to sell to Chardan up to the lesser of (i) $100,000,000 in aggregate gross purchase price of newly issued shares of our Common Stock, and (ii) the Exchange Cap (379,299 shares of Common Stock), subject to certain conditions.

As of March 31, 2025, we have received $1.0 million in net proceeds from sales of shares of our Common Stock pursuant to the Purchase Agreement with Chardan.

*Revenue Interest Financing Agreement*

On August 1, 2023, we received $40.0 million in proceeds from the Revenue Interest Financing Agreement with RTW, which matures in December 2030. We entered into the Revenue Interest Financing Agreement on February 9, 2023 and received the proceeds at the closing of the Business Combination. On April 14, 2024, the Revenue Interest Financing Agreement was amended to, among other things, increase the rate of revenue interest payments to be paid to RTW. The Revenue Interest Financing Agreement is included in Revenue Interest Financing liability on our condensed consolidated balance sheet as of March 31, 2025. See Note 10, *Revenue Interest Financing, Side Letter, and PIPE Conversion Option* in the notes to our unaudited interim condensed consolidated financial statements for the three months ended March 31, 2024 and March 31, 2023 included within this Quarterly Report on Form 10-Q/A for additional details regarding the Revenue Interest Financing Agreement.

On October 22, 2024, funds affiliated with RTW provided notice of their election under the Amended and Restated RTW Side Letter to surrender 30,000 shares of Common Stock representing $7.5 million in consideration for an additional Revenue Interest Financing Agreement. Accordingly, on October 30, 2024, the Company and the funds affiliated with RTW entered into the New RIFA.

***Material Cash Requirements for Known Contractual and Other Obligations***

*Leases*

We have entered into various non-cancellable operating leases for our corporate office, manufacturing facilities, research and development labs, management office space and certain equipment. The leases have varying terms expiring between 2025 and 2028. See Note 17, *Commitments and Contingencies* for additional details related to our noncancelable operating leases.

*RTW Convertible Notes* 

On April 16, 2024, we received $48.0 million in gross proceeds from the Amended Note Purchase Agreement with RTW, which proceeds were used to repay all outstanding principal, accrued and unpaid interest and other obligations with respect to the Fortress Term Loan.

On April 15, 2025, we entered into the Second Amendment to Note Purchase Agreement. On April 16, 2025, pursuant to the Second Amendment to Note Purchase Agreement, the Purchasers provided notice of conversion of $5.0 million of principal amount of the RTW Convertible Notes based on the closing price of the Common Stock on the immediately preceding trading day and resulting market capitalization of less than $15.0 million. The parties agreed that the Market Capitalization Condition was triggered and such mandatory conversion of $5.0 million of principal amount of the RTW Convertible Notes shall occur at the floor price of $3.35 per share. We subsequently issued an aggregate of 1,492,539 shares of Common Stock (subject to rounding for fractional shares) in accordance with the terms of the Second Amendment to Note Purchase Agreement.

*Revenue Interest Financing* 

We received $40.0 million in proceeds from the Revenue Interest Financing Agreement with RTW on August 1, 2023. In exchange, we are obligated to remit to RTW certain revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at certain specified rates. On April 14, 2024, the Revenue Interest Financing Agreement was amended to, among other things, increase the rate of revenue interest payments to be paid to RTW for net sales less than or equal to $100 million prior to December 31, 2026 from 6% to 12%, and increase the royalty rate on net sales less than or equal to $100 million on or after January 1, 2027 from 10% to 12%.

If RTW has not received aggregate revenue interest payments equal to at least 100% of the Investment Amount by December 31, 2027, we must make a cash payment in an amount sufficient to catch RTW up to 100% of the Investment Amount. If RTW has not received revenue interest payments equal to at least 240% of the Investment Amount by December 31, 2030, we must make a cash payment in an amount sufficient to catch RTW up to 240% of the Investment Amount.

------

##### [**Table of Contents**](#toc)
Further, on October 22, 2024, funds affiliated with RTW provided notice of their election under the Amended and Restated RTW Side Letter to surrender 30,000 shares of our Common Stock representing $7.5 million in consideration for an additional Revenue Interest Financing Agreement. Accordingly, on October 30, 2024, the Company and the funds affiliated with RTW entered into the New RIFA. The New RIFA has substantially identical terms and conditions as the Revenue Interest Financing Agreement, as amended by the Omnibus Amendment, except that the amount of financing provided under the New RIFA is equal to the conversion amount of $7.5 million.

*Research and Development Costs*

We are nearing the completion of our AUDACITY clinical trial in the United States and expect our expenses to decrease significantly as we continue to make payments related to the obligations with each clinical trial site. Our clinical trial costs are dependent on, among other things, the size, number, and length of our clinical trial.

*Other Capital Requirements*

We enter into agreements in the normal course of business with various vendors, which are generally cancelable upon notice. Payments due upon cancellation typically consist only of payments for services provided or expenses incurred, including non-cancelable obligations of service providers, up to the date of cancellation.

***Cash Flows***

The following table sets forth a summary of cash flows for the periods presented:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| **(In thousands)** | **2025** | **2024** |
|  Net cash used in operating activities | $(9469) | $(8636) |
|  Net cash used in investing activities |  | (104) |
|  Net cash provided by financing activities | 14499 | 387 |
|  Net increase (decrease) in cash and cash equivalents, and <br>restricted cash | $5030 | $(8353) |

---

***Net Cash Used in Operating Activities (Restated)***

*Three Months Ended March 31, 2025* 

During the three months ended March 31, 2025, operating activities used $9.5 million of cash resulting from cash used from changes in our operating assets and liabilities of $4.8 million, non-cash income of $3.2 million (as restated), and a net loss of $1.5 million (as restated).

Non-cash income consisted of $5.7 million of income related mark to market adjustments related to our warrant liabilities, $3.3 million (as restated) of income related to the change in fair value of our convertible debt, $0.9 of income related to the change in fair value of our earn-out liabilities, and $0.3 million on unrealized gains. This non-cash income was partially offset by $3.8 million (as restated) of expense related to the change in fair value of our Revenue Interest Financing, $1.1 million of issuance costs associated with warrants recorded at fair value, $0.9 million of stock-based compensation expense, a $0.7 million loss on changes in fair value of the Share Obligation, $0.2 million of non-cash lease expense, and $0.2 million of depreciation and amortization expense.

Net cash used in our operating assets and liabilities consisted of a $3.9 million decrease in accounts payable, accrued expenses, and other current liabilities, a $0.9 million increase in accounts receivable, and a $0.2 million decrease in our lease liabilities, partially offset by a $0.1 million decrease in prepaid expenses, other current and long-term assets and a less than $0.1 million increase in inventory.

The net decrease in accounts payable, accrued expenses and other current liabilities was primarily related to decreased expenses resulting from the restructuring implemented during the fourth quarter of 2024 and timing of payments. The increase in accounts receivable was the result of an increase in revenue and decrease in cash collections.

*Three Months Ended March 31, 2024* 

During the three months ended March 31, 2024, net income of $2.0 million (as restated) and net cash provided by changes in our operating assets and liabilities of $2.6 million was more than offset by non-cash income of $13.2 million (as restated), resulting in cash used from operating activities of $8.6 million.

------

##### [**Table of Contents**](#toc)
Non-cash income consisted of $14.2 million of income related to the change in fair value of our earn-out liabilities and $3.1 million of mark to market adjustments related to our warrant liabilities. This non-cash income was partially offset by $2.1 million (as restated) of expense related to the change in fair value of the Revenue Interest Financing and PIPE Conversion Option, $0.6 million of stock-based compensation expenses, $0.4 million of depreciation and amortization expense, $0.3 million of non-cash interest expense primarily related to the accretion of debt discount associated with our Fortress Term Loan, $0.3 million of unrealized loss on foreign exchange, a $0.2 million provision for inventory, and $0.2 million of non-cash lease expense.

Net cash provided by changes in our operating assets and liabilities consisted of a $1.7 million decrease in accounts receivable, a $0.3 million decrease in inventory, a $0.2 million decrease in prepaid expenses, other current and long-term assets, and a net $0.6 million increase in accounts payable, accrued expenses and other current liabilities.

The decrease in accounts receivable was the result of an increase in cash collections. The decrease in inventory was primarily related to a decrease in raw materials and work in progress. The decrease in prepaid expenses, other current and long-term assets was primarily related to a decrease in payroll deposits. The net increase in accounts payable, accrued expenses and other current liabilities was primarily related to timing of payments.

***Net Cash Used in Investing Activities***

*Three Months Ended March 31, 2025 and 2024*

During the three months ended March 31, 2025 and 2024, cash used in investing activities was zero and $0.1 million, respectively, consisting of purchases of property and equipment.

***Net Cash Provided by Financing Activities***

*Three Months Ended March 31, 2025 and 2024*

During the three months ended March 31, 2025, cash provided by financing activities was $14.5 million, consisting of $14.5 million of net proceeds from the RTW Private Placement, January 2025 Offering, February 2025 Offering, and Leavitt Private Placement.

During the three months ended March 31, 2024, cash provided by financing activities was $0.4 million, consisting of $0.4 million of proceeds from our equity line financing.

**Critical Accounting Policies and Estimates**

Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

There have been no material changes in our critical accounting policies and significant judgments and estimates as compared to those disclosed in "Part II, Item 7-Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. See Note 3, *Summary of Significant of Accounting Policies* in the accompanying notes to the condensed consolidated financial statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q/A for additional details of our accounting policies.

**Recent Accounting Pronouncements**

See Note 3, *Summary of Significant of Accounting Policies* in the accompanying notes to the condensed consolidated financial statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q/A for a description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations or cash flows.

**Emerging Growth Company and Smaller Reporting Company** 

We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act ("JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that (i) we are no longer an emerging growth company or (ii) we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies.

------

##### [**Table of Contents**](#toc)
Additionally, we are a "smaller reporting company" as defined in Item 10(f)(1) of Regulation S-K, which allows us to take advantage of certain exemptions from disclosure requirements including exemption from compliance with the auditor attestation requirements of Section 404. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of the shares of our Common Stock held by non-affiliates exceeds $250 million as of the prior June 30, and (ii) our annual revenue exceeded $100 million during such completed fiscal year or the market value of the shares of our Common Stock held by non-affiliates exceeds $700 million as of the prior June 30. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible.

------

##### [**Table of Contents**](#toc)
**Item 3. Quantitative and Qualitative Disclosures About Market Risk.** 

*Interest Rate Risk*

We had cash and cash equivalents totaling $20.4 million at March 31, 2025. Cash equivalents were invested primarily in money market funds. Our investment policy is focused on the preservation of capital and supporting our liquidity needs. Under our investment policy, we invest in highly rated securities, issued by the U.S. government or liquid money market funds. We do not invest in financial instruments for trading or speculative purposes, nor do we use leveraged financial instruments. We utilize external investment managers who adhere to the guidelines of our investment policy. A hypothetical 10% change in interest rates would not have a material impact on the value of our cash, cash equivalents, net loss or cash flows.

As of March 31, 2025, we had no variable rate debt outstanding.

*Foreign Currency Exchange Risk*

We are exposed to foreign currency risks that arise from normal business operations. These risks include transaction gains and losses associated with transactions denominated in currencies other than a location's functional currency and the remeasurement of foreign currencies to our U.S. dollar reporting currency. As such, we have exposure to adverse changes in exchange rates associated with operating expenses of our foreign operations. Transaction gains or losses are included in Other income (expense), net in the condensed consolidated statements of operations, as incurred.

We believe that a 10% increase or decrease in current exchange rates between the U.S. dollar and our foreign currencies could have a material impact on our business, financial condition or results of operations. Our primary exposures related to foreign currency denominated sales and expenses are in Europe and we also have exposure in the Middle East and the Asia-Pacific region, and are monitoring potential developing exposure in the Latin American, Canadian and African markets.

To date, we have not engaged in any foreign currency hedging activities. As our international operations grow, we will continue to reassess our approach to managing the risks relating to fluctuations in foreign currency exchange rates. During the three months ended March 31, 2025, the effect of an immediate 10% adverse change in foreign exchange rates on foreign-denominated accounts would have had an impact of approximately 5% on revenues and 3% on expenses and would have impacted our net income by approximately 1%. During the three months ended March 31, 2024, the effect of an immediate 10% adverse change in foreign exchange rates on foreign-denominated accounts would have had an impact of approximately 7% on revenues and 7% on expenses and would have impacted our net loss by approximately 6%.

**Item 4. Controls and Procedures.** 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934, as amended (the "Exchange Act") is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

*Evaluation of Disclosure Controls and Procedures* 

In connection with the filing of our Original Form 10-Q on May 15, 2025, our Chief Executive Officer, who is our principal executive officer and principal financial officer, reviewed and evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act) as of March 31, 2025. Based on that review and evaluation, the Chief Executive Officer previously concluded that the Company's disclosure controls and procedures were not effective as of March 31, 2025 as a result of the material weaknesses in our internal control over financial reporting discussed below. Subsequent to the original evaluation, and as described in the Explanatory Note to the Form 10-Q/A, the Company identified an Error which led to the restatement of certain of the Company's historical consolidated financial statements. The Company's management determined that the Error and the related restatements were the result of the existing material weaknesses in the Company's internal control over financial reporting. The Company determined that the Error originated from the lack of sufficient levels of staff with public company and technical accounting experience to maintain proper control activities and perform risk assessment and monitoring activities.

In connection with the audits of our consolidated financial statements as of and for the years ended December 31, 2024 and 2023, we identified material weaknesses in our internal control over financial reporting that we are currently working to remediate, which relate to: (a) insufficient segregation of duties in the financial statement close process; (b) a lack of sufficient levels of staff with public company and technical accounting experience to maintain proper control activities and perform risk assessment and monitoring activities; and (c) insufficient information systems controls, including access and change management controls. We have concluded that these material weaknesses in our internal control over financial reporting occurred because we did not have the necessary business processes, personnel and related internal controls to operate in a manner to satisfy the accounting and financial reporting timeline requirements prior to being a public company.

------

##### [**Table of Contents**](#toc)
We are focused on designing and implementing effective internal controls measures to improve our evaluation of disclosure controls and procedures, including internal control over financial reporting, and remediating the material weaknesses. In order to remediate these material weaknesses, we have taken and plan to take the following actions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• hired and planned continued hiring of additional accounting staff with public company experience,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• implemented a new enterprise resource planning system to replace the prior enterprise resource planning system,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• implementation of additional review controls and processes requiring timely account reconciliation and analyses
of certain transactions and accounts, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• hired a national accounting firm to assist in the design and implementation of controls and remediation of
controls gaps.

While progress has been made to enhance our internal control over financial reporting, we are still in the process of building and enhancing our processes, procedures, and controls. Additional time is required to complete the remediation of these material weaknesses and the assessment to ensure the sustainability of these remediation actions. We believe the above actions, when complete, will be effective in the remediation of the material weaknesses described above.

*Changes in Internal Control Over Financial Reporting* 

During the most recently completed fiscal quarter, there has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

*Limitations on Effectiveness of Controls and Procedures* 

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

------

##### [**Table of Contents**](#toc)
**PART II-OTHER INFORMATION** 

**Item 1. Legal Proceedings.** 

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not currently a party to any material legal proceedings. Regardless of outcome, such proceedings or claims can have an adverse impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.

**Item 1A. Risk Factors.** 

Information regarding risk factors appears in Part I, Item 1A. "Risk Factors" of our Annual Report on Form 10-K. There have been no material changes from the risk factors previously disclosed in such Annual Report on Form 10-K. In addition to the matters set forth herein, investors should review the risks factors and other information provided in the Annual Report on Form 10-K prior to making an investment in the Company. Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described in the Annual Report on Form 10-K, any one or more of which could, directly or indirectly, cause our actual financial condition and operating results to vary materially from past, or from anticipated future, financial conditions and operating results. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results and stock price.

------

##### [**Table of Contents**](#toc)
**Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities** 

*Unregistered Sales of Equity Securities, Use of Proceeds* 

Not applicable.

*Issuer Purchases of Equity Securities* 

Not applicable.

**Item 3. Defaults Upon Senior Securities.** 

None.

**Item 4. Mine Safety Disclosures.** 

Not applicable.

**Item 5. Other Information.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) None of our directors or "officers," as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, adopted or terminated a Rule 10b5-1 trading plan or arrangement or a non-Rule 10b5-1 trading plan or arrangement, as defined in Item 408(c) of Regulation S-K, during the fiscal quarter covered by this Quarterly Report on Form 10-Q/A.

------

##### [**Table of Contents**](#toc)
**Item 6. Exhibits.** 

The following list of exhibits includes exhibits submitted with this Quarterly Report on Form 10-Q/A as filed with the SEC and those incorporated by reference to other filings.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Exhibit**<br>**Number** | **Description** | **Incorporated by<br>Reference herein<br>from—Form or<br>Schedule** | **File<br>Number** | **Exhibit** | **Filed Date** |
| &nbsp;&nbsp;&nbsp;&nbsp;3.1 | Amended and Restated Certificate of Incorporation of Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) | 8-K | 001-41767 | 3.1 | August 7, 2023 |
| &nbsp;&nbsp;&nbsp;&nbsp;3.2 | Bylaws of Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) | 8-K | 001-41767 | 3.2 | August 7, 2023 |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | Warrant Agreement, dated February 4, 2021, between Compute Health Acquisition Corp. and Continental Stock Transfer & Trust Company, as warrant agent. | 8-K | 001-40001 | 4.1 | February 9, 2021 |
| &nbsp;&nbsp;&nbsp;&nbsp;4.2 | Amendment to Warrant Agreement, dated August 1, 2023, by and between Compute Health and Continental Stock Transfer & Trust Company. | 8-K | 001-41767 | 4.2 | August 7, 2023 |
| &nbsp;&nbsp;&nbsp;&nbsp;4.3 | Warrant Assignment, Assumption and Amendment Agreement, dated August 1, 2023, by and among Compute Health Acquisition Corp., New Allurion Holdings, Inc., and Continental Stock Transfer & Trust Company. | 8-K | 001-41767 | 4.3 | August 7, 2023 |
| &nbsp;&nbsp;&nbsp;&nbsp;4.4 | Form of Public Warrant. | 8-K | 001-41767 | 4.1 | July 1, 2024 |
| &nbsp;&nbsp;&nbsp;&nbsp;4.5 | Form of Private Placement Warrant. | 8-K | 001-41767 | 4.2 | July 1, 2024 |
| &nbsp;&nbsp;&nbsp;&nbsp;4.6 | Form of Common Warrant (January 2025). | 8-K | 001-41767 | 4.1 | January 28, 2025 |
| &nbsp;&nbsp;&nbsp;&nbsp;4.7 | Form of Common Warrant (February 2025). | 8-K | 001-41767 | 4.1 | February 21, 2025 |
| &nbsp;&nbsp;&nbsp;&nbsp;4.8 | Form of Private Placement Warrant (February 2025). | 8-K | 001-41767 | 4.2 | February 21, 2025 |
| 10.1# | Omnibus Amendment, dated as of January 7, 2025, by and among Allurion Technologies, Inc., Allurion Technologies, LLC, Allurion Technologies Australia Pty Ltd, Allurion France, RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., RTW Biotech Opportunities Operating Ltd., and RTW Investments, L.P. | S-1/A | 333-283701 | 10.49 | January 8, 2025 |
| 10.2 | Subscription Agreement, dated as of January 14, 2025, by and between Allurion Technologies, Inc. and the purchasers named therein. | 8-K | 001-41767 | 10.1 | January 17, 2025 |
| 10.3 | Securities Purchase Agreement, dated as of January 24, 2025, by and between Allurion Technologies, Inc. and the purchasers named therein. | 8-K | 001-41767 | 10.1 | January 28, 2025 |
| 10.4 | Form of Securities Purchase Agreement. | 8-K | 001-41767 | 10.1 | February 21, 2025 |
| 10.5 | Subscription Agreement, dated as of February 19, 2025, between Allurion Technologies, Inc. and the investors named therein. | 8-K | 001-41767 | 10.2 | February 21, 2025 |
| 10.6 | Second Amendment to Note Purchase Agreement, dated as of April 15, 2025, by and among Allurion Technologies, Inc., the purchasers party thereto, and RTW Investments, LP, as agent for the purchasers. | 8-K | 001-41767 | 10.1 | April 17, 2025 |
| 31.1\* | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |
| 32.1\*\* | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |  |  |  |  |
| 101.INS | Inline XBRL Instance Document—the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. |  |  |  |  |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |  |  |  |  |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  |  |

---

------

##### [**Table of Contents**](#toc)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Exhibit**<br>**Number** | **Description** | **Incorporated by<br>Reference herein<br>from—Form or<br>Schedule** | **File<br>Number** | **Exhibit** | **Filed Date** |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |  |  |  |  |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |  |  |  |  |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  |  |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |  |  |  |  |

---

\* Filed herewith.

\*\* Furnished herewith

# Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish supplementally a copy of all omitted exhibits and schedules to the SEC upon its request.

------

##### [**Table of Contents**](#toc)
**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Allurion Technologies, Inc. | Allurion Technologies, Inc. |
| Date: August 19, 2025 | By: | /s/ Shantanu Gaur |
|  |  | **Shantanu Gaur** |
|  |  | **Chief Executive Officer and President** |

---